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A B S T R A C T
Background
This is an updated version of the Cochrane Review previously published in 2016. This review is one in a series of Cochrane Reviews
investigating pair-wise monotherapy comparisons.
Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked
seizures. It is believed that with effective drug treatment, up to 70% of individuals with active epilepsy have the potential to become
seizure-free and go into long-term remission shortly after starting drug therapy with a single antiepileptic drug in monotherapy.
Worldwide, carbamazepine and phenobarbitone are commonly used broad-spectrum antiepileptic drugs, suitable for most epileptic
seizure types. Carbamazepine is a current first-line treatment for focal onset seizures, and is used in theUSA and Europe. Phenobarbitone
is no longer considered a first-line treatment because of concerns over associated adverse events, particularly documented behavioural
adverse events in children treated with the drug. However, phenobarbitone is still commonly used in low- and middle-income countries
because of its low cost. No consistent differences in efficacy have been found between carbamazepine and phenobarbitone in individual
trials; however, the confidence intervals generated by these trials are wide, and therefore, synthesising the data of the individual trials
may show differences in efficacy.
Objectives
To review the time to treatment failure, remission and first seizure with carbamazepine compared with phenobarbitone when used
as monotherapy in people with focal onset seizures (simple or complex focal and secondarily generalised), or generalised onset tonic-
clonic seizures (with or without other generalised seizure types).
Search methods
For the latest update, we searched the following databases on 24May 2018: theCochrane Register of Studies (CRSWeb), which includes
Cochrane Epilepsy’s Specialized Register and CENTRAL; MEDLINE; the US National Institutes of Health Ongoing Trials Register
(ClinicalTrials.gov); and the World Health Organization International Clinical Trials Registry Platform (ICTRP). We handsearched
relevant journals and contacted pharmaceutical companies, original trial investigators, and experts in the field.
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Selection criteria
Randomised controlled trials comparing monotherapy with either carbamazepine or phenobarbitone in children or adults with focal
onset seizures or generalised onset tonic-clonic seizures.
Data collection and analysis
This was an individual participant data (IPD), review. Our primary outcome was time to treatment failure. Our secondary outcomes
were time to first seizure post-randomisation, time to six-month remission, time to 12-month remission, and incidence of adverse events.
We used Cox proportional hazards regression models to obtain trial-specific estimates of hazard ratios (HRs), with 95% confidence
intervals (CIs), using the generic inverse variance method to obtain the overall pooled HR and 95% CI.
Main results
We included 13 trials in this review and IPD were available for 836 individuals out of 1455 eligible individuals from six trials, 57%
of the potential data. For remission outcomes, a HR of less than 1 indicates an advantage for phenobarbitone and for first seizure and
treatment failure outcomes a HR of less than 1 indicates an advantage for carbamazepine.
Results for the primary outcome of the review were: time to treatment failure for any reason related to treatment (pooled HR adjusted
for seizure type for 676 participants: 0.66, 95% CI 0.50 to 0.86, moderate-quality evidence), time to treatment failure due to adverse
events (pooled HR adjusted for seizure type for 619 participants: 0.69, 95% CI 0.49 to 0.97, low-quality evidence), time to treatment
failure due to lack of efficacy (pooled HR adjusted for seizure type for 487 participants: 0.54, 95% CI 0.38 to 0.78, moderate-quality
evidence), showing a statistically significant advantage for carbamazepine compared to phenobarbitone.
For our secondary outcomes, we did not find any statistically significant differences between carbamazepine and phenobarbitone: time
to first seizure post-randomisation (pooled HR adjusted for seizure type for 822 participants: 1.13, 95% CI 0.93 to 1.38, moderate-
quality evidence), time to 12-month remission (pooled HR adjusted for seizure type for 683 participants: 1.09, 95% CI 0.84 to 1.40,
low-quality evidence), and time to six-month remission pooled HR adjusted for seizure type for 683 participants: 1.01, 95% CI 0.81
to 1.24, low-quality evidence).
Results of these secondary outcomes suggest that there may be an association between treatment effect in terms of efficacy and seizure
type; that is, that participants with focal onset seizures experience seizure recurrence later and hence remission of seizures earlier on
phenobarbitone than carbamazepine, and vice versa for individuals with generalised seizures. It is likely that the analyses of these
outcomes were confounded by several methodological issues and misclassification of seizure type, which could have introduced the
heterogeneity and bias into the results of this review.
Limited information was available regarding adverse events in the trials and we could not compare the rates of adverse events between
carbamazepine and phenobarbitone. Some adverse events reported on both drugs were abdominal pain, nausea, and vomiting, drowsi-
ness, motor and cognitive disturbances, dysmorphic side effects (such as rash), and behavioural side effects in three paediatric trials.
Authors’ conclusions
Moderate-quality evidence from this review suggests that carbamazepine is likely to be a more effective drug than phenobarbitone in
terms of treatment retention (treatment failures due to lack of efficacy or adverse events or both). Moderate- to low-quality evidence
from this review also suggests an association between treatment efficacy and seizure type in terms of seizure recurrence and seizure
remission, with an advantage for phenobarbitone for focal onset seizures and an advantage for carbamazepine for generalised onset
seizures.
However, some of the trials contributing to the analyses had methodological inadequacies and inconsistencies that may have impacted
upon the results of this review. Therefore, we do not suggest that results of this review alone should form the basis of a treatment
choice for a patient with newly onset seizures. We recommend that future trials should be designed to the highest quality possible with
consideration of masking, choice of population, classification of seizure type, duration of follow-up, choice of outcomes and analysis,
and presentation of results.
P L A I N L A N G U A G E S U M M A R Y
Carbamazepine versus phenobarbitone monotherapy (single drug treatment) for epilepsy
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This is an updated version of the Cochrane Review previously published in Issue 12, 2016 of the Cochrane Database of Systematic
Reviews.
Background
Epilepsy is a common neurological disorder in which abnormal electrical discharges from the brain cause recurrent seizures. We studied
two types of epileptic seizures in this review: generalised onset seizures, in which electrical discharges begin in one part of the brain and
move throughout the brain; and focal onset seizures, in which the seizure is generated in and affects one part of the brain (the whole
hemisphere of the brain or part of a lobe of the brain). Focal seizures may become generalised (secondary generalisation), and move
from one part of the brain throughout the brain. For around 70% of people with epilepsy, a single antiepileptic medication can control
generalised onset or focal onset seizures.
This review applies to people with focal seizures (with or without secondary generalisation) and people with generalised tonic-clonic
seizures, a specific generalised seizure type. This review does not apply to people with other generalised seizure types such as absence
seizures or myoclonic seizures, as the recommended treatments for these seizure types are different.
Worldwide, phenobarbitone and carbamazepine are commonly used antiepileptic drugs, however, carbamazepine is used more com-
monly in the USA and Europe because of concerns over side-effects associated with phenobarbitone, particularly concerns over be-
havioural changes in children treated with phenobarbitone. Phenobarbitone is still commonly used in low- and middle-income coun-
tries in Africa, Asia, and South America because of the low cost of the drug.
Objective
The aim of this review was to compare how effective these drugs are at controlling seizures, to find out if they are associated with side
effects that may result in individuals stopping the medication, and to inform a choice between these medications.
Methods
The last search for trials was inMay 2018. We assessed the evidence from 13 clinical trials in which people received either carbamazepine
or phenobarbitone and their treatment was decided randomly. We were able to combine data for 836 people from six of the 13 trials;
for the remaining 619 people from seven trials, data were not available to use in this review.
Key results
Results of the review suggest that people are likely to stop taking phenobarbitone treatment earlier than carbamazepine treatment,
because of seizure recurrence, side-effects of the drug, or both. Results also suggest that recurrence of seizures after starting treatment
with phenobarbitone may happen later than treatment with carbamazepine (and therefore a seizure free period of 6 months or 12
months may occur earlier with phenobarbitone than with carbamazepine) for people with focal onset seizures, and vice-versa for people
with generalised onset seizures.
Some side effects reported by people taking carbamazepine and people taking phenobarbitone were abdominal pain, nausea, vomiting,
tiredness, motor problems (such as poor co-ordination), cognitive problems (poormemory), rashes and other skin problems. Behavioural
side effects such as aggression were reported on both drugs in three trials in children.
Quality of the evidence
Some of the trials contributing data to the review had methodological problems, which may have introduced bias and inconsistent
results into this review, and some individuals over the age of 30 with newly diagnosed generalised onset seizures may have had their
seizure type wrongly diagnosed. These problems may have affected the results of this review and we judged the quality of the evidence
provided by this review to be moderate to low quality. We do not suggest using the results of this review alone for making a choice
between carbamazepine or phenobarbitone for the treatment of epilepsy. We recommend that all future trials comparing these drugs
or any other antiepileptic drugs should be designed using high-quality methods to ensure results are also of high quality.
3Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Carbamazepine compared with phenobarbitone for epilepsy (time to treatment failure)
Patient or population: adults and children with newly onset focal or generalised epilepsy
Settings: outpat ients
Intervention: carbamazepine
Comparison: phenobarbitone
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Phenobarbitone Carbamazepine
Time to treatment fail-
ure (any reason related
to treatment)
All participants
Range of follow-up: 0 to
4653 days
The median t ime to
treatment failure was
1059 days in the pheno-
barbitone group
The median t ime to
treatment failure was
2717 days (1658 days
longer) in the carba-
mazepine group
HR 0.66 (0.50 to 0.86)a 676
(4 trials)
⊕⊕⊕©
Moderateb
HR < 1 indicates a clin-
ical advantage for car-
bamazepine.
Treatment failure due
to adverse events (HR
0.69, 95% CI 0.49 to
0.97, P = 0.03, I² =
55%), and due to lack
of ef f icacy (HR 0.54,
95% CI 0.38 to 0.78,
P = 0.0008, I² = 0%)
, also occurred signif i-
cant ly earlier on pheno-
barbitone compared to
carbamazepine
Time to treatment fail-
ure (any reason related
to treatment)
Subgroup: focal onset
seizures
Range of follow-up: 0 to
The median t ime to
treatment failure was
913 days in the pheno-
barbitone group
The median t ime to
treatment failure was
2422 days (1509 days
longer) in the carba-
mazepine group
HR 0.66 (0.49 to 0.88) 520
(4 trials)
⊕⊕⊕©
Lowb,c
HR < 1 indicates a clin-
ical advantage for car-
bamazepine.
Treatment failure due
to adverse events (HR
4
C
a
rb
a
m
a
z
e
p
in
e
v
e
rsu
s
p
h
e
n
o
b
a
rb
ito
n
e
m
o
n
o
th
e
ra
p
y
fo
r
e
p
ile
p
sy
:
a
n
in
d
iv
id
u
a
l
p
a
rtic
ip
a
n
t
d
a
ta
re
v
ie
w
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
4272 days 0.67, 95% CI 0.46 to 0.
96, P = 0.03, I² = 70%),
and due to lack of ef f i-
cacy (HR0.54, 95%CI 0.
36 to 0.80,P = 0.002, I² =
0%), also occurred sig-
nif icant ly earlier on phe-
nobarbitone compared
to carbamazepine
Time to treatment fail-
ure (any reason related
to treatment)
Subgroup: generalised on-
set tonic-clonic seizures
Range of follow-up: 0 to
4653 days
The 25th percent iled of
t ime to treatment fail-
ure was 605 days in the
phenobarbitone group
The 25th percent iled of
t ime to treatment fail-
ure was 825 days (220
days longer) in the car-
bamazepine group
HR 0.65 (0.35 to 1.23) 156
(3 trials)
⊕⊕⊕©
Lowb,e
HR < 1 indicates a clin-
ical advantage for car-
bamazepine.
There was also no sta-
t ist ically signif icant dif -
ference between drugs
in treatment failure due
to adverse events (HR
0.84, 95% CI 0.35 to 2.
00, P = 0.69, I² = 0%), or
treatment failure due to
lack of ef f icacy: HR 0.
56 (95%CI 0.23 to 1.35,
P = 0.20, I² = 0%)
* Illustrat ive risks in the carbamazepine and phenobarbitone groups are calculated at the median t ime to treatment failure (i.e. the t ime to 50% of part icipants failing or
withdrawing f rom allocated treatment) within each group across all t rials. The relat ive ef fect (pooled hazard rat io) shows the comparison of ’t ime to treatment failure’ between
the treatment groups
CI: 95% conf idence interval; HR: hazard rat io
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aPooled HR for all part icipants adjusted for seizure type.5
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bDowngraded once for risk of bias: There was high risk of bias for at least one element of three trials included in the analysis;
de Silva 1996 and Heller 1995 were open-label, and the lack of masking may have inf luenced the withdrawal rates in the trial.
Placencia 1993 did not adequately conceal allocat ion for all part icipants, which may have inf luenced the withdrawal rates in
the trial. There were inconsistencies in Placencia 1993 between published data and individual part icipant data, which the trial
authors could not resolve.
cDowngraded once for inconsistency: substant ial heterogeneity was present between trials (I² = 66%); sensit ivity analyses
showed that Placencia 1993 contributed the largest amount of variability to analysis.
dThe 25th percent ile of t ime to treatment failure (i.e. the t ime to 50% of part icipants failing or withdrawing f rom allocated
treatment) is presented for the subgroup with generalised seizures, as fewer than 50% of part icipants failed/ withdrew f rom
treatment we could not calculate median t ime.
eDowngraded once for imprecision: the subgroup of part icipants with generalised onset tonic-clonic seizures is relat ively
small (23% of total part icipants) and conf idence intervals around pooled results are fairly wide.
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B A C K G R O U N D
This is an updated version of the Cochrane Review previously
published in Issue 12, 2016 of the Cochrane Database of Systematic
Reviews (Nolan 2016a).
Description of the condition
Epilepsy is a common neurological condition in which abnormal
electrical discharges from the brain cause recurrent unprovoked
seizures. Epilepsy is a disorder of many heterogenous seizure types,
with an estimated incidence of 33 to 57 per 100,000 person-
years worldwide (Annegers 1999; Hirtz 2007; MacDonald 2000;
Olafsson 2005; Sander 1996), accounting for approximately 1%
of the global burden of disease (Murray 1994).
The lifetime risk of epilepsy onset is estimated to be 1300 to
4000 per 100,000 person-years (Hauser 1993; Juul-Jenson 1983),
and the lifetime prevalence could be as large as 70 million people
worldwide (Ngugi 2010). It is believed that with effective drug
treatment, up to 70% of individuals with active epilepsy have
the potential to go into long-term remission shortly after starting
drug therapy (Cockerell 1995; Hauser 1993; Sander 2004), and
around 70% of individuals can achieve seizure freedom using a
single antiepileptic drug in monotherapy (Cockerell 1995). Cur-
rent National Institute for Health and Care Excellence (NICE),
guidelines recommend that both adults and children with epilepsy
should be treated with monotherapy, wherever possible (NICE
2012). The remaining 30% of individuals experience refractory or
drug-resistant seizures, which often require treatment with com-
binations of antiepileptic drugs or alternative treatments, such as
epilepsy surgery (Kwan 2000).
We studied two seizure types in this review: generalised onset
seizures, in which electrical discharges begin in one part of the
brain and move throughout the brain, and focal onset seizures, in
which the seizure is generated in and affects one part of the brain
(the whole hemisphere of the brain or part of a lobe of the brain).
Description of the intervention
Carbamazepine and phenobarbitone are among the most com-
monly used and earliest drugs licensed for the treatment of epilep-
tic seizures; phenobarbitone has been used as monotherapy for
focal seizures and generalised tonic-clonic seizures for over 50
years (Gruber 1962), and carbamazepine, for over 30 years (Shakir
1980). Current NICE guidelines for adults and children rec-
ommend carbamazepine as a first-line treatment for focal onset
seizures and as a second-line treatment for generalised tonic-clonic
seizures if first-line treatments, sodium valproate and lamotrigine,
are deemed unsuitable (NICE 2012). However, there is evidence
that carbamazepine may exacerbate some other generalised seizure
types, such as myoclonic and absence seizures (Liporace 1994;
Shields 1983; Snead 1985).
Phenobarbitone is no longer considered a first-line treatment in the
USA andmost of Europe because of concerns over short- and long-
term tolerability (Wallace 1997); particularly in children, there is
concern about behavioural disturbance caused by phenobarbitone
(Trimble 1988). One open-label paediatric trial in the UK, de
Silva 1996, withdrew the phenobarbitone arm of the trial because
of concerns about behavioural problems and difficulties getting
paediatricians to randomise individuals. However, the largest re-
ported randomised controlled trial (RCT), investigating pheno-
barbitone as monotherapy in adults with focal seizures, Mattson
1985, did not find phenobarbitone to be more associated with ad-
verse events than other trial drugs (carbamazepine, phenytoin, and
primidone). In fact, phenobarbitone was significantly associated
with the lowest incidence of motor disturbances (ataxia (lack of
voluntary co-ordination of muscle movements), incoordination,
nystagmus, and tremor), and gastrointestinal problems.
Phenobarbitone is still used as a first-line drug in low- and mid-
dle-income countries (Banu 2007; Ogunrin 2005; Pal 1998).
Two paediatric trials conducted in Bangladesh (Banu 2007), and
rural India (Pal 1998), comparing phenobarbitone with carba-
mazepine and phenytoin, respectively, found no excess in be-
havioural side-effects from phenobarbitone, but a trial in Nige-
rian adults (Ogunrin 2005), showed evidence of an association be-
tween phenobarbitone and worsening of cognitive impairments,
particularly memory deficits.
Both carbamazepine and phenobarbitone have been shown to have
teratogenic (disturbances to foetal development), effects (Bromley
2014; Weston 2016), where the risk is estimated to be two to
three times that of the general population (Meador 2008; Morrow
2006); carbamazepine is associated particularly with neural tube
defects (Matlow 2012), and has also been shown to be associated
with negative neurodevelopmental outcomes, such as a lower de-
velopmental quotient compared to children born to women with-
out epilepsy (Bromley 2014). Phenobarbitone is associated with
low folic acid levels and megaloblastic anaemia (anaemia charac-
terised by many large immature and dysfunctional red blood cells;
Meador 2008). In addition to concerns over behavioural and cog-
nitive adverse events, phenobarbitone is commonly associatedwith
somnolence (sedation), and connective tissue abnormalities, such
as Dupuytren’s contracture and frozen shoulder (Baulac 2002),
and exposure to phenobarbitone has also been shown to be associ-
ated with significantly higher rates of cardiac malformations com-
pared to exposure to other antiepileptic drugs during pregnancy
in a recent systematic review (Weston 2016).
How the intervention might work
Antiepileptic drugs suppress seizures by reducing neuronal ex-
citability (MacDonald 1995). Phenobarbitone and carbamazepine
are broad-spectrum treatments suitable for many seizure types,
and both have an anticonvulsant mechanism through block-
ing ion channels, binding with neurotransmitter receptors, or
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through inhibiting the metabolism or reuptake of neurotransmit-
ters (Ragsdale 1991), and the modulation of gamma-aminobu-
tyric acid-A (GABA-A), receptors (Rho 1996).
Why it is important to do this review
The aim of this review was to summarise efficacy and tolerability
data from existing trials comparing carbamazepine and phenobar-
bitone when used as monotherapy treatments. The adverse event
profiles of the two drugs are well documented (see example ref-
erences from Description of the intervention), and the largest re-
ported RCT investigating carbamazepine and phenobarbitone as
monotherapy in adults with focal seizures, Mattson 1985, found
carbamazepine to be significantly better at controlling seizures
than phenobarbitone, but other trials, including trials recruiting
individuals with generalised onset seizures, have found no differ-
ences in efficacy between the two drugs (Banu 2007; Bidabadi
2009; Cereghino 1974; Chen 1996; Cossu 1984; Czapinski 1997;
de Silva 1996; Feksi 1991; Heller 1995; Mitchell 1987; Ogunrin
2005; Placencia 1993). Although individual trials have found no
consistent differences in efficacy, the confidence intervals gener-
ated by these trials are wide, and they have not excluded important
differences in efficacy, which synthesising the data of the individ-
ual trials may show.
There are difficulties in undertaking a systematic review of
epilepsy monotherapy trials as the important efficacy outcomes
require analysis of time-to-event data (for example, time to first
seizure after randomisation). Although methods have been devel-
oped to synthesise time-to-event data using summary informa-
tion (Parmar 1998; Williamson 2002), the appropriate statistics
are not commonly reported in published epilepsy trials (Nolan
2013a; Williamson 2000). Furthermore, although most epilepsy
monotherapy trials collect seizure data, there has been no uni-
formity in the definition and reporting of outcomes. For exam-
ple, trials may report time to 12-month remission but not time
to first seizure or vice versa, or some trials may define time to
first seizure from the date of randomisation while others use the
date of achieving maintenance dose. Trial investigators have also
adopted differing approaches to the analysis, particularly with
respect to the censoring of time-to-event data. For these rea-
sons, we performed this review using individual participant data
(IPD), which helps to overcome these problems. This review is
one in a series of Cochrane IPD reviews investigating pair-wise
monotherapy comparisons (Marson 2000; Nevitt 2017b; Nevitt
2018a; Nevitt 2018c; Nolan 2013c; Nolan 2016b; Nevitt 2018b).
These data have also been included in IPD network meta-analyses
of antiepileptic drug monotherapy (Nevitt 2017a; Tudur Smith
2007).
O B J E C T I V E S
To review the time to treatment failure, remission and first seizure
with carbamazepine compared with phenobarbitone when used
as monotherapy in people with focal onset seizures (simple or
complex focal and secondarily generalised), or generalised onset
tonic-clonic seizures (with or without other generalised seizure
types).
M E T H O D S
Criteria for considering studies for this review
Types of studies
• Randomised controlled trials (RCTs), using either an
adequate method of allocation concealment (e.g. sealed, opaque
envelopes), or a ’quasi’ method of randomisation (e.g. allocation
by date of birth).
• Trials may have been double-blind, single-blind, or
unblinded.
• Trials must have included a comparison of carbamazepine
monotherapy with phenobarbitone monotherapy in individuals
with epilepsy.
Types of participants
• We included children or adults with focal onset seizures
(simple focal, complex focal or secondarily generalised tonic-
clonic seizures), or generalised onset tonic-clonic seizures, with
or without other generalised seizure types (in other words, those
who had only generalised tonic-clonic seizures and those who
had both generalised onset tonic-clonic seizures and generalised
seizures of other types (e.g. absence, myoclonic etc.)).
• We excluded individuals with other generalised seizure
types alone without generalised tonic-clonic seizures (e.g. those
who had only absence seizures without any generalised clonic
tonic-seizures), due to differences in first-line treatment
guidelines for other generalised seizure types (NICE 2012).
• We included individuals with a new diagnosis of epilepsy,
or who had had a relapse following antiepileptic monotherapy
withdrawal.
Types of interventions
Carbamazepine or phenobarbitone as monotherapy.
Types of outcome measures
Below is a list of outcomes investigated in this review. Reporting
of these outcomes in the original trial report was not an eligibility
requirement for this review.
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Primary outcomes
Time to treatment failure (retention time). This was a combined
outcome reflecting both efficacy and tolerability, as the following
may have led to failure of treatment: continued seizures, side ef-
fects, non-compliance or the initiation of additional add-on treat-
ment. This is an outcome to which the participant makes a contri-
bution and is the primary outcome measure recommended by the
Commission on Antiepileptic Drugs of the International League
Against Epilepsy (ILAE 1998; ILAE 2006).
Time to treatment failure is considered according to three defini-
tions:
• Time to treatment failure for any treatment-related reason
(continued seizures, side effects, non-compliance or the
initiation of additional add-on treatment)
• Time to treatment failure due to adverse events (i.e. side
effects)
• Time to treatment failure due to lack of efficacy (i.e.
continued seizures)
Secondary outcomes
• Time to first seizure post-randomisation
• Time to achieve 12-month remission (seizure-free period)
• Time to achieve six-month remission (seizure-free period)
• Incidence of adverse events (all reported whether related or
unrelated to treatment)
Search methods for identification of studies
Electronic searches
Searches were run for the original review in 2003 and subsequent
searches were run in October 2013, September 2014, and August
2016. For the latest update we searched the following databases
on 24 May 2018, with no language restrictions.
• The Cochrane Register of Studies (CRS Web), which
includes Cochrane Epilepsy’s Specialized Register and the
Cochrane Central Register of Controlled Trials (CENTRAL),
using the search strategy outlined in Appendix 1
• MEDLINE Ovid (1946-24 May 2018), using the search
strategy outlined in Appendix 2
• US National Institutes of Health Ongoing Trials Register (
ClinicalTrials.gov), using the search strategy outlined in
Appendix 3
• The World Health Organization International Clinical
Trials Registry Platform ( ICTRP), using the search strategy
outlined in Appendix 4.
Previously we also searched SCOPUS (1823 to 18 September
2014), as an alternative to Embase, using the search strategy out-
lined in Appendix 5, but this is no longer necessary, because RCTs
and quasi-RCTs in Embase are now included in CENTRAL.
Searching other resources
In addition, we handsearched relevant journals, reviewed the ref-
erence lists of retrieved trials to search for additional reports of
relevant trials, and contacted Novartis (manufacturers of carba-
mazepine), and experts in the field for information of any ongoing
trials, as well as original investigators of relevant trials found.
Data collection and analysis
Selection of studies
Two review authors (SJN and AGM), independently assessed trials
for inclusion, resolving any disagreements by mutual discussion.
Data extraction and management
We requested the following IPD for all trials meeting our inclusion
criteria.
Trial methods
• method of generation of random list
• method of concealment of randomisation
• stratification factors
• blinding methods
Participant covariates
• gender
• age
• seizure types
• time between first seizure and randomisation
• number of seizures prior to randomisation (with dates)
• presence of neurological signs
• electroencephalographic (EEG), results
• computerised tomography/magnetic resonance imaging
(CT/MRI), results
Follow-up data
• treatment allocation
• date of randomisation
• dates of follow-up
• dates of seizures post-randomisation or seizure frequency
data between follow-up visits
• dates of treatment failure and reasons for treatment failure
• dose
• dates of dose changes
For each trial for which we did not obtain IPD, we carried out
an assessment to see whether any relevant aggregate-level data had
been reported or could be indirectly estimated using the methods
of Parmar 1998 and Williamson 2002.
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Three trials involving 804 participants, provided seizure data in
terms of the number of seizures recorded between each follow-up
visit rather than specific dates of seizures (Feksi 1991; Mattson
1985; Placencia 1993). To enable the calculation of time-to-event
outcomes, we applied linear interpolation to approximate dates of
seizures between follow-up visits. For example, if the trial recorded
four seizures between two visits that occurred on 1 March 1990
and 1May 1990 (interval of 61 days), then the date of first seizure
would be approximately 13 March 1990. This allowed the com-
putation of an estimate of the time to six-month remission, 12-
month remission, and first seizure.
We calculated time to six-month and 12-month remission from
the date of randomisation to the date (or estimated date), that
the individual had first been free of seizures for six or 12 months,
respectively. If the person had one or more seizures in the titration
period, a six-month or 12-month seizure-free period could also
occur between the estimated date of the last seizure in the titration
period and the estimated date of the first seizure in themaintenance
period.
We calculated time to first seizure from the date of randomisation
to the date that we estimated their first seizure to have occurred. If
seizure data were missing for a particular visit, we censored these
outcomes at the previous visit. We also censored these outcomes if
the individual died or if follow-up ceased prior to the occurrence of
the event of interest. We used these methods in the remaining four
trials involving 326 participants (Banu 2007; de Silva 1996; Heller
1995; Ogunrin 2005), for which we directly received outcome
data (dates of seizures after randomisation).
In the Ogunrin 2005 trial, all 37 participants completed the 12-
week trial duration and no participants withdrew from the trial
or from the allocated treatment. For four trials (685 participants),
we extracted dates and reason for treatment failure or withdrawal
from trial case report forms for the original review (de Silva 1996;
Heller 1995; Mattson 1985; Placencia 1993).
Two review authors independently extracted data from all case re-
port forms, resolving disagreements by reconsidering the case re-
port forms at conference. For the analysis of time-to-event data,
we defined an ’event’ as either the failure of the allocated treat-
ment because of poor seizure control, adverse events, or both. We
also classed non-compliance with the treatment regimen or the
addition of another antiepileptic drug as ’events’ for the outcome
’time to treatment failure.’ We censored the outcome if treatment
was stopped because the individual achieved a period of remission
or if the individual was still on allocated treatment at the end of
follow-up.
For the Banu 2007 trial (108 participants), we were provided with
the reason for treatment failure or treatment withdrawal and the
date of last follow-up visit. Treatment failure date did not always
coincide with date of last follow-up visit (i.e. several participants
had the allocated treatment substituted for the other trial drug and
continued to be followed up), and dates of treatment failure could
not be provided. Therefore, we could not include participants
from this trial in the outcome ’time to treatment failure’.
Assessment of risk of bias in included studies
Two review authors (SJN and JW), independently assessed all in-
cluded trials for risk of bias according to the Cochrane ’Risk of
bias’ tool (Higgins 2017), resolving any disagreements by discus-
sion. We rated each of the following six domains as low, unclear or
high risk of bias: method of generating random sequence, alloca-
tion concealment, blinding methods, incomplete outcome data,
selective outcome reporting and other sources of bias. Any discrep-
ancies in the two authors’ ’Risk of bias’ judgements were resolved
by discussion.
Measures of treatment effect
We measured all outcomes in this review as time-to-event out-
comes with the hazard ratio (HR), and 95% confidence interval
(CI), used as the measure of treatment effect. We calculated out-
comes from IPD provided, where possible, or extracted from pub-
lished trials if possible.
Unit of analysis issues
We did not have any unit of analysis issues. The unit of allocation
and analysis was individual for all included trials, and no trials
included in meta-analysis were of a repeated measures (longitudi-
nal), nature or of a cross-over design.
Dealing with missing data
For each trial that supplied IPD, we reproduced results from trial
results where possible and performed consistency checks.
• We cross-checked trial details against any published report
of the trial and contacted original trial authors if we found
missing data, errors, or inconsistencies.
• If trial authors could not resolve inconsistencies between
IPD and published data, depending on the extent of the
inconsistencies, we performed sensitivity analysis (see Sensitivity
analysis), or excluded the data from the meta-analysis.
• We reviewed the chronological randomisation sequence and
checked the balance of prognostic factors, taking account of
factors stratified for in the randomisation procedure.
Assessment of heterogeneity
We assessed heterogeneity statistically using the Q test (P < 0.10
for significance), and the I² statistic (greater than 50% indicating
considerable heterogeneity; Higgins 2003), output produced us-
ing the generic inverse variance approach in Data and analyses,
and visually by inspecting forest plots.
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Assessment of reporting biases
Two review authors (SJN and JW), undertook all full quality and
’Risk of bias’ assessments. In theory, a review using IPD should
overcome issues of reporting biases, as unpublished data can be
provided and unpublished outcomes calculated. Any selective re-
porting bias detected could be assessed with the Outcome Report-
ing Bias In Trials (ORBIT), classification system (Kirkham 2010).
Data synthesis
We carried out our analysis on an intention-to-treat basis (that
is, we analysed participants in the group to which they were ran-
domised, irrespective of which treatment they actually received).
Therefore, for the time-to-event outcomes ’time to six-month re-
mission’, ’time to 12-month remission’, and ’time to first seizure
post-randomisation’, we did not censor participants if treatment
was withdrawn or failed.
For all outcomes, we investigated the relationship between the
time-to-event and treatment effect of the antiepileptic drugs. We
used Cox proportional hazards regression models to obtain trial-
specific estimates of log (HR), or treatment effect and associ-
ated standard errors in Stata Statistical Software, version 14 (Stata
2015). The model assumes that the ratio of hazards (risks), be-
tween the two treatment groups is constant over time (i.e. hazards
are proportional). We tested this proportional hazards assumption
of the Cox regression model for each outcome of each trial by
testing the statistical significance of a time-varying covariate in the
model. We evaluated overall estimates of HRs (with 95% confi-
dence intervals (CIs)), using the generic inverse variance method
in MetaView. We expressed results as a HR and a 95% CI.
By convention, a HR greater than 1 indicates that an event is more
likely to occur earlier on carbamazepine than on phenobarbitone.
Hence, for time to treatment failure or time to first seizure, a HR
greater than 1 indicates a clinical advantage for phenobarbitone
(e.g. a HR of 1.2 would suggest a 20% increase in risk of treatment
failure from carbamazepine compared with phenobarbitone), and
for time to six-month and 12-month remission, a HR greater than
1 indicates a clinical advantage for carbamazepine.
Subgroup analysis and investigation of heterogeneity
Because of the strong clinical belief that some antiepileptic
drugs are more effective in some seizure types than others (see
Description of the intervention and How the intervention might
work), we stratified all analyses by seizure type (focal onset versus
generalised onset), according to the classification of main seizure
type at baseline. We classified focal seizures (simple or complex),
and focal secondarily generalised seizures as focal epilepsy.
We classified primarily generalised seizures as generalised epilepsy.
We conducted a Chi² test of interaction between treatment and
seizure type. If we found significant statistical heterogeneity to be
present, we performedmeta-analysis with a random-effects model
in addition to a fixed-effect model, presenting the results of both
models and performing sensitivity analyses to investigate differ-
ences in trial characteristics.
Sensitivity analysis
We performed several sensitivity analyses to test the robustness of
our results to characteristics of the included trials.
• Placencia 1993 concealed allocation via opaque sealed
envelopes; however, the trial did not use this method for all trial
participants. As inadequate allocation concealment could lead to
biased selection of participants, we performed sensitivity analysis
excluding data from Placencia 1993 for each outcome and
observed any change to results and conclusions.
• Following consistency checks of IPD for Placencia 1993
and Banu 2007, we found some inconsistencies between the data
provided and the results in the publications in terms of treatment
failure and seizure recurrences, respectively. Therefore, we
performed sensitivity analyses for outcomes ’time to treatment
failure’ and ’time to first seizure’, respectively, to investigate any
impact of these inconsistencies on our results. For Placencia
1993, we compared reason for treatment failure in the data
provided with reasons reported in the publication and performed
a sensitivity analysis of those reasons that we classed as ’events’ or
’censored observations’ (see Effects of interventions for further
details). Regarding Banu 2007, we did not have sufficient
information to examine the classification of participants as
’events’ and ’censored observations’ in the analysis of ’time to first
seizure’; therefore, we performed a simple sensitivity analysis
excluding data from Banu 2007 from the outcome of ’time to
first seizure’ and observed any change to results and conclusions.
• de Silva 1996 withdrew the phenobarbitone arm of the trial
after 10 children were randomised to phenobarbitone due to
concerns over unacceptable side-effects. The trial did not
randomise any further children to phenobarbitone and
continued with the three other treatment arms: carbamazepine,
phenytoin, and sodium valproate. For the primary and
secondary outcomes of this review, we included all children
randomised to carbamazepine (n = 54), and phenobarbitone (n =
10), from de Silva 1996, and to account for the imbalance
between children randomised to the two drugs on this trial, we
performed sensitivity analysis including only those children who
were randomised before the withdrawal of the phenobarbitone
arm from the trial. For sensitivity analysis, we analysed 20
children (10 boys and 10 girls), 10 randomised to each drug,
nine with generalised seizures and 11 with focal seizures. We
performed this sensitivity analysis for each outcome and
observed any change to results and conclusions.
• Misclassification of seizure type is a recognised problem in
epilepsy, whereby some people with generalised seizures have
been mistakenly classed as having focal onset seizures and vice
versa. There is clinical evidence that individuals with generalised
onset seizures are unlikely to have an ’age of onset’ greater than
25 to 30 years (Malafosse 1994). Such misclassification affected
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the results of three reviews in our series of pair-wise reviews for
monotherapy in epilepsy comparing carbamazepine to
phenobarbitone, phenytoin and sodium valproate in which
around 30% to 50% of participants analysed may have had their
seizure type misclassified as generalised onset (Marson 2000;
Nevitt 2017b; Nevitt 2018b). Given the potential biases
introduced into those reviews, we examined the distribution of
age at onset for individuals with generalised seizures in the trials
included in this review, to assess the potential impact of
misclassification of seizure type on the outcomes.
◦ 22 out of 70 individuals (31%), with generalised onset
seizures were over the age of 30 in Heller 1995,
◦ 19 out of 30 individuals (63%), with generalised onset
seizures were over the age of 30 in Ogunrin 2005
◦ 24 out of 59 individuals (41%), with generalised onset
seizures were over the age of 30 in Placencia 1993.
Banu 2007 and de Silva 1996 were paediatric trials, and Mattson
1985 recruited participants with focal seizures only, so there were
no participants with new onset generalised seizures over the age
of 30 in these trials. Therefore, out of 245 participants classified
as experiencing generalised seizures from the six trials providing
IPD, 65 (27%), may have been wrongly classified.
To investigate misclassification for each outcome, we undertook
the following two analyses to investigate misclassification.
• We reclassified all individuals with generalised seizures and
age at onset greater than 30 into an ’uncertain seizure type’
group.
• We reclassified individuals with generalised seizures and age
at onset greater than 30 as having focal onset seizures.
’Summary of findings’ tables and quality of the
evidence (GRADE)
For the 2016 update, we added two ’Summary of findings’ tables
to the review (outcomes in the tables decided before the update
started based on clinical relevance).
Summary of findings for themain comparison reports the primary
outcome of ’time to treatment failure’ in the subgroups of par-
ticipants with focal onset seizures, generalised onset seizures and
overall adjusted by seizure type.
Summary of findings 2 reports the secondary outcomes of ’time
to first seizure’ and ’time to 12-month remission’ in the subgroups
of participants with focal onset seizures, generalised onset seizures
and overall adjusted by seizure type.
We determined the quality of the evidence using the GRADE ap-
proach, where we downgraded evidence in the presence of high
risk of bias in at least one trial, indirectness of the evidence, unex-
plained heterogeneity or inconsistency, imprecision of results and
high probability of publication bias. We downgraded evidence by
one level if we considered the limitation serious and two levels for
very serious.
R E S U L T S
Description of studies
Results of the search
We identified 433 records from the databases and search strategies
outlined in Electronic searches. We found one further record by
searching other resources (handsearching). We removed 140 du-
plicate records and screened 294 records (title and abstract), for
inclusion in the review. We excluded 272 records based on the title
and abstract and assessed 22 full-text articles for inclusion in the
review. We excluded seven trials (see Excluded studies below), and
included 13 trials (reported in 15 full-text articles) in the review
(see Included studies). See Figure 1 for a PRISMA study flow di-
agram (Moher 2009).
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Figure 1. Study flow diagram
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Included studies
We included 13 trials in this review (Banu 2007; Bidabadi 2009;
Cereghino 1974; Chen 1996; Cossu 1984; Czapinski 1997; de
Silva 1996; Feksi 1991; Heller 1995; Mattson 1985; Mitchell
1987; Ogunrin 2005; Placencia 1993). Two included trials were
available in abstract form only (Bidabadi 2009; Czapinski 1997),
andone included trial was published in Italian,whichwe translated
into English (Cossu 1984).
Two trials recruited individuals of all ages (Feksi 1991; Placencia
1993); five trials recruited children only (de Silva 1996 defined
children as under the age of 16, Banu 2007 andChen 1996 defined
children as under the age of 15, and Bidabadi 2009 and Mitchell
1987 defined children as under the age of 12), and the remain-
ing six trials recruited adults only. Of the adults-only trials, three
defined adults to be individuals above the age of 18 (Cereghino
1974; Czapinski 1997; Mattson 1985), one trial classed adults as
older than 13 years (Heller 1995), one trial classed adults as older
than 14 years (Ogunrin 2005), and one trial classed adults as older
than 15 years (Cossu 1984).
Seven trials recruited individuals with focal onset seizures and
generalised onset seizures (Banu 2007; Chen 1996; de Silva
1996; Feksi 1991; Heller 1995; Ogunrin 2005; Placencia 1993),
three trials recruited individuals with focal onset seizures only
(Cereghino 1974; Mattson 1985; Mitchell 1987), one trial re-
cruited individuals with focal seizures and secondarily generalised
seizures (Bidabadi 2009), one trial recruited individuals with com-
plex focal seizures only (Czapinski 1997), and one trial recruited
individuals with temporal lobe epilepsy only (Cossu 1984). Ten
trials recruited individuals with new onset seizures, or previously
untreated seizures, or both (Banu 2007; Chen 1996; Cossu 1984;
Czapinski 1997; de Silva 1996; Feksi 1991; Heller 1995; Mitchell
1987; Ogunrin 2005; Placencia 1993); one trial recruited insti-
tutionalised participants with uncontrolled seizures (Cereghino
1974); one trial recruited “previously untreated or under-treated”
individuals (Mattson 1985); and one trial (reported only in ab-
stract form) provided no information regarding new onset of
seizures in participants (Bidabadi 2009).
Four trials were conducted in Europe ( Cossu 1984; Czapinski
1997; de Silva 1996; Heller 1995); three trials were conducted
in the USA (Cereghino 1974; Mattson 1985; Mitchell 1987);
one trial was conducted in Iran (Bidabadi 2009), one trial was
conducted in Taiwan (Chen 1996); and four trials were conducted
in rural areas or low- or middle-income countries, or both: one
trial in Bangladesh (Banu 2007), one trial in Ecuador (Placencia
1993), one trial in Kenya (Feksi 1991), and one trial in Nigeria
(Ogunrin 2005).
Individual participant data were provided by trial authors for six
trials, which recruited a total of 836 participants, representing
57% of 1455 individuals from all 13 identified eligible trials. Four
trials provided computerised data directly (Banu 2007; Mattson
1985; Ogunrin 2005; Placencia 1993), and the authors of two
trials (de Silva 1996;Heller 1995), supplied a combination of both
computerised andhard copy data (althoughmostly computerised).
Data were available for the following participant characteristics
(percentage of 836participantswith data available): sex (99%, data
missing for 6 participants in de Silva 1996 and 4 participants in
Mattson 1985); seizure type (100%); drug randomised (99%, data
missing for 6 participants in de Silva 1996); age at randomisation
(99%, data missing for 1 participant inHeller 1995, 6 participants
in de Silva 1996, and 4 participants in Mattson 1985); number of
seizures in six months prior to randomisation (98%, data missing
for 5 participants from Banu 2007, 1 participant in Heller 1995,
6 participants in de Silva 1996, and 7 participants in Mattson
1985); and time since first seizure to randomisation (94%, data
missing for 2 participants inHeller 1995, 6 participants in de Silva
1996, 5 participants in Mattson 1985, and all 37 participants in
Ogunrin 2005). See the Characteristics of included studies table
and Table 1 for further details.
Three trials provided the results of neurological examinations for
220 participants (27%), (de Silva 1996; Heller 1995; Ogunrin
2005). All participants had a normal neurological examination in
Ogunrin 2005, 95% of participants and 94% of participants had
a normal neurological examination in de Silva 1996 and Heller
1995 respectively.
Three trials provided electroencephalographic (EEG), results for
581 participants (69%), (103 participants from Banu 2007,
307 participants from Mattson 1985, and 192 participants from
Placencia 1993). In Banu 2007, 52% of participants had an ab-
normal EEG, in Mattson 1985 71% of participants had an ab-
normal EEG and in Placencia 1993, 47% of participants had an
abnormal EEG.
Four trials provided computerised tomography/magnetic reso-
nance imaging (CT/MRI), results for 438 participants (52%), (26
fromBanu 2007, 273 fromMattson 1985, 27 fromOgunrin 2005
and 112 fromPlacencia 1993). In Banu 2007, 19% of participants
had an abnormal scan, in Mattson 1985 27% of participants had
an abnormal scan, in Ogunrin 2005 no participants had an ab-
normal scan and in Placencia 1993, 33% of participants had an
abnormal scan.
We did not obtain individual participant data (IPD), for six trials,
with a total of 317 participants, as suitable seizure data for the
outcomes examined in this review were not recorded (Chen 1996;
Mitchell 1987), the trial authors no longer had a copy of the data
(Cereghino 1974), or trial authors did not respond to our data
requests (Bidabadi 2009; Cossu 1984; Czapinski 1997). A further
trial, which randomised 302 participants (Feksi 1991), provided
access to an IPD dataset, but this was not the final dataset used for
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the analysis published by the original authors. The pharmaceu-
tical company that sponsored the trial, Ciba-Geigy, who at that
time held the product license for carbamazepine, held the final
dataset. Since the trial was undertaken, there have been a num-
ber of mergers and restructures within the industry, and the cur-
rent owners of the data are Novartis. Unfortunately, Novartis were
unable to locate the data for this trial. The dataset that we had
for this trial contained a number of problems and inconsistencies,
and we therefore decided not to include this trial in the meta-
analysis. None of these seven trials reported the specific time-to-
event outcomes chosen for this review, and we could not extract
sufficient aggregate data from the trial publications in any other
trial. Therefore, we could not include them in data synthesis. Table
2 contains full details of outcomes considered and summaries of
results in each eligible trial for which IPD were not available.
Excluded studies
We excluded five trials that were not randomised controlled trials
(RCTs), (Bird 1966; Castro-Gago 1998; Hansen 1980; Kuzuya
1993; Sabers 1995), and we excluded two trials that did not use
carbamazepine and phenobarbitone monotherapy (Marjerrison
1968; Meador 1990). See the ’Characteristics of excluded studies’
tables for further details.
Risk of bias in included studies
For further details, see the ’Characteristics of included studies’
tables, Figure 2, and Figure 3.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each ’Risk of bias’ item presented as
percentages across all included trials
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included trial
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Allocation
Trials for which we received IPD
Three trials reported adequate methods of randomisation and al-
location concealment and we judged all three to be at low risk of
bias: two trials used permuted blocks to generate a random list and
concealed allocation by using sealed opaque envelopes (de Silva
1996; Heller 1995); and one trial used number tables to generate a
random list and concealed allocation by allocating the randomised
drug on a different site to where participants were randomised
(Ogunrin 2005). One trial reported only that participants were
randomised with stratification for seizure type (Mattson 1985); no
further information was provided in the trial publication or from
the authors regarding the methods of generation of the random
list and concealment of allocation and we judged this trial at un-
clear risk of bias. For two trials, neither the trial publication nor
the authors provided the method of generation of the random list
(Banu 2007; Placencia 1993), therefore these trials were judged to
be at unclear risk of bias from random sequence generation. One
of these trials reported that allocation was concealed using sealed
envelopes prepared on a different site to recruitment of partici-
pants (Banu 2007, low risk of bias), and the other trial reported
that allocation was concealed by sealed opaque envelopes, but this
method was not used for all participants in the trial, therefore we
judged this trial to be at high risk of bias for allocation conceal-
ment (Placencia 1993). This inadequate allocation concealment
may have resulted in selection bias in this trial, so we performed
sensitivity analyses for all outcomes excluding participants from
this trial (see Sensitivity analysis and Effects of interventions).
Trials for which no IPD were available
Two trials reported adequate methods of randomisation (low risk
of selection bias): random number tables (Cereghino 1974); and
simple randomisation of block size three (Chen 1996), but they
provided no details on concealment of allocation.
Three trials (Bidabadi 2009; Cossu 1984; Czapinski 1997) re-
ported that the participants were ’randomised’ or ’randomly allo-
cated’, etc. but did not provide information about the method of
generation of the random list or allocation concealment (unclear
risk of selection bias).
One trial ((Feksi 1991) reported that it concealed allocation by
the use of sealed opaque envelopes (low risk of bias) but did not
report the method of generation of the random list (unclear risk of
bias), and one trial reported that it “randomised [children] using
a scheme that balanced drug distribution by age and sex” but did
not provide further details about the method of generation of the
random list (Mitchell 1987). This trial also did not report any
details on allocation concealment, and the trial used some non-
randomised children in some analyses (see Other potential sources
of bias).
Blinding
Trials for which we received IPD
One trial (Mattson 1985) double-blinded participants and per-
sonnel using an additional blank tablet (low risk of bias) ; however,
it was unclear if this trial blinded the outcome assessor (unclear
risk of bias). One trial blinded participants and the outcome as-
sessors who performed cognitive testing but did not blind a re-
search assistant recruiting participants and providing counselling
on medication adherence (Ogunrin 2005). Similarly, another trial
blinded participants and a psychologist and therapist throughout
the trial, while not blinding the treating physician for practical
and ethical reasons (Banu 2007). We judged that the open-label
elements of these two trials were unlikely to have influenced the
results of these trials. However, the latter trial blinded a researcher
throughout the trial duration, but unblinded the researcher for
analysis, which may have impacted upon results.
One trial, Placencia 1993, did not report any information on
blinding in the trial publication, and no information was available
from the trial authors (unclear risk of bias). Two trials were un-
blinded for “practical and ethical reasons” (de Silva 1996; Heller
1995); however, it is likely that the unblinded design of de Silva
1996 contributed to the early withdrawal of the phenobarbitone
arm, which is likely to have had an effect on the overall results
of the trial. Further, as the two trials were conducted under the
same protocol, the open design may have also contributed to the
withdrawal rates in Heller 1995 and influenced the overall results;
we judged both trials at high risk of performance and detection
bias.
Trials for which no IPD were available
One trial was described as double-blind (Cossu 1984), but it was
unclear exactly whowas blinded (participants, personnel, outcome
assessors). One paediatric trial blinded participants (and parents),
and psychometric testers but unblinded clinicians for follow-up
(Mitchell 1987). One trial described that cognitive testers were
single-blinded, Chen 1996, but gave no further details on blinding
of participants and personnel.
The remaining four trials did not provide any information on
masking of participants, personnel, or outcome assessors; we
judged them tobe at unclear risk of performance anddetectionbias
(Bidabadi 2009; Cereghino 1974; Czapinski 1997; Feksi 1991).
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Incomplete outcome data
Trials for which we received IPD
In theory, a review using IPD should overcome issues of attrition
bias as unpublished data can be provided, unpublished outcomes
calculated, and all randomised participants can be analysed by
an intention-to-treat approach. All six trials provided IPD for all
randomised individuals and reported the extent of follow-up for
each individual; we judged all six trials to be at low risk of attrition
bias (Banu 2007; de Silva 1996; Heller 1995; Mattson 1985;
Ogunrin 2005; Placencia 1993).We queried anymissing datawith
the original trial authors. From the information provided by the
trial authors, we deemed the small amount of missing data present
(included trials), to be missing at random and not affecting our
analysis.
Trials for which no IPD were available
Two trials reported attrition rates and analysed all randomised
participants using an intention-to-treat approach so were judged
to be at low risk of bias (Cossu 1984; Mitchell 1987). Two tri-
als reported attrition rates, but it was unclear if they analysed all
participants (Cereghino 1974; Czapinski 1997), and one trial did
not report attrition rates, and it was unclear if it analysed all par-
ticipants (Bidabadi 2009). These three trials were judged to be at
unclear risk of attrition bias.
Two trials included only those who completed the trial in the final
analysis (Chen 1996; Feksi 1991), excluding 6% and 17.5% of
participants, respectively, from the final results. This approach is
not intention-to-treat, so we deemed these two trials to be at a
high risk of attrition bias.
Selective reporting
We requested trial protocols in all IPD requests; however, pro-
tocols were not available for any of the 13 included trials, so we
made a judgement of the risk of bias based on the information
included in the publications or from the IPD we received (see the
’Characteristics of included studies’ tables for more information).
Trials for which we received IPD
In theory, a review using IPD should overcome issues of report-
ing biases as unpublished data can be provided and unpublished
outcomes calculated so all trials providing IPD were judged to be
at low risk of reporting bias. We received sufficient IPD to cal-
culate the four outcomes (’time to treatment failure’, ’time to six-
month remission, ’time to 12-month remission’, and ’time to first
seizure’), for four of the six trials (de Silva 1996; Heller 1995;
Mattson 1985; Placencia 1993). The trial duration of Ogunrin
2005 was 12 weeks, and all randomised participants completed
the trial; therefore, we could only calculate ’time to first seizure’
for this trial. Banu 2007 did not record the dates of all seizures
after randomisation and dates of treatment failure for allocated
treatment for all participants; therefore, we could only calculate
’time to first seizure’ for this trial.
Trials for which no IPD were available
Four trials reported either cognitive outcomes, seizure outcomes,
adverse events, or a combination of these and were judged to be
at low risk of reporting bias (Chen 1996; Cereghino 1974; Feksi
1991;Mitchell 1987).One trial reported cognitive outcomes only,
but no adverse events or seizure outcomes (Cossu 1984); however,
as noprotocolswere available for this trial, we donot knowwhether
either seizure outcomes, recording of adverse events, or both, were
planned a priori (unclear risk of reporting bias). Two trials were
in abstract form only (Bidabadi 2009; Czapinski 1997) and did
not provide sufficient information to assess selective reporting bias
(unclear risk of reporting bias).
Other potential sources of bias
We detected another source of bias in six of the 13 included trials
as described below (high risk of bias); the remaining seven trials
were judged to be at low risk of other bias.
Following consistency checks of IPD for Placencia 1993 and Banu
2007, we found some inconsistencies between the data provided
and the results in the publications in terms of treatment failure
and seizure recurrences, respectively, which the authors could not
resolve and we judged these trials to be at high risk of other bias.
We performed sensitivity analysis to investigate the impact of the
inconsistent data on our outcomes (see Sensitivity analysis and
Effects of interventions). Furthermore, we received IPD for a sev-
enth trial (Feksi 1991), but too many inconsistencies were present
for this data to be usable (see Included studies for further details).
One trial had a cross-over design (Cereghino 1974); such a de-
sign is unlikely to be appropriate for monotherapy treatment be-
cause of carryover effects from one treatment period into another
(participants were also treated during washout periods with their
’regular medication’), and such a design does not allow long-term
outcomes, such as the time-to-event outcomes of interest in this
review. For future updates of this review, we will exclude trials of
a cross-over design.
We included one trial with very small participant numbers (six
participants randomised to each drug), and very short-term fol-
low-up (three weeks), and it was unclear if this trial was adequately
powered and of sufficient duration to detect differences (Cossu
1984). For future updates of this review, we will review our inclu-
sion criteria in terms of participant numbers and trial duration.
Another trial had several potential sources of other bias (Mitchell
1987); there was evidence that the trial may have been under-
powered to detect differences between the treatments, one of the
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tools for outcome assessment was not fully validated, and non-
randomised children from a related pilot trial were included in
analysis for some of the outcomes.
Effects of interventions
See: Summary of findings for the main comparison
Carbamazepine compared with phenobarbitone for epilepsy (time
to treatment failure); Summary of findings 2 Carbamazepine
compared with phenobarbitone for epilepsy (secondary outcomes)
We have provided a summary of the outcomes reported in trials
for which no IPD were available in Table 2.
See Table 3 for details regarding the number of individuals con-
tributing IPD to each analysis, Summary of findings for the main
comparison for a summary of the results for the primary outcome
’time to treatment failure’ (stratified by seizure type), andSummary
of findings 2 for a summary of results for the secondary outcomes
’time to first seizure’ and ’time to 12-month remission’. Survival
curve plots are shown in Figure 4; Figure 5; Figure 6; Figure 7;
Figure 8; Figure 9; Figure 10; Figure 11; Figure 12; Figure 13;
Figure 14 and Figure 15. We used Stata software version 14 to
produce all survival curve plots using data from all trials providing
IPD combined (Stata 2015).
Figure 4. Time to treatment failure - any reason related to the treatment (CBZ: carbamazepine; PB:
phenobarbitone)
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Figure 5. Time to treatment failure - any reason related to the treatment, by seizure type (CBZ:
carbamazepine; PB: phenobarbitone)
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Figure 6. Time to treatment failure due to adverse events (CBZ: carbamazepine; PB: phenobarbitone)
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Figure 7. Time to treatment failure due to adverse events, by seizure type (CBZ: carbamazepine; PB:
phenobarbitone)
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Figure 8. Time to treatment failure due to lack of efficacy (CBZ: carbamazepine; PB: phenobarbitone)
23Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 9. Time to treatment failure due to lack of efficacy, by seizure type (CBZ: carbamazepine; PB:
phenobarbitone)
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Figure 10. Time to first seizure post randomisation (CBZ: carbamazepine; PB: phenobarbitone)
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Figure 11. Time to first seizure post randomisation - by seizure type (CBZ: carbamazepine; PB:
phenobarbitone)
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Figure 12. Time to 12-month remission (CBZ: carbamazepine; PB: phenobarbitone)
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Figure 13. Time to 12-month remission - by seizure type (CBZ: carbamazepine; PB: phenobarbitone)
28Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 14. Time to six-month remission (CBZ: carbamazepine; PB: phenobarbitone)
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Figure 15. Time to six-month remission - by seizure type (CBZ: carbamazepine; PB: phenobarbitone)
We note that participants with event times of zero (i.e. those who
experienced treatment failure or experienced seizure recurrence on
the day of randomisation), are not included in the ’Numbers at
risk’ on the graphs and that data are not stratified by trial within
these survival curve plots. All figures are intended to provide a
visual representation of outcomes, extent of follow-up and visual
differences between seizure types. These graphs are not intended to
show statistical significance and numerical values may vary com-
pared to the text due to differences in methodology.
We calculated all hazard ratios (HRs), presented below by generic
inverse variance meta-analysis. All analyses met the assumption of
proportional hazards (addition of time-varying covariate into the
model non-significant), unless otherwise stated.
Primary outcome
Time to treatment failure (retention time)
For this outcome, a HR less than one indicates a clinical advantage
for carbamazepine.
Times to treatment failure and reasons for treatment failure were
available for 676 participants from four of the six trials providing
IPD (97.8% of 691 participants from de Silva 1996, Heller 1995,
Mattson 1985, and Placencia 1993 (see Included studies andTable
3), and 46.4% of the total 1455 participants from the 13 included
trials). See Table 4 for reasons for premature discontinuation of
treatment (treatment failure), by treatment and how we classified
these reasons in analysis.
Mattson 1985 did not record follow-up data for one participant
randomised to carbamazepine. de Silva 1996 did not record the
randomised drug for six participants, and the reason for treatment
failure was not available for one participant randomised to carba-
mazepine and could not be determined from the case notes. Sim-
ilarly, in Heller 1995, for one participant randomised to carba-
mazepine and three participants randomised to phenobarbitone
and in Placencia 1993, for one participant randomised to carba-
mazepine and two participants randomised to phenobarbitone,
the reason for treatment failure was not available and could not
be determined from the case notes. We did not include these 15
participants with missing outcome data in the analysis of ’time
to treatment failure.’ All participants completed the 12-week trial
in Ogunrin 2005 and so could not contribute to the analysis of
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’time to treatment failure.’ From the IPD provided by Banu 2007,
we were able to establish reasons for treatment failure for all par-
ticipants (see Table 4), but the date of treatment failure was not
available for all participants (see Data extraction and management
for further details); therefore, we could not calculate the ’time to
treatment failure’ for this trial.
Out of the 784 participants for whom we had reasons for treat-
ment failure or withdrawal (Banu 2007; de Silva 1996; Heller
1995; Mattson 1985; Placencia 1993), 415 participants prema-
turely withdrew from treatment (53% of total participants): 216
out of 415 participants randomised to carbamazepine (52%), and
199 out of 369 participants randomised to phenobarbitone (54%)
We deemed 257 participants (62% of total treatment failures), to
have withdrawn for reasons related to the trial drug, 126 (58%), on
carbamazepine and131 (66%), onphenobarbitone, andwe classed
these reasons as ’events’ in analysis. The most common treatment-
related reason for treatment failure was a combination of adverse
events and lack of efficacy: 94 withdrawals (23% of total treatment
failures), 41 (19% of total treatment failures), on carbamazepine
and53 (27%of total treatment failures), onphenobarbitone.Non-
compliance with treatment or patient choice was the treatment-
related reason in 14% of total treatment failures, lack of efficacy
in 13% of total treatment failures and adverse events in 12% of
total treatment failures.
We classed the other 158 reasons (90 on carbamazepine and 68 on
phenobarbitone), which were mostly losses to follow-up (57% of
other withdrawals), to be not related to the treatment and censored
these participants in the analysis, in addition to the 369 partici-
pants (199 on carbamazepine and 170 on phenobarbitone), who
completed the trial without withdrawing or failing treatment.
Considering time to treatment failure for any reason related to the
treatment, the overall pooled HR (for 676 participants), was 0.66
(95% confidence interval (CI), 0.51 to 0.86; P = 0.002; fixed-
effect meta-analysis; Analysis 1.1), indicating a statistically signifi-
cant advantage for carbamazepine; in other words, treatment fail-
ure occurred significantly earlier on phenobarbitone than carba-
mazepine in the four included trials.
There was a considerable amount of statistical heterogeneity be-
tween trials (I² = 58%, see Analysis 1.1). When we repeated the
analysis using random-effects meta-analysis, the pooled HR was
0.66 (95%CI 0.42 to 1.04; P = 0.08), still indicating an advantage
for carbamazepine, but this advantage was no longer statistically
significant. We have investigated the heterogeneity present within
the analysis in subgroup and sensitivity analyses described below.
Considering time to treatment failure due to adverse events (all
other reasons for treatment failure or treatment withdrawal cen-
sored in analysis), the overall pooled HR (for 676 participants),
was 0.67 (95% CI 0.48 to 0.93; P = 0.02; fixed-effect meta-analy-
sis; Analysis 1.2), indicating a statistically significant advantage for
carbamazepine; in other words, treatment failure due to adverse
events occurred significantly earlier on phenobarbitone than car-
bamazepine in the four included trials. However, again a moderate
amount of heterogeneity was present in analysis (I² = 57%, see
Analysis 1.2), and when we repeated the analysis with random-
effects meta-analysis, the pooled HR was 0.59 (95% CI 0.32 to
1.09, P = 0.09), still indicating an advantage for carbamazepine,
but this advantage was no longer statistically significant.
Considering time to treatment failure due to lack of efficacy (all
other reasons for treatment failure or treatment withdrawal cen-
sored in analysis), 487 participants provided IPD from three tri-
als; no participants withdrew due to lack of efficacy in one of the
trials (Placencia 1993, see Table 4). The overall pooled HR was
0.54 (95% CI 0.38 to 0.77; P = 0.0007; fixed-effect meta-anal-
ysis; Analysis 1.3), indicating a statistically significant advantage
for carbamazepine; in other words, treatment failure due to lack
of efficacy occurred significantly earlier on phenobarbitone than
carbamazepine in the three included trials. There was no evidence
of statistical heterogeneity between trials (I² = 0%).
Subgroup analyses: seizure type (focal versus generalised
onset)
Considering time to treatment failure for any reason related to the
treatment, for participants with focal onset seizures (520 partic-
ipants from four trials), the pooled HR was 0.66 (95% CI 0.49
to 0.88, P = 0.005; low-quality evidence, fixed-effect meta-anal-
ysis; Analysis 1.4), indicating a statistically significant advantage
for carbamazepine, but a large amount of statistical heterogene-
ity was present between trials (I² = 66%). When we repeated the
analysis using random-effects meta-analysis, the pooled HR for
participants with focal onset seizures was 0.63 (95% CI 0.32 to
1.22, P = 0.17), still indicating an advantage for carbamazepine,
but this advantage was no longer statistically significant. For par-
ticipants with generalised onset seizures (156 participants from
three trials), the pooled HR was 0.65 (95% CI 0.35 to 1.23, P
= 0.19; low-quality evidence, fixed-effect meta-analysis; Analysis
1.4), suggesting an advantage for carbamazepine that was not sta-
tistically significant. There was no evidence of statistical hetero-
geneity between trials (I² = 0%).
The test for subgroup differences between focal and generalised
onset seizures was not statistically significant (P = 0.99, I² = 0% for
variability due to subgroup differences; Analysis 1.4). The overall
pooledHR (adjusted by seizure type for 676 participants from four
trials), was 0.66 (95% CI 0.50 to 0.86; P = 0.002; moderate-qual-
ity evidence; fixed-effect meta-analysis; Analysis 1.4), indicating
a statistically significant advantage for carbamazepine. Numerical
results in this analysis adjusted for seizure type are very similar to
the unadjusted analysis (Analysis 1.1), and heterogeneity present
within analysis is reduced within the adjusted analysis (I² = 35%
in Analysis 1.4 compared to I² = 58% in Analysis 1.1).
Considering time to treatment failure due to adverse events, 619
participants provided IPD from four trials; no participants in the
carbamazepine group with generalised onset seizures withdrew
due to adverse events in one of the trials (Placencia 1993), so we
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could not calculate a hazard ratio. For participants with focal onset
seizures (520 participants from four trials), the pooled HR was
0.67 (95% CI 0.46 to 0.96, P = 0.03; low-quality evidence; fixed-
effect meta-analysis; Analysis 1.5), indicating a statistically signifi-
cant advantage for carbamazepine, but a large amount of statistical
heterogeneity was present between trials (I² = 70%). When we re-
peated the analysis using random-effects meta-analysis, the pooled
HR for participants with focal onset seizures was 0.53 (95% CI
0.20 to 1.44, P = 0.21), still indicating an advantage for carba-
mazepine, but this advantage was no longer statistically signifi-
cant. For participants with generalised onset seizures (99 partic-
ipants from two trials), the pooled HR was 0.84 (95% CI 0.35
to 2.00, P = 0.69; low-quality evidence; fixed-effect meta-analysis;
Analysis 1.5), suggesting an advantage for carbamazepine that was
not statistically significant. There was no evidence of statistical
heterogeneity between trials in the subgroup of participants with
generalised onset seizures (I² = 0%).
The test for subgroup differences between focal and generalised
onset seizures was not statistically significant (P = 0.64, I² = 0% for
variability due to subgroup differences; Analysis 1.5). The overall
pooled HR (adjusted by seizure type for 619 participants from
four trials), was 0.69 (95% CI 0.49 to 0.97; P = 0.03; low-qual-
ity evidence; fixed-effect meta-analysis; Analysis 1.5), indicating
a statistically significant advantage for carbamazepine. Numerical
results in this analysis adjusted for seizure type are very similar to
the unadjusted analysis (Analysis 1.2), but a similar amount of
heterogeneity is present within this adjusted analysis (I² = 55%).
When we repeated the analysis using random-effects meta-analy-
sis, the pooled HR for participants with focal onset seizures was
0.60 (95%CI 0.31 to 1.17, P = 0.14), still indicating an advantage
for carbamazepine, but this advantage was no longer statistically
significant.
Considering time to treatment failure due to lack of efficacy,
for participants with focal onset seizures (388 participants from
three trials), the pooled HR was 0.54 (95% CI 0.36 to 0.80,
P = 0.002; moderate-quality evidence; fixed-effect meta-analysis;
Analysis 1.6), indicating a statistically significant advantage for
carbamazepine. There was no evidence of statistical heterogene-
ity between trials in the subgroup of participants with focal onset
seizures (I² = 0%). For participants with generalised onset seizures
(99 participants from two trials), the pooled HR was 0.56 (95%
CI 0.23 to 1.35, P = 0.20; low-quality evidence; fixed-effect meta-
analysis; Analysis 1.6), suggesting an advantage for carbamazepine
that was not statistically significant. There was no evidence of sta-
tistical heterogeneity between trials in the subgroup of participants
with generalised onset seizures (I² = 0%).
The test for subgroup differences between focal and generalised
onset seizures was not statistically significant (P = 0.94, I² = 0% for
variability due to subgroup differences; Analysis 1.6). The overall
pooled HR (adjusted by seizure type for 487 participants from
three trials), was 0.54 (95% CI 0.38 to 0.78; P = 0.0008; mod-
erate-quality evidence; fixed-effect meta-analysis; Analysis 1.6),
indicating a statistically significant advantage for carbamazepine.
Numerical results in this analysis adjusted for seizure type are very
similar to the unadjusted analysis (Analysis 1.3), and there was no
evidence of statistical heterogeneity between trials in this adjusted
analysis (I² = 0%).
Sensitivity analysis
Weusedfixed-effectmeta-analysis to performed all sensitivity anal-
yses.
We performed sensitivity analysis excluding participants from
Placencia 1993 from the analysis of time to treatment failure for
any reason related to treatment because of high risk of selection
bias due to inadequate allocation concealment (see Allocation
(selection bias) and Table 5). This sensitivity analysis resulted in a
slightly larger advantage for carbamazepine with a pooled HR of
0.59 (95% CI 0.44 to 0.79, P = 0.0003, adjusted for seizure type;
fixed-effect meta-analysis), and reduced heterogeneity (I² = 6%),
compared to the original analysis (see Table 5), but no change to
conclusions.
We also performed sensitivity analysis excluding Placencia 1993
from time to treatment failure due to adverse events; results were
very similar to the Analysis 1.5, heterogeneity was still present in
analysis and conclusions unchanged (result unchanged for indi-
viduals with generalised seizures (no participants with generalised
seizures withdrew from carbamazepine due to adverse events in
Placencia 1993), for individuals with focal onset seizures, pooled
HR 0.63, (95% CI 0.43, 0.91; P = 0.01; I² = 73%), and overall
pooled HR adjusted for seizure type, 0.65 (95% CI 0.46 to 0.92;
P = 0.02, I² = 55%). No participants withdrew from Placencia
1993 due to lack of efficacy so we did not perform any sensitivity
analysis excluding Placencia 1993 for time to treatment failure due
to adverse events.
Further, in Placencia 1993, we also found inconsistencies (between
IPD dataset and published results), in the number of participants
who failed treatment or withdrew from treatment for certain rea-
sons, which the trial authors could not resolve. These inconsisten-
cies were as follows.
• Results from the IPD dataset: treatment failed in 51
participants, 31 from carbamazepine and 20 from
phenobarbitone: 16 participants left the area (lost to follow-up),
10 failed due to adverse effects, 22 withdrew from treatment for
personal reasons or no stated reason (classed as an event), and
three died (cause of death not related to treatment, censored in
analysis). See Table 4 for further details.
• Results in the trial report: 53 participants failed treatment,
31 from carbamazepine and 22 from phenobarbitone: 18
participants left the area (lost to follow-up), five failed because of
adverse effects, three died, and 27 withdrew from treatment for
personal reasons or no stated reason.
As the overall number of events and censored observations was
similar (results from the IPD dataset: 51 withdrew, 32 events, 19
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censored; and results in the trial report: 53 withdrew, 32 events,
21 censored), and as our sensitivity analysis excluding results of
Placencia 1993 gave similar results and an unchanged conclusion,
we felt that these inconsistencies were minor and were unlikely to
have had a large impact on the overall results.
In the primary analysis of Placencia 1993, we classed those who
withdrew for ’no clearly articulated reason’ as events in the analy-
sis; in other words, the treatment failure was due to the trial drug.
However, it is also possible that these participants may have with-
drawn for reasons not related to the trial drug, and we therefore
should have censored them in the analysis. We performed a further
sensitivity analysis censoring the 19 participants who withdrew for
’no clearly articulated reason’. Again, the results of the sensitivity
analysis were similar to the primary analysis, showing a statistically
significant advantage for carbamazepine (pooled HR 0.61, 95%
CI 0.46 to 0.81, P = 0.0006, adjusted for seizure type; fixed-effect
meta-analysis), and again, heterogeneity was substantially reduced
after censoring these participants (I² = 6%). Heterogeneity was
also reduced in the subgroup with focal onset seizures, pooled HR
0.60 (95% CI 0.44 to 0.82, P = 0.001, I² = 38%), compared to
Analysis 1.4.
The sensitivity analysis of ’time to treatment failure for any rea-
son related to treatment’ including only the 20 participants ran-
domised in de Silva 1996 before the withdrawal of the phenobar-
bitone arm gave similar results with a pooled HR (adjusted for
seizure type for 633 participants), of 0.69 (95% CI 0.53 to 0.91, P
= 0.009), and heterogeneity between trials was reduced to I² = 0%
in this analysis. Results within each seizure group were also very
similar in this sensitivity analysis (see Table 5 for further details).
Results were also very similar for ’time to treatment failure due to
adverse events’ (pooled HR adjusted for seizure type, 0.56 (95%
CI 0.38 to 0.81); P = 0.002, I² = 0%; fixed-effect meta-analysis),
and conclusions unchanged, but for ’time to treatment failure due
to adverse events’, the clinical advantage for carbamazepine was
no longer statistically significant in this sensitivity analysis (pooled
HR adjusted for seizure type, 0.71 (95% CI 0.49 to 1.01); P =
0.06, I² = 12%; fixed-effect meta-analysis).
In the sensitivity analyses to investigate misclassification of seizure
type, following reclassification of the 46 participants aged 30 or
older in Heller 1995 and Placencia 1993 with new onset gener-
alised seizures reclassified to focal onset seizures or an uncertain
seizure type, results were very similar and conclusions were un-
changed (see Table 5).
Summary of results for the primary outcome
Results for the primary outcome ’time to treatment failure for any
reason related to treatment’, in addition to the outcomes ’time
to treatment failure due to adverse events’ and ’time to treatment
failure due to lack of efficacy’ suggest a statistically significant ad-
vantage to carbamazepine; in other words, treatment failure may
occur significantly earlier on phenobarbitone than carbamazepine.
A statistically significant advantage for carbamazepine is also ob-
served in the subgroupof participants experiencing new focal onset
seizures and a potential (non-statistically significant), advantage
for the smaller subgroup of individuals experiencing generalised
onset seizures (23% of total participants). There was no evidence
of any interaction between treatment and seizure type.
Inadequate allocation concealment in Placencia 1993 may have
influenced withdrawal rates if participants or personnel, or both,
were aware of which drug the participants had been assigned; from
the data we received, 19% of participants withdrew from the car-
bamazepine arm, and 15% of participants withdrew from the phe-
nobarbitone arm while the other three trials included in the anal-
ysis showed more participants withdrawing from the phenobarbi-
tone arm than the carbamazepine arm. Furthermore, inconsisten-
cies between published data and data provided to us and unclear
definitions for reason of treatment failure (participants withdrew
for ’no clearly articulated reason’), was likely to have influenced
the results of our analysis. These factors in the Placencia 1993 trial,
in addition to the continuation of the carbamazepine arm in de
Silva 1996 after the withdrawal of the phenobarbitone arm, are all
factors that are likely to have contributed to the heterogeneity in
Analysis 1.1 and Analysis 1.4. These factors may have confounded
the results of our primary analyses in this review.
Secondary outcomes
Time to first seizure post-randomisation
For this outcome, a HR less than one indicates a clinical advantage
for carbamazepine.
We had data for 822 participants from six trials (98.3% of 836
participants fromBanu 2007; de Silva 1996;Heller 1995;Mattson
1985;Ogunrin 2005 and Placencia 1993 (see Included studies and
Table 3)). de Silva 1996 did not record the randomised drug for
six participants, and dates of seizure recurrence were not available
for eight participants (4 randomised to carbamazepine and 4 to
phenobarbitone), in Mattson 1985; therefore, we did not include
these 14 participants in the analysis.
Four hundred and fifty-three out of 822 participants (55%), ex-
perienced seizure recurrence, 264 out of 434 (61%), on carba-
mazepine and 189 out of 388 (49%), on phenobarbitone. The
overall pooled HR (for 822 participants), was 1.15 (95% CI 0.95
to 1.40, P = 0.15; fixed-effect meta-analysis; Analysis 1.7), sug-
gesting a potential advantage for phenobarbitone (i.e. that first
seizure recurrence may occur later on phenobarbitone compared
to carbamazepine), that was not statistically significant. There was
no evidence of any important statistical heterogeneity between tri-
als (I² = 30%).
Subgroup analyses: seizure type (focal versus generalised
onset)
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For participants with focal onset seizures (584 participants from
six trials), the pooled HR of 1.31 (95% CI 1.04 to 1.66, P = 0.02;
moderate-quality evidence; fixed-effect meta-analysis; Analysis
1.8), suggested a statistically significant advantage for phenobar-
bitone; in other words that first seizure recurrence occurs later on
phenobarbitone compared to carbamazepine. There was no ev-
idence of statistical heterogeneity between trials for participants
with focal onset seizures (I² = 0%). For participants with gener-
alised onset seizures (238 participants from five trials), the pooled
HRwas 0.80 (95%CI0.55 to 1.15, P =0.22; low-quality evidence;
fixed-effect meta-analysis; Analysis 1.8), suggesting a potential ad-
vantage for carbamazepine that was not statistically significant. A
considerable amount of statistical heterogeneity was present be-
tween trials for participants with generalised onset seizures (I² =
54%). When we repeated the analysis with random-effects meta-
analysis, the pooled HR of 0.85 (95% CI 0.48 to 1.50, P = 0.58),
still showed an advantage for carbamazepine that was not statis-
tically significant. There was a statistically significant interaction
between treatment and seizure type (generalised versus focal onset;
test for subgroup differences: P = 0.02, I² = 80.2% variability due
to subgroup differences; Analysis 1.8, calculated with fixed-effect
meta-analysis). In other words, phenobarbitone may have an ad-
vantage over carbamazepine for individuals with focal seizures and
vice versa for individuals with generalised onset seizures.
Overall, the pooled HR (adjusted for seizure type for 822 partici-
pants, fixed-effect), was 1.13 (95%CI 0.93 to 1.38, P = 0.22;mod-
erate-quality evidence; fixed-effect meta-analysis; Analysis 1.8),
suggesting a potential advantage for phenobarbitone that was not
statistically significant. A moderate amount of heterogeneity was
present between trials (I² = 46%). When we repeated the analy-
sis with random-effects meta-analysis, the results were similar and
conclusions unchanged (pooledHR adjusted for seizure type 1.11,
95% CI 0.82 to 1.51, P = 0.22).
Sensitivity analysis
We used fixed-effect meta-analysis to perform all sensitivity anal-
yses.
We performed sensitivity analysis excluding participants from
Placencia 1993 from analysis because of high risk of selection
bias due to inadequate allocation concealment (see Allocation
(selection bias) and Table 5). This sensitivity analysis suggested in
a potential advantage for phenobarbitone which was not statisti-
cally significant; overall pooled HR of 1.10 (95% CI 0.89 to 1.37,
P = 0.38, adjusted for seizure type, fixed-effect meta-analysis), and
slightly reduced heterogeneity (I² = 39% reduced from I² = 46%
in Analysis 1.8; see Table 5). Results for individuals with focal
seizures also suggested a potential advantage for phenobarbitone
that was not statistically significant; pooled HR of 1.22 (95% CI
0.94 to 1.58, P = 0.13; fixed-effect meta-analysis); there was no
heterogeneity present in the original analysis (Analysis 1.8), or
within sensitivity analysis (I² = 0%). For individuals with gener-
alised onset seizures, the sensitivity analysis suggested a potential
advantage for carbamazepine, which was not statistically signifi-
cant; pooled HR of 0.86 (95% CI 0.57 to 1.28; P = 0.46; fixed-
effect meta-analysis), but a slight increase in heterogeneity (I² =
62% reduced from I² = 54% in Analysis 1.8; see Table 5). Fol-
lowing sensitivity analysis, there was no significant evidence of an
interaction between treatment and seizure type (test for subgroup
differences: P = 0.15, I² = 52% variability due to subgroup differ-
ences)
In Banu 2007, we found inconsistencies (between the IPD dataset
and published results), which the trial authors could not resolve;
the publication reported that only seven participants not had expe-
rienced any seizures from the start of treatment (three participants
randomised to phenobarbitone and four randomised to carba-
mazepine); however, from IPD provided, 21 participants did not
experience any seizures from the start of treatment (12 randomised
tophenobarbitone andnine randomised to carbamazepine).Given
these inconsistencies and the limited data available on seizure re-
currence, we performed sensitivity analysis excluding the partici-
pants from Banu 2007 from Analysis 1.8. This sensitivity analysis
resulted in a pooled HR of 1.20 (95% CI 0.97 to 1.48, P = 0.31;
adjusted for seizure type; fixed-effect meta-analysis), suggesting a
slightly larger advantage to phenobarbitone, which was still not
statistically significant. There was also a slight increase in hetero-
geneity (I² = 52% reduced from I² = 46% in Analysis 1.8). For
individuals with focal onset seizures, following sensitivity analy-
sis, results were numerically similar and conclusions unchanged
(pooled HR 1.38, 95% CI 1.08 to 1.78; P = 0.01; I² = 0%).
For individuals with generalised seizures, the sensitivity analysis
resulted in similar numerical results and unchanged conclusions
(pooled HR 0.81, 95% CI 0.54 to 1.22; P = 0.31), but again
slightly increased heterogeneity (I² = 65% reduced from I² = 54%
in Analysis 1.8). There was a statistically significant interaction
between treatment and seizure type (generalised versus focal on-
set), in this sensitivity analysis (test for subgroup differences: P =
0.03, I² = 78.9% variability due to subgroup differences).
The sensitivity analysis including only the 20 participants ran-
domised in de Silva 1996 before the withdrawal of the pheno-
barbitone arm gave very similar numerical results and no change
to conclusions or the amount of heterogeneity present in analysis
overall in both seizure type subgroups for individuals with focal
onset seizures (see Table 5 for further details). There was a statis-
tically significant interaction between treatment and seizure type
(generalised versus focal onset), in this sensitivity analysis (test for
subgroup differences: P = 0.04, I² = 76.1% variability due to sub-
group differences).
In the sensitivity analyses to investigate misclassification of seizure
type, following reclassification of the 65 participants aged 30 or
older with new onset generalised seizures inHeller 1995, Ogunrin
2005 and Placencia 1993 to focal onset seizures or an uncertain
seizure type, in both sensitivity analyses, heterogeneity within the
subgroup of individuals with generalised seizures is reduced to I²
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= 0% (compared to I² = 54% in Analysis 1.8, see Table 5). From
visual inspection of forest plots in Analysis 1.8, it was clear that
Ogunrin 2005 appears to be the main source of the heterogene-
ity between trials in the subgroup of participants with generalised
onset seizures. The other four trials showed moderate, non-signif-
icant advantages to carbamazepine, while Ogunrin 2005 showed
a large, significant effect size in favour of phenobarbitone. This
effect was not observed in the subgroup of participants with focal
onset seizures in Ogunrin 2005. Following reclassification of 19
participants aged 30 or older with new onset generalised seizures
in Ogunrin 2005 to an uncertain seizure type, a large, but impre-
cise effect towards phenobarbitone is also shown (Analysis 1.9),
therefore it appears to be these participants introducing incon-
sistency into Analysis 1.8. Within the remaining 11 participants
classified as experiencing new onset seizures (over the age of 30
at seizure onset), no participants on phenobarbitone experienced
first seizure recurrence, therefore we could not calculate a hazard
ratio for this reclassified subgroup (see Analysis 1.9). For both of
the analyses reclassifying seizure type, there was statistically sig-
nificant evidence of an interaction between treatment and seizure
type (test for subgroup differences: P = 0.01, I² = 83.9% variabil-
ity due to subgroup differences for generalised onset and over the
age of 30 at onset reclassified to focal onset, and test for subgroup
differences: P = 0.03, I² = 71.6% variability due to subgroup dif-
ferences for generalised onset and over the age of 30 at onset reclas-
sified to uncertain seizure type); in other words phenobarbitone
may have an advantage over carbamazepine for individuals with
focal seizures and vice versa for individuals with generalised onset
seizures.
Summary of results for time to first seizure post-
randomisation
Overall, the results for secondary outcome ’time to first seizure
post-randomisation’ suggest that there may be a difference in effi-
cacy of the drugs (in terms of time to first seizure recurrence after
randomisation), by seizure type. That is, that participants with
generalised seizures experience seizure recurrence later on carba-
mazepine than phenobarbitone, and that participants with focal
onset seizures experience seizure recurrence later on phenobarbi-
tone than carbamazepine. The overall trend towards a slight po-
tential advantage for phenobarbitone for all included participants
probably reflects that the majority of participants included in this
analysis had focal onset seizures (71% of 822 included partici-
pants). However, heterogeneity was present within some analy-
ses, and results were robust to all sensitivity analyses. It was possi-
ble that inconsistencies in data provided to us (Banu 2007), and
misclassification of seizure type in participants over the age of 30
(Heller 1995; Ogunrin 2005; Placencia 1993), inadequate alloca-
tion concealment in the Placencia 1993 trial, in addition to the
continuation of the carbamazepine arm in de Silva 1996 after the
withdrawal of the phenobarbitone arm may have confounded the
results of this analysis.However, within some sensitivity analyses to
take account of these confounding factors, particularly within the
sensitivity analyses to take account of misclassification of seizure
type, heterogeneity was greatly reduced and the association be-
tween treatment and seizure type still existed and therefore could
be a true association.
Time to achieve 12-month remission
For this outcome, a HR less than one indicates a clinical advantage
for phenobarbitone.
Data for 683 participants from four trials were available for anal-
yses of time to 12-month remission and time to six-month re-
mission (98.8% of 691 participants from de Silva 1996; Heller
1995;Mattson 1985 and Placencia 1993 (see Included studies and
Table 3), and 46.9% of the total 1455 participants from the 13
included trials). Mattson 1985 recorded no follow-up data for one
participant randomised to carbamazepine. de Silva 1996 did not
record the randomised drug for six participants, and in Placencia
1993, seizure data after occurrence of first seizure were not avail-
able for one participant randomised to phenobarbitone, so we did
not include this participant in the analyses. The trial duration
of Ogunrin 2005 was 12 weeks, so 12-month remission was not
possible among participants in this trial. Banu 2007 recorded the
date of first seizure after randomisation, but all dates of subsequent
seizures were not available; therefore, we could calculate ’time to
first seizure’ but not ’time to six-month remission’ and ’time to 12-
month remission’.
Two hundred and eighty out of 683 participants (41%), achieved
12-month remission; 163 out of 384 (45%), on carbamazepine
and 117 out of 319 (37%), on phenobarbitone. The overall pooled
HR (for 683 participants), was 1.09 (95% CI 0.85 to 1.40, P
= 0.51; fixed-effect meta-analysis; Analysis 1.10), suggesting no
clear advantage for either drug. There was no evidence of statistical
heterogeneity between trials (I² = 0%).
Subgroup analyses: seizure type (focal versus generalised
onset)
For participants with focal onset seizures (525 participants from
four trials), the pooled HR was 0.92 (95% CI 0.67 to 1.25, P
= 0.59; low-quality evidence; fixed-effect meta-analysis; Analysis
1.11), suggesting no clear advantage for either drug. A consider-
able amount of statistical heterogeneity was present between trials
for participants with focal onset seizures (I² = 67%). When we re-
peated the analysis with random-effects, the pooled HR was 1.24
(95% CI 0.69 to 2.22, P = 0.49), suggesting a potential advantage
to phenobarbitone that was not statistically significant; in other
words, six-month remission may occur earlier on phenobarbitone
that carbamazepine but confidence intervals are wide so we cannot
rule out an advantage to carbamazepine or no differences between
the drugs. For participants with generalised onset seizures (158
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participants from three trials), the pooled HR was 1.56 (95% CI
0.99 to 2.44, P = 0.05; low-quality evidence; fixed-effect meta-
analysis; Analysis 1.11), suggesting a borderline statistically sig-
nificant advantage for carbamazepine. There was no evidence of
statistical heterogeneity between trials for participants with gen-
eralised seizures (I² = 0%). There was potential evidence of an
interaction between treatment and seizure type (generalised onset
versus focal onset), (test for subgroup differences: P = 0.06, I² =
72.2% variability due to subgroup differences, see Analysis 1.11,
calculated with fixed-effect meta-analysis).
Overall, the pooled HR (adjusted for seizure type for 683 partic-
ipants), was 1.09 (95% CI 0.84 to 1.40, P = 0.52; low-quality
evidence; fixed-effect meta-analysis; Analysis 1.11), suggesting no
clear overall advantage for either drug, but a considerable amount
of heterogeneity was present between trials (I² = 51%). When we
repeated the analysis with random-effects, results were similar and
conclusions unchanged (pooled HR 1.06 (95% CI 0.72 to 1.57,
P = 0.77).
Sensitivity analysis
We used fixed-effect meta-analysis to perform all sensitivity anal-
yses.
We performed sensitivity analysis excluding participants from
Placencia 1993 from the analysis of ’time to treatment failure for
any reason related to treatment’ because of high risk of selec-
tion bias due to inadequate allocation concealment (see Allocation
(selection bias) and Table 5). This sensitivity analysis suggested a
potential advantage for carbamazepine, which was not statistically
significant; overall pooled HR of 1.22 (95% CI 0.91 to 1.63, P
= 0.18, adjusted for seizure type, fixed-effects meta-analysis), and
greatly reduced heterogeneity (I² = 0% reduced from I² = 51%
in Analysis 1.11; see Table 5). Results for individuals with focal
seizures also suggested a potential advantage for carbamazepine,
which was not statistically significant; pooled HR of 1.14 (95%
CI 0.80 to 1.62, P = 0.47; fixed-effect meta-analysis), and greatly
reduced heterogeneity (I² = 0% reduced from I² = 63% in Analysis
1.11; see Table 5). For individuals with generalised onset seizures,
therewas noheterogeneity present in the original analysis (Analysis
1.11), or within sensitivity analysis (I² = 0%). The sensitivity anal-
ysis suggested a potential advantage for carbamazepine, which was
not statistically significant; pooled HR of 1.41 (95% CI 0.84 to
2.37; P = 0.19; fixed-effect meta-analysis). Following sensitivity
analysis, there was no evidence of an interaction between treat-
ment and seizure type (test for subgroup differences: P = 0.50, I²
= 0% variability due to subgroup differences)
Also, within Placencia 1993, there was evidence that the propor-
tional hazards assumption of the Cox model may have been vio-
lated; the P value of the time-varying covariate was < 0.001. On
closer inspection of the participants in Placencia 1993, all 60 par-
ticipants who achieved 12-month remission achieved immediate
remission (i.e. did not have any seizures at all in the first 12months
of follow-up). The trial followed up a further 42 participants for
more than 365 days (up to 548 days); however, none of these par-
ticipants achieved a 12-month period of seizure freedom during
the trial, so we censored them all at their last follow-up date (after
365 days). This observation would explain the apparent change
in treatment effect over time in Placencia 1993, and therefore the
violation of the proportional hazards assumption. When we anal-
ysed separately those who achieved immediate 12-month remis-
sion, the proportional hazards assumption was satisfied (P value
of time-varying covariate was 0.872). The proportional hazards
assumption of the Cox model were satisfied for all other trials in-
cluded in the analysis.
The sensitivity analysis including only the 20 participants ran-
domised in de Silva 1996 before the withdrawal of the pheno-
barbitone arm gave very similar numerical results and no change
to conclusions or the amount of heterogeneity present in analysis
overall and for individuals with focal onset seizures. For individu-
als with generalised onset seizures, results were numerically similar,
but sensitivity analysis showed a statistically significant advantage
to carbamazepine, pooled HR for 137 participants, 1.68 (95% CI
1.06 to 2.69; P = 0.03, I² = 0%; fixed-effect meta-analysis); in
other words, 12-month remission occurred significantly earlier on
carbamazepine than phenobarbitone for individuals with gener-
alised seizures (see Table 5 for further details).
In the sensitivity analyses to investigate misclassification of seizure
type, following reclassification of the 46 participants aged 30 or
older with new onset generalised seizures in Heller 1995 and
Placencia 1993 to focal onset seizures or an uncertain seizure type,
results were very similar and there was no change to conclusions or
the amount of heterogeneity present in analysis overall and for in-
dividuals with focal onset seizures. For the subgroup of individuals
with generalised seizures (following reclassification), the potential
advantage to carbamazepine was no longer statistically significant
(see Table 5). For both of the analyses reclassifying seizure type,
there was no evidence of an interaction between treatment and
seizure type (test for subgroups differences: P = 0.11, I² = 61.4%
variability due to subgroup differences for generalised onset and
over the age of 30 at onset reclassified to focal onset and test for
subgroups differences: P = 0.10, I² = 57.4% variability due to sub-
group differences for generalised onset and over the age of 30 at
onset reclassified to uncertain seizure type.)
Summary of results for time to achieve 12-month remission
Overall, the results for secondary outcome ’time to 12-month re-
mission’ do not show consistent or clear differences between the
drugs and heterogeneity between may have confounded the re-
sults. Subgroup analyses by seizure type and sensitivity analyses
suggest a potential advantage for carbamazepine, that is, that 12-
month remission may be achievedmore quickly on carbamazepine
than phenobarbitone but these results are not statistically signifi-
cant.
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From visual inspection of forest plots and sensitivity analysis, it
was clear that Placencia 1993 was the main source of the hetero-
geneity between trials in the subgroup of participants with focal
onset seizures and overall in all participants. The other three tri-
als showed moderate, non-significant effect sizes, while Placencia
1993 showed a large, significant effect size in favour of pheno-
barbitone (see Analysis 1.11). This effect was not shown in the
subgroup of participants with generalised onset seizures in partic-
ipants in Placencia 1993 and when we excluded Placencia 1993
from the meta-analysis in sensitivity analysis, the heterogeneity
present in analysis was reduced to zero. This could have been a
knock-on effect of the inadequate allocation concealment in this
trial, which was likely to have influenced the withdrawal rates in
this trial, and in turn the number of participants remaining in the
trial who could achieve 12-month remission. Furthermore, the
distribution of 12-month remission times in Placencia 1993 (all
participants who achieved 12 month remission achieved it imme-
diately, and all those who did not were censored), may have in-
fluenced the result of this trial. As for our primary outcome, we
conclude that the inclusion of this trial may have confounded the
results of this outcome.
Time to achieve six-month remission
For this outcome, a HR less than one indicates a clinical advantage
for phenobarbitone.
Time to six-month remission was available for 683 participants
from four of the trials providing IPD (de Silva 1996; Heller 1995;
Mattson 1985; Placencia 1993; see ’time to 12-month remission’
for further details of available data). Three hundred and eighty-
seven out of 683 participants (57%), achieved six-month remis-
sion, 213 out of 384 (59%), on carbamazepine and 117 out of
319 (55%), on phenobarbitone. The overall pooled HR (for 683
participants), was 0.98 (95%CI 0.80 to 1.21, P = 0.86; moderate-
quality evidence; fixed-effect meta-analysis; Analysis 1.12), sug-
gesting no clear advantage for either drug. There was no evidence
of statistical heterogeneity between trials (I² = 17%).
Subgroup analyses: seizure type (focal versus generalised
onset)
For participants with focal onset seizures (525 participants from
four trials), the pooled HR of 0.86 (95% CI 0.67 to 1.11, P
= 0.24; low-quality evidence; fixed-effect meta-analysis; Analysis
1.13), which suggests a potential advantage for phenobarbitone
that was not statistically significant. A considerable amount of sta-
tistical heterogeneity was present between trials for participants
with focal onset seizures (I² = 62%). When we repeated the analy-
sis with random-effects, the pooled HR of 0.87 (95% CI 0.55 to
1.37, P = 0.54), results were similar and conclusions unchanged.
For participants with generalised onset seizures (158 participants
from three trials), the pooled HR was 1.45 (95% CI 0.99 to
2.12, P = 0.06; moderate-quality evidence; fixed-effect meta-anal-
ysis; Analysis 1.13), suggesting a potential advantage for carba-
mazepine, which is not statistically significant. There was no ev-
idence of statistical heterogeneity between trials for participants
with generalised seizures (I² = 0%). There was statistically signifi-
cant evidence of an interaction between treatment and seizure type
(generalised versus focal onset; P = 0.03, I² = 80.0% variability due
to subgroup differences, see Analysis 1.13, calculated with fixed-
effect meta-analysis).
Overall, the pooled HR (adjusted for seizure type for 683 partici-
pants, fixed-effect meta-analysis), was 1.01 (95% CI 0.81 to 1.24,
P = 0.95; low-quality evidence; fixed-effect meta-analysis; Analysis
1.13), suggesting no clear advantage for either drug, but a con-
siderable amount of heterogeneity was present between trials (I² =
58%). When we repeated the analysis with random-effects meta-
analysis, results were similar and conclusions unchanged (pooled
HR 1.06 (95% CI 0.74 to 1.51, P = 0.75).
Sensitivity analysis
We used fixed-effect meta-analysis to perform all sensitivity anal-
yses.
We performed sensitivity analysis excluding participants from
Placencia 1993 from the analysis of ’time to treatment failure for
any reason related to treatment’ because of high risk of selec-
tion bias due to inadequate allocation concealment (see Allocation
(selection bias) and Table 5). This sensitivity analysis suggested a
potential advantage for carbamazepine, which was not statistically
significant; overall pooled HR of 1.13 (95% CI 0.87 to 1.47, P
= 0.34, adjusted for seizure type; fixed-effect meta-analysis), and
greatly reduced heterogeneity (I² = 0% reduced from I² = 58%
in Analysis 1.13; see Table 5). Results for individuals with focal
seizures also suggested a potential advantage for carbamazepine,
which was not statistically significant; pooled HR of 1.10 (95%
CI 0.81 to 1.49, P = 0.56; fixed-effect meta-analysis), and greatly
reduced heterogeneity (I² = 0% reduced from I² = 62% in Analysis
1.13; see Table 5). For individuals with generalised onset seizures,
therewas noheterogeneity present in the original analysis (Analysis
1.13), or within sensitivity analysis (I² = 0%). The sensitivity anal-
ysis suggested a potential advantage for carbamazepine, which was
not statistically significant; pooled HR of 1.23 (95% CI 0.76 to
1.99; P = 0.40; fixed-effect meta-analysis). Following sensitivity
analysis, there was no evidence of an interaction between treat-
ment and seizure type (test for subgroup differences: P = 0.69, I²
= 0% variability due to subgroup differences)
The sensitivity analysis including only the 20 participants ran-
domised in de Silva 1996 before the withdrawal of the pheno-
barbitone arm gave very similar numerical results and no change
to conclusions or the amount of heterogeneity present in analysis
overall and for individuals with focal onset seizures. For individu-
als with generalised onset seizures, results were numerically similar,
but sensitivity analysis showed a statistically significant advantage
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to carbamazepine, pooled HR for 137 participants, 1.51 (95% CI
1.02 to 2.23; P = 0.04, I² = 0%; fixed-effect meta-analysis); in
other words, six-month remission occurred significantly earlier on
carbamazepine than phenobarbitone for individuals with gener-
alised seizures (see Table 5 for further details).
In the sensitivity analyses to investigate misclassification of seizure
type, following reclassification of the 46 participants aged 30 or
older with new onset generalised seizures in Heller 1995 and
Placencia 1993 to focal onset seizures or an uncertain seizure type,
results were very similar and there was no change to conclusions or
the amount of heterogeneity present in analysis overall and for in-
dividuals with focal onset seizures. For the subgroup of individuals
with generalised seizures (following reclassification), the potential
advantage to carbamazepine was no longer statistically significant
(see Table 5). For both of the analyses reclassifying seizure type,
there was no evidence of an interaction between treatment and
seizure type (test for subgroups differences: P = 0.17, I² = 46.1%
variability due to subgroup differences for generalised onset and
over the age of 30 at onset reclassified to focal onset, and test for
subgroups differences: P = 0.09, I² = 58.5% variability due to sub-
group differences for generalised onset and over the age of 30 at
onset reclassified to uncertain seizure type.
Summary of results for time to achieve six-month remission
Overall, the results for secondary outcome ’time to six-month re-
mission’ are very similar to results for ’time to 12-month remission.’
No consistent or clear differences between the drugs have been
shown and heterogeneity between themmay have confounded the
results. Subgroup analyses by seizure type suggest a potential inter-
action between treatment and seizure type (that phenobarbitone
may have an advantage over carbamazepine for individuals with
focal seizures and vice versa for individuals with generalised onset
seizures). However, this potential interaction was not robust to
sensitivity analysis (excluding Placencia 1993 from analysis and
reclassification of seizure type).
As for the analysis of ’time to six-month remission,’ from visual
inspection of forest plots and sensitivity analysis, it was clear that
Placencia 1993 was the main source of the heterogeneity between
trials in the subgroup of participants with focal onset seizures and
overall in all participants. The other three trials showed moderate,
non-significant effect sizes, while Placencia 1993 showed a large,
significant effect size in favour of phenobarbitone (see Analysis
1.13). This effect was not shown in the subgroup of participants
with generalised onset seizures in participants in Placencia 1993,
and when Placencia 1993 was excluded from the meta-analysis
in sensitivity analysis, the heterogeneity present in analysis was
reduced to zero. This could have been a knock-on effect of the
inadequate allocation concealment in this trial, which was likely to
have influenced the withdrawal rates in this trial, and in turn the
number of participants remaining in the trial who could achieve
six-month remission. As for other outcomes of this review, we
conclude that the inclusion of this trial may have confounded the
results of this outcome.
Incidence of adverse events
We extracted all reported information related to adverse events
from the trial publications. Cossu 1984 did not report any find-
ings related to adverse events, and without access to protocols we
are uncertain if these data were collected (see Selective reporting
(reporting bias)). See Table 6 for details of all adverse event data
provided in the other 12 trials included in this review. Two trials
reported only numbers of withdrawals from the trial due to ad-
verse events (Chen 1996; Czapinski 1997), and two reported the
rate of adverse events/number of participants reporting adverse
events (Bidabadi 2009; Placencia 1993); these four trials did not
report specific adverse events. It was difficult to summarise the
’most common’ adverse events overall across the 12 trials or deduce
whether carbamazepine or phenobarbitone were most associated
with specific adverse events because of the differences in methods
of reporting adverse event data across the trials. For the eight trials
that did report specific adverse events, the events reported by two
or more trials were as follows.
Adverse events with carbamazepine
• Gastrointestinal side effects including abdominal pain,
nausea, and vomiting (Cereghino 1974; Mattson 1985)
• Drowsiness/tiredness/fatigue/sedation (Banu 2007; de Silva
1996; Heller 1995)
• Headaches (Banu 2007; Heller 1995)
• Motor disturbance (including ataxia, incoordination,
nystagmus, tremor, slowing of mental function, inattention,
psychomotor retardation), (Banu 2007; Mattson 1985; Ogunrin
2005)
• Dysmorphic and idiosyncratic side effects (rash, gum
hypertrophy, hirsutism, acne, other skin problems), (Feksi 1991;
Heller 1995; Mattson 1985; Mitchell 1987; Ogunrin 2005)
• Cognitive side effects and impairments including
depression and memory problems (Banu 2007; Feksi 1991;
Heller 1995; Ogunrin 2005)
• Behaviour-related side effects (aggression, behavioural
changes, etc.), (Banu 2007; Feksi 1991; Mitchell 1987)
Adverse events with phenobarbitone
• Gastrointestinal side effects including abdominal pain,
nausea, and vomiting (Banu 2007; Cereghino 1974; Heller
1995; Mattson 1985)
• Drowsiness/tiredness/fatigue/sedation (Banu 2007; de Silva
1996; Heller 1995)
• Motor disturbance (including ataxia, incoordination,
nystagmus, tremor, slowing of mental function, inattention,
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psychomotor retardation), (Banu 2007; Mattson 1985; Ogunrin
2005)
• Dysmorphic and idiosyncratic side effects (rash, gum
hypertrophy, hirsutism, acne, other skin problems), (de Silva
1996; Feksi 1991; Heller 1995; Mattson 1985)
• Cognitive side effects and impairments, including
depression and memory problems (Banu 2007; Feksi 1991;
Ogunrin 2005)
• Behaviour-related side effects (aggression, behavioural
changes, etc.), (Banu 2007; de Silva 1996; Mitchell 1987)
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Carbamazepine compared with phenobarbitone for epilepsy (secondary outcomes)
Patient or population: adults and children with newly onset focal or generalised epilepsy
Settings: outpat ients
Intervention: carbamazepine
Comparison: phenobarbitone
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Phenobarbitone Carbamazepine
Time to first seizure
(post- randomisation)
All participants
Range of follow-up: 0 to
4108 days
The median t ime to f irst
seizure post-randomi-
sat ion was 218 days
in the phenobarbitone
group
The median t ime to
f irst seizure post-ran-
domisat ion was 113
days (105 days shorter)
in the carbamazepine
group
HR 1.13
(0.93 to 1.38)a
822
(6 trials)
⊕⊕⊕©
Moderateb
HR < 1 indicates a clin-
ical advantage for car-
bamazepine
Time to first seizure
(post- randomisation)
Subgroup: focal onset
seizures
Range of follow-up: 0 to
4108 days
The median t ime to f irst
seizure post-randomi-
sat ion was 266 days
in the phenobarbitone
group
The median t ime to
f irst seizure post-ran-
domisat ion was 84
days (182 days shorter)
in the carbamazepine
group
HR 1.31
(1.04 to 1.66)
584
(6 trials)
⊕⊕⊕©
Moderateb
HR < 1 indicates a clin-
ical advantage for car-
bamazepine
Time to first seizure
(post- randomisation)
Subgroup: generalised on-
set tonic-clonic seizures
Range of follow-up: 0 to
4070 days
The median t ime to f irst
seizure post-randomi-
sat ion was 209 days
in the phenobarbitone
group
The median t ime to f irst
seizure post-randomi-
sat ion was 303 days
(94 days longer) in the
carbamazepine group
HR 0.80
(0.55 to 1.15)
238
(5 trials)
⊕⊕©©
Lowb,c
HR < 1 indicates a clin-
ical advantage for car-
bamazepine
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Time to achieve 12-
month remission
(seizure- free period)
All participants
Range of follow-up: 0 to
4222 days
The median t ime to
achieve to 12-month re-
m ission was 413 days
in the phenobarbitone
group
The median t ime to
achieve to 12-month re-
m ission was 446 days
(33 days longer) in the
carbamazepine group
HR 1.09
(0.84 to 1.40)a
683
(4 trials)
⊕⊕©©
Lowb,d
HR < 1 indicates a
clinical advantage for
phenobarbitone
Time to achieve 12-
month remission
(seizure- free period)
Subgroup: focal onset
seizures
Range of follow-up: 0 to
4222 days
The median t ime to
achieve to 12-month re-
m ission was 369 days
in the phenobarbitone
group
The median t ime to
achieve to 12-month re-
m ission was 531 days
(162 days longer) in the
carbamazepine group
HR 0.92
(0.67 to 1.25)
525
(4 trials)
⊕⊕©©
Lowb,d
HR < 1 indicates a
clinical advantage for
phenobarbitone
Time to achieve 12-
month remission
(seizure- free period)
Subgroup: generalised on-
set tonic-clonic seizures
Range of follow-up: 0 to
4163 days
The median t ime to
achieve to 12-month re-
m ission was 421 days
in the phenobarbitone
group
The median t ime to
achieve to 12-month re-
m ission was 366 days
(55 days shorter) in the
carbamazepine group
HR 1.56
(0.99 to 2.44)
158
(3 trials)
⊕⊕©©
Lowb,e
HR < 1 indicates a
clinical advantage for
phenobarbitone
* Illustrat ive risks in the carbamazepine and phenobarbitone groups are calculated at the median t ime to f irst seizure or t ime to 12-month remission (i.e. the t ime to 50% of
part icipants experiencing a f irst seizure or 12-months of remission) within each group across all t rials. The relat ive ef fect (pooled hazard rat io) shows the comparison of ’t ime
to f irst seizure’ or ’t ime to 12-month remission’ between the treatment groups
CI: 95% conf idence interval; HR: hazard rat io
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aPooled HR for all part icipants adjusted for seizure type.
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bDowngraded due to risk of bias: there was high risk of bias for at least one element of several of the trials included in
the analysis; de Silva 1996 and Heller 1995 were open-label, and the lack of masking may have inf luenced the withdrawal
rates in the trial. Placencia 1993 did not adequately conceal allocat ion for all part icipants, which may have inf luenced the
withdrawal rates in the trial and therefore the remission rates in the trial. There were inconsistencies between published data
and individual part icipant data, which the trial authors could not resolve in Banu 2007.
cDowngraded due to inconsistency: substant ial heterogeneity was present between trials (I² = 54%) and misclassif icat ion of
seizure type in Ogunrin 2005 for 19 individuals may have had an impact on the trial result . Sensit ivity analysis to adjust for
m isclassif icat ion reduced the amount of heterogeneity in the analysis.
dDowngraded due to inconsistency: substant ial heterogeneity was present between trials; sensit ivity analyses showed that
Placencia 1993 contributed the largest amount of variability to the analysis.
eDowngraded once for imprecision: the subgroup of part icipants with generalised onset tonic-clonic seizures is relat ively
small (23% of total part icipants) and conf idence intervals around pooled results are fairly wide.
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D I S C U S S I O N
Summary of main results
The results of this review provide statistically significant, moder-
ate-quality evidence of an advantage for carbamazepine over phe-
nobarbitone for our primary global effectiveness outcome ’time
to treatment failure’. In other words, treatment failure may occur
significantly earlier on phenobarbitone than carbamazepine.
Considering time to treatment failure for any reason related to
treatment, for 676 participants providing IPD from four trials,
the pooled HR adjusted for seizure type was 0.66 (95% CI 0.50
to 0.86; P = 0.002; adjusted for seizure type; moderate-quality
evidence). This advantage was also present for time to treatment
failure due to adverse events (pooled HR adjusted for seizure type:
0.69 (95% CI 0.49 to 0.97; P = 0.03; low-quality evidence), and
time to treatment failure due to lack of efficacy (pooled HR ad-
justed for seizure type: 0.54 (95% CI 0.38 to 0.78; P = 0.0008;
moderate-quality evidence).
A statistically significant advantage for carbamazepine is also ob-
served in the subgroupof participants experiencing new focal onset
seizures and a potential (non-statistically significant), advantage
for the smaller subgroup of individuals experiencing generalised
onset seizures (23% of total participants); there was no evidence
of any interaction between treatment and seizure type. However,
a substantial amount of heterogeneity was present between results
for individuals with focal seizures, which is likely to have origi-
nated from inadequate allocation concealment, which may have
influenced withdrawal rates in one trial precutting 192 partici-
pants (Placencia 1993, contributing 28% of data to this meta-
analysis), and the early withdrawal of the phenobarbitone arm in
another trial due to concerns of serious behavioural adverse events
(de Silva 1996), and may have confounded the results the primary
outcomes of this review.
For our secondary outcomes, ’time to first seizure post-randomi-
sation’, ’time to 12-month remission’ and ’time to six-month re-
mission’), we did not find any statistically significant differences
between carbamazepine and phenobarbitone overall and evidence
for these outcomes was moderate to low quality. Any differences
found by seizure type were not consistent or robust to sensitivity
analysis and some subgroup analyses were likely confounded by
heterogeneity. For all of these outcomes, over 70%of included par-
ticipants were classified as experiencing new onset focal seizures,
therefore the direction of overall results (adjusted by seizure type),
are likely influenced by this majority seizure type.
Results of these outcomes suggest that there may be an association
between treatment effect in terms of efficacy and seizure type; that
is, that participants with focal onset seizures experience seizure re-
currence later and hence remission of seizures earlier on phenobar-
bitone than carbamazepine, and vice versa for individualswith gen-
eralised seizures. It is likely that the analyses of these outcomeswere
confounded by several methodological issues, which could have
introduced the heterogeneity and inconsistency; such as misclas-
sification of seizure type in participants over the age of 30 in these
trials (Heller 1995; Ogunrin 2005; Placencia 1993), which seems
to have had a particular impact on the results of Ogunrin 2005,
inconsistencies in IPD provided to us (Banu 2007), in addition
to the methodological issues within de Silva 1996 and Placencia
1993 described above. Therefore it is unknown whether this ap-
parent association between treatment efficacy and seizure type is
a true association or not.
Limited information was available regarding adverse events in the
trials and we were unable to compare the rates of adverse events
between carbamazepine and phenobarbitone. Some adverse events
reported on both drugs were abdominal pain, nausea, and vom-
iting, drowsiness, motor and cognitive disturbances, dysmorphic
side effects (such as rash), and behavioural side effects in three
paediatric trials.
Overall completeness and applicability of
evidence
We have gratefully received IPD for 1138 individuals (78% of
individuals from all eligible trials), from the authors of seven tri-
als (Banu 2007; de Silva 1996; Feksi 1991; Heller 1995; Mattson
1985; Ogunrin 2005; Placencia 1993), which included a compar-
ison of phenobarbitone with carbamazepine for the treatment of
epilepsy. However, we were not able to include the data from one
trial (Feksi 1991), recruiting 302 participants (representing 21%
of the total number in the 13 eligible trials and 27% of the total
number of participants from the trials for which we received IPD),
because of many inconsistencies in the dataset that could not be
resolved and we felt were too extensive to account for in sensitivity
analysis (see Included studies).
We also could not include 317 individuals (22%), from the other
six relevant trials (Bidabadi 2009; Cereghino 1974; Chen 1996;
Cossu 1984; Czapinski 1997; Mitchell 1987), in any analysis, as
IPD were not available and the published reports did not report
outcomes of interest. Therefore, we could include IPD for 836
participants in at least one outcome of this review, representing
57% of 1455 individuals from all 13 identified eligible trials.
While we received IPD for 836 participants, we were not able to
include all data in all of our analyses. Because of the short, three-
month duration of the trial, we were unable to include 37 partic-
ipants from Ogunrin 2005 in our remission analyses, and in this
short follow-up time, no participants withdrew from treatment;
therefore, this trial could not contribute to our primary outcome
of ’time to treatment failure’ either.We were also unable to include
108 participants from Banu 2007 in analyses of treatment failure
and remission as we did not receive dates of treatment failures and
subsequent seizures after first seizure recurrence. Therefore, our
primary outcome was, in fact, based on 676 participants (47% of
individuals from all eligible trials).
Having to exclude data from nearly half of the eligible participants
due to lack of IPD and insufficient reporting in trial publications
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was likely to have had an impact on the applicability of the ev-
idence; therefore, we encourage caution in the interpretation of
all results in this review. However, it was difficult to quantify ex-
actly how large this impact was on the results of this review (see
Potential biases in the review process).
Four trials contributing around 80% of the participant data to
this review recruited adults only (Heller 1995; Mattson 1985;
Ogunrin 2005; Placencia 1993); the other two trials contributing
around 20% of data were paediatric trials (Banu 2007; de Silva
1996). Also, the largest single trial contributing over a third of the
participant data to this review,Mattson 1985, recruited individuals
with focal onset seizures only. Therefore, only around 30% of
participants included in this review were experiencing generalised
onset seizures. Furthermore, there is evidence within this review to
suggest that up to 27% of individuals with newly onset generalised
seizures may have had their seizure type misclassified. For these
reasons, the results of this review may not be fully generalisable
to children or to individuals with generalised onset seizures, and
more evidence recruiting these types of participants is required.
The adverse event profiles of the two drugs, particularly pheno-
barbitone with relation to behavioural changes in children, are
well documented (see Description of the intervention). Results
of this review suggest that phenobarbitone may be more likely
to be failed earlier than carbamazepine for any treatment-related
reason and due to adverse events; however, results across trials
were variable and should be interpreted with caution. While we
found no consistent differences between the two drugs in terms
of efficacy; results of this review suggest a potential association be-
tween treatment efficacy and seizure type (see Summary of main
results); yet the direction of this association (advantage for car-
bamazepine for generalised seizures and advantage for phenobar-
bitone for focal seizures), was unexpected given documented evi-
dence that carbamazepinemay exacerbate some generalised seizure
types, such as myoclonic and absence seizures (Liporace 1994;
Shields 1983; Snead 1985), and that current guidelines recom-
mend carbamazepine as a first-line drug for the treatment of focal
seizures (NICE 2012).
Evidence from previous reviews conducted by Cochrane Epilepsy
as part of this series of pair-wise reviews for monotherapy in
epilepsy (Marson 2000; Nevitt 2018b; Nevitt 2017b), suggests
that misclassification of seizure type is an important issue in
epilepsy trials (Malafosse 1994). We believe that the results of the
original trials, and hence the results of the outcome ’time to first
seizure’ in this review, are likely to have been confounded by clas-
sification bias, particularly the 19 individuals fromOgunrin 2005
classified with new onset generalised seizures over the age of 30,
and contributing a large amount of variability to the analysis.
Ogunrin 2005 classified generalised and focal onset seizures ac-
cording to the International League Against Epilepsy (ILAE), clas-
sification of 1981 (Commission 1981), rather than the revised
ILAE classification in 1989 (Commission 1989), which may have
led to misclassification. Furthermore, Ogunrin 2005 was con-
ducted in Nigeria, a lower middle-income country without access
to the same facilities as trials conducted in the USA and Europe;
therefore, seizure types were classified clinically, and electroen-
cephalographics (EEGs)/magnetic resonance images (MRIs), were
not required for diagnosis of epilepsy. Clinical classification may
also have contributed to potential misclassification in this trial.
As described in Summary of main results, results of this review
are likely to be confounded by heterogeneity and methodological
inadequacies of the included trials. Therefore, this apparent asso-
ciation may not be a true association and all results of this review
should be interpreted with caution. We would not advocate bas-
ing a choice between these two drugs on the results of this review
alone.
Quality of the evidence
The six trials for which IPD were made available were generally
of relatively good methodological quality; however, four out of
the six trials for which we received IPD were at high risk of bias
for at least one aspect (see Figure 3), which may have introduced
bias into analyses. While an IPD approach to analysis allows us to
use unpublished data, therefore reducing attrition and reporting
bias, for two of the trials contributing 36% of participant data, we
found inconsistencies between published data and participant data
provided tous in terms of treatment failure information and seizure
recurrence, respectively (Banu 2007; Placencia 1993), which the
trial authors could not resolve. In both cases, it was likely that the
inconsistencies within these trials contributed to the considerable
heterogeneity present within the analyses in this review.
Three of the trials contributing 27% of the participant data to this
review described adequate methods of randomisation and alloca-
tion concealment (de Silva 1996; Heller 1995; Ogunrin 2005);
however, the other two largest single trials contributing 50% of
participant data to this review did not describe the method of ran-
domisationor allocation concealment used, or both, and this infor-
mation was not available from trial authors (Banu 2007; Mattson
1985). We are uncertain whether this lack of information has af-
fected the results of this review. One trial contributing 23% of
participant data to this review reported that an adequate method
of allocation concealment was not used for all randomised partici-
pants, and following sensitivity analyses, we believe this inadequate
allocation concealment may have influenced rates of withdrawal
if participants, or clinicians, or both, were aware of the allocated
treatment, which may have had a further knock-on effect on our
seizure and remission outcomes.
Three of the trials providing IPD blinded participants and out-
come assessors (Banu 2007; Mattson 1985; Ogunrin 2005); and
the other two trials, de Silva 1996 and Heller 1995, were designed
as pragmatic open-label trials, as masking of treatment would not
be “practicable or ethical”, would “undermine compliance”, and
would “introduce bias due to a very large dropout rate” as blinding
does not conform to standard clinical practice of increasing drug
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doses to therapeutic ranges (Heller 1995). Despite this reasoning,
considering the largest trials conducted within the USA and Eu-
rope, the rates of treatment failure for reasons related to the trial
drug across the double-blind (Mattson 1985), and open-label (de
Silva 1996; Heller 1995), trials included in ’time to treatment fail-
ure’ were quite similar (see Table 4 for further details):
• 44% of participants failed treatment in Mattson 1985
(52% randomised to phenobarbitone and 36% randomised to
carbamazepine);
• 34% of participants failed treatment in Heller 1995 (40%
randomised to phenobarbitone and 28% randomised to
carbamazepine);
• 46% of participants failed treatment in de Silva 1996 (80%
from phenobarbitone and 40% from carbamazepine).
It is however, debatable whether double-blind design is the most
appropriate for trials of monotherapy in epilepsy of long duration,
and whether such a design does have an impact upon the dropout
rate, and therefore, the results of the trial. The overall treatment
failure rate in de Silva 1996 was greatly influenced by the high
treatment failure rate of children randomised to phenobarbitone
(80%), which led to the withdrawal of that treatment arm from the
four-treatment trial because of concerns of serious adverse events.
It is difficult to know if preconceptions of phenobarbitone and
documented associations of the drug with adverse behavioural ef-
fects in children directly led to the withdrawal of the drug, and
if the same outcome would have occurred if the trial had been
double-blinded. It is also interesting to note that within the other
paediatric trial within this review, which was blinded and con-
ducted in a rural area of Bangladesh (Banu 2007), there were no
documented failures of the allocated treatment (carbamazepine or
phenobarbitone), due to adverse events, and in fact, in this trial,
significantly more children withdrew from carbamazepine than
phenobarbitone for reasons related to the trial drug (11% with-
drew from phenobarbitone, 26% withdrew from carbamazepine,
Chi² test, P = 0.05, see Table 4). Unfortunately, we could not
include this trial in the analysis of ’time to treatment failure’ as
dates of treatment failure were not available for all participants.
Furthermore, a trial comparing phenobarbitone with phenytoin
conducted in India (Pal 1998), in which phenobarbitone was con-
cluded to be an “effective and acceptable antiepileptic drug for
rural Indian children” did not report concerns regarding adverse
events of phenobarbitone in children.
We note the influence of country of recruitment over the method-
ological design and perhaps the results of the trial.Within theUSA
and Europe, where many treatment options are available, pheno-
barbitone is no longer considered to be a first-line agent, in favour
of more tolerable first-line agents, such as carbamazepine and lam-
otrigine (NICE 2012), whereas in low- and middle-income coun-
tries or rural regions, where income is limited and newer gener-
ation antiepileptic drugs are not readily available or affordable,
older and cheaper drugs, such as phenobarbitone, are more likely
to be used as comparators.
Trials for which no IPD were available were generally of poorer
quality than those for which we received IPD. A lot of method-
ological information in these trials was not reported or was un-
clear. Two trials presented incomplete outcome data following ex-
clusion of participants (Chen 1996; Feksi 1991); one trial used an
inadequate cross-over design for investigating monotherapy treat-
ments (Cereghino 1974); two trials were likely to have been un-
derpowered to detect a difference between the drugs (Cossu 1984;
Mitchell 1987); one trial may have been underpowered, too; and
two trials available only in abstract or summary form, provided
only very limited information on trial methodology (Bidabadi
2009; Czapinski 1997).
Overall, due to the documented methodological issues that may
have introduced heterogeneity, biases and imprecision into our
meta-analyses, we rated the evidence provided in this review
as moderate to low quality according to GRADE criteria (See
Summary of findings for the main comparison and Summary of
findings 2), and would not advocate use of the evidence in this
review for clinical decision-making between the two drugs.
Potential biases in the review process
We were able to include IPD for 836 out of 1455 eligible partici-
pants (57%), from six out of 13 trials in this review and conducted
all analyses as IPD analyses. Such an approach has many advan-
tages, such as allowing the standardisation of definitions of out-
comes across trials, and attrition and reporting biases are reduced,
as we can perform additional analyses and calculate additional
outcomes from unpublished data. For the outcomes we used in
this review that are of a time-to-event nature, an IPD approach is
considered to be the ’gold standard’ approach to analysis (Parmar
1998).
However, despite the advantages of this approach, for reasons out
of our control, we were not able to obtain IPD for 619 participants
from seven eligible trials, and no aggregate data were available
for our outcomes of interest in trial publications. We therefore
had to exclude 43% of eligible participants from our analyses,
which may have introduced bias into the review. Given that no
statistically significant differences were found between the drugs in
terms of proportions of participants seizure-free and proportions
of participants withdrawing from allocated treatment in the seven
trials for which IPD were not available (where recorded, see Table
2), we do not believe that our conclusions would have changed for
the outcomes of this review had the IPD for the seven trials been
available. We do however, recommend caution when interpreting
results of analyses of this review because of potential retrieval bias
from the exclusion of 43% of eligible participants from seven trials
in this review.
Furthermore, five out of the seven trials that we were not able to
include in meta-analysis were at high risk of bias for at least one
methodological aspect (see Figure 3 and Risk of bias in included
studies); therefore, inclusion of this data may have introduced bias
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into our results. We also judged four out of the six trials with
IPD provided for analysis to be at high risk of bias for at least
one methodological element. We addressed these issues in sensi-
tivity analysis and discussed each analysis at length (see Sensitivity
analysis and Effects of interventions).
Finally, we made some assumptions in the statistical methodology
used in this review. Firstly, when we received only follow-up dates
and seizure frequencies, we used linear interpolation to estimate
seizure times. We are aware that an individual’s seizure patterns
may be non-linear; therefore, we recommend caution when inter-
preting the numerical results of the seizure-related outcomes. We
also made an assumption that treatment effect for each outcome
did not change over time (proportional hazards assumption, see
Data synthesis). We are aware that in trials of long duration (e.g.
de Silva 1996, Heller 1995 and Mattson 1985 followed up par-
ticipants for between 3 and 10 years), the assumption of treat-
ment effect remaining constant over time may not be appropri-
ate. For example, there is likely to be a difference between partic-
ipants who achieve immediate remission compared with partici-
pants who achieve later remission, and we encourage that results
should be interpreted with this limitation in mind.
Agreements and disagreements with other
studies or reviews
To our knowledge, together with previous versions of this review,
this is the only systematic review and meta-analysis that com-
pares phenobarbitone and carbamazepine monotherapy for focal
onset seizures and generalised onset tonic-clonic seizures. A net-
work meta-analysis has been published ( Nevitt 2017a), compar-
ing all direct and indirect evidence from phenobarbitone, carba-
mazepine, and other standard and new antiepileptic drugs licensed
for monotherapy. The results of this review generally agree with
the results of the network meta-analysis; results of this network
meta-analysis showed a statistically significant advantage for car-
bamazepine compared with phenobarbitone for ’time to treatment
failure’ for participants with focal onset seizures and a statistically
significant advantage for phenobarbitone compared with carba-
mazepine for ’time to first seizure’ for participants with focal on-
set seizures. No statistically significant differences were found be-
tween the drugs for participants with generalised onset seizures.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Current UK guidelines recommend carbamazepine or lamotrigine
as first-line treatment for adults and children with new onset focal
seizures and sodium valproate for adults and children with new
onset generalised seizures (NICE 2012).
Moderate-quality evidence suggests that carbamazepine is likely
to be a more effective drug than phenobarbitone in terms of treat-
ment retention (treatment failures due to lack of efficacy or ad-
verse events or both). Moderate- to low-quality evidence from this
review also suggests an association between treatment efficacy and
seizure type in terms of seizure recurrence and seizure remission,
with an advantage for phenobarbitone for focal onset seizures and
an advantage for carbamazepine for generalised onset seizures.
However, some of the trials contributing to the analyses had
methodological inadequacies and inconsistencies, whichmay have
had an impact on the results of this review. Therefore, we do not
suggest that results of this review alone should form the basis of a
treatment choice for a patient with newly onset seizures. Because
of documented evidence of carbamazepine worsening certain gen-
eralised seizure types and behavioural-related adverse events asso-
ciated with phenobarbitone, particularly in children, we empha-
sise caution and careful clinical follow-up if these drugs are chosen
for these specific subgroups of patients. We also encourage cau-
tion in the use of these drugs in women of child-bearing poten-
tial because of documented teratogenic effects, where the risk is
estimated to be two to three times that of the general population
(Bromley 2014; Meador 2008; Morrow 2006; Weston 2016).
Implications for research
Few consistent differences in efficacy have been found between
these two commonly used antiepileptic drugs in individual trials.
The methodological quality of trials comparing these two drugs
has been variable, producing variable individual trial results in-
troducing heterogeneity into the pooled results of this review and
therefore making the pooled results difficult to interpret. If there
are differences in efficacy and tolerability across heterogeneous
populations of individuals such as those studied here, it is likely
that these differences are small. It has been argued that future com-
parative antiepileptic drug trials should be powered to establish
equivalence (Jones 1996), and therefore be capable of detecting
what is considered to be the smallest important clinical difference.
This review highlights the need for the design of future antiepilep-
tic drug monotherapy trials that recruit individuals with specific
epilepsy syndromes to be powered to detect a difference between
particular antiepileptic drugs. An approach likely to reflect and in-
form clinical practice, as well as being statistically powerful, would
be to recruit heterogeneous populations for whom epilepsy syn-
dromes have been adequately defined, with testing for interaction
between treatment and epilepsy syndrome. In view of potential
problems of misclassification, syndromes will have to be well de-
fined, with adequate checking mechanisms to ensure that classi-
fications are accurate and a system to recognise uncertainty sur-
rounding epilepsy syndromes in individuals within trials. It is also
important that future trials are of a sufficient duration to measure
long-term effectiveness of antiepileptic drugs (treatments that will
be life-long for many individuals with epilepsy), as well as psy-
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chosocial, quality-of-life and health economic outcomes.
Consideration is also required in the design of a trial regarding
whether to blind participants and outcome assessors to treatment
allocation. While an open-label design is a more pragmatic and
practical approach for large long-term trials, when trials involve
drugs with documented adverse event profiles, such as phenobar-
bitone, masking of treatment may be important to avoid precon-
ceptions of the drug being more likely to be associated with serious
adverse events, which the results of this review did not show.
The choice of outcomes at the design stage of a trial and the pre-
sentation of the results of outcomes, particularly of a time-to-event
nature, require very careful consideration. While the majority of
trials of a monotherapy design record an outcome measuring ef-
ficacy (seizure control), and an outcome measuring tolerability
(adverse events), there is little uniformity between the definition
of the outcomes and the reporting of the summary statistics re-
lated to the outcomes (Nolan 2013a), making an aggregate data
approach to meta-analysis in reviews of monotherapy trials im-
possible. Where trial authors cannot or will not make individual
participant data (IPD), available for analysis, we are left with no
choice but to exclude a proportion of relevant evidence from the
review, which will impact upon the interpretation of results of
the review and applicability of the evidence and conclusions. The
International League Against Epilepsy recommends that trials of
a monotherapy design should adopt a primary effectiveness out-
come of ’time to treatment failure (retention time)’ and should be
of a duration of at least 48 weeks to allow for assessment of longer-
term outcomes, such as remission (ILAE 1998; ILAE 2006). If tri-
als followed these recommendations, an aggregate data approach
to meta-analysis may be feasible, reducing the resources and time
required from an IPD approach.
A network meta-analysis has also been published (Nevitt 2017a),
comparing all direct and indirect evidence from phenobarbitone,
carbamazepine, and other standard and new antiepileptic drugs
licensed for monotherapy. This network meta-analysis will be up-
dated as more information becomes available; however, we ac-
knowledge that as phenobarbitone is no longer considered to be a
first-line agent for newly diagnosed individuals, in favour of newer
agents, such as lamotrigine and levetiracetam, it is unlikely that a
substantial amount of new evidence will become available for this
review.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Banu 2007
Methods Single-centre, double-blind randomised controlled trial of participants recruited from
clinical referral to a multidisciplinary child development centre at a children’s hospital
in Dhaka, Bangladesh
2 treatment arms: CBZ and PB
Participants 108 children between the ages of 2-15 with ≥ 2 generalised tonic-clonic, focal, or
secondarily generalised seizures in the previous year
Number randomised: CBZ = 54, PB = 54
61 boys (56%)
59 with focal seizures (55%)
26 had previous AED treatment (24%)
Mean age (range): 6 (2-15 years)
Trial duration: 12 months
Range of follow-up: 0-20.5 months
Interventions Monotherapy with CBZ (immediate release), or PB
Starting daily dose: CBZ = 1.5 mg/kg/day, PB = 5 mg/kg/day
Maximum daily dose: CBZ = 4 mg/kg/day, PB = 16 mg/kg/day
Outcomes • Seizure control: seizure freedom during the last quarter of the 12-month follow-up
• Time to first seizure after randomisation
• Time to treatment failure due to adverse events
• Change in behaviour from baseline according to age-appropriate questionnaire
• Incidence of behavioural side-effects
Notes We received IPD for all randomised participants. We received reasons for treatment
failure as well as the date of the last follow-up visit, but date of treatment failure did not
always coincide with the date of the last follow-up visit (i.e. several participants had the
allocated treatment substituted for the other trial drug and continued to be followed up).
Dates of treatment failure could not be provided; therefore, we could not calculate ’time
to treatment failure’. We received the date of first seizure after randomisation, but dates
of other seizures in the follow-up time could not be provided; therefore, we calculated
’time to first seizure’ for all participants, but we could not calculate the time to 6- and
12-month remission
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were ’randomly assigned to
treatment’; the method of randomisation
was not stated and not provided by the trial
authors
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Banu 2007 (Continued)
Allocation concealment (selection bias) Low risk Allocation was concealed by sealed en-
velopes prepared on a different site to the
site of recruitment of participants
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants, a psychologist, and a thera-
pist were blinded throughout the trial. The
treating physician was unblinded for prac-
tical and ethical reasons
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk A researcher performing outcome assess-
ment was blinded throughout the trial but
unblinded for analysis. It was unclear if this
could have influenced the results
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates were reported. We analysed
all randomised participants from the IPD
provideda .
Selective reporting (reporting bias) Low risk We calculated 1 outcome for this review
from the IPD provideda .We could not cal-
culate other outcomes for this review as
the appropriate data were not recorded/not
available. All cognitive outcomes from the
trial were well reported
Other bias High risk There were inconsistencies between rates
of seizure recurrence between the data pro-
vided and the published paper, which the
authors could not resolve (see Sensitivity
analysis).
Bidabadi 2009
Methods 6-month, systematic, simple randomised trial of children referred to a child neurology
clinic (the author was from Guilan University of Medical Sciences, Iran, so it was likely
that the trial was also conducted there)
2-arm trial: CBZ and PB
Participants Children aged 2-12 years with focal seizures with secondary generalisation
Number randomised: CBZ = 36, PB = 35
36 boys (53%)
100% focal seizures
Per cent newly diagnosed was not stated
Age range: 2-12 years
Trial duration: 6 months
Mean follow-up: not stated
Interventions Monotherapy with PB or CBZ. Doses started or achieved not stated
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Bidabadi 2009 (Continued)
Outcomes • Proportion seizure-free
• Response rate and rate of side-effects
• Seizure frequency and seizure duration
Notes The trial was reported in abstract form only with very limited information. Outcomes
chosen for this review were not reported; IPD were not available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial was described as a ’systematic sim-
ple randomised trial’; no further informa-
tion was provided
Allocation concealment (selection bias) Unclear risk No information was provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information was provided on blinding.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information was provided on blinding.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No attrition rates were reported; it was un-
clear if all participants were analysed
Selective reporting (reporting bias) Unclear risk There was no protocol available; the trial
was available in abstract format only. Out-
comes for this review were not available
Other bias Low risk We detected no other bias.
Cereghino 1974
Methods Randomised, double-blind, cross-over trial with 3, 21-day treatment periods and a 2-
week washout period (regular medications used)
Trial appears to have been conducted in the UK from affiliations of trial authors, but
setting unclear
3 treatment arms: CBZ, phenytoin, and PB
Participants Institutionalised adult participants with uncontrolled seizures on current medication
Number randomised: PB = 45, CBZ = 45
41 participants (91%), with focal epilepsy
28 (62%), male participants
Age range: 18-51 years
Trial duration: 13 weeks (3 x 21-day treatment periods plus 2 x 2-week washout periods)
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Cereghino 1974 (Continued)
Interventions Monotherapy with PB or CBZ
Daily dose: PB = 300 mg/day or CBZ = 1200 mg/day
Outcomes • Behaviour outcomes
• Adverse effects
• Seizure frequency
• Time to treatment failure due to poor seizure control
Notes The outcomes chosen for this review were not reported due to the cross-over design of
the trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation of groups from random
number tables (confirmed by trial author)
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided on blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided on blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal rates reported, no further in-
formation provided
Selective reporting (reporting bias) Low risk All efficacy and tolerability outcomes spec-
ified in the methods sections reported well
in the results section.Noprotocol available,
outcomes for this review not available due
to trial cross-over design
Other bias High risk Cross-over design may not be appropriate
for monotherapy designs, likely carryover
effects from one period to another so the
comparison may not be entirely monother-
apy
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Chen 1996
Methods Randomised, parallel-group trial conducted in Taiwan
3 treatment arms: CBZ, PB, sodium valproate
Participants Children with ≥ 2 previously untreated unprovoked epileptic seizures
Number randomised: PB = 25, CBZ = 26; number analysed: PB = 23, CBZ = 25 (see
notes)
Mean age (range): PB = 9.9 (7-15 years), CBZ = 10.8 (7-15 years)
CBZ versus PB: 26 (54%), participants with focal epilepsy
25 (52%), male participants
Trial duration: 12 months
Range of follow-up: not stated
Interventions Monotherapy with PB or CBZ. Dose started or achieved not stated
Outcomes • Cognitive/psychometric outcomes: IQ (WISC-R scale), and developmental delay
(Bender-Gestalt test)
• Auditory event-related potentials (neurophysiological outcome)
• Incidence of allergic reactions
• Seizure control
Notes 2 children from the PB group and 1 child from the CBZ group withdrew from the trial
because of allergic reactions. Published results were presented for childrenwho completed
the trial only. Outcomes chosen for this review were not reported; IPD were not available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were allocated with “simple
randomisation of block size 3.”
Allocation concealment (selection bias) Unclear risk No information was provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The cognitive assessor was ’single-blinded’,
implying that participants and personnel
were unblinded, but no further informa-
tion was provided
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The cognitive assessor was single-blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawal rates were reported; results
were presented only for those who com-
pleted the trial (CBZ versus PB: 3/51 (6%),
excluded from analysis). An ITT approach
was not taken
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Chen 1996 (Continued)
Selective reporting (reporting bias) Low risk All cognitive, efficacy, and tolerability out-
comes specified in the methods sections
were reportedwell in the results section.No
protocol was available. Outcomes chosen
for this review were not reported
Other bias Low risk We detected no other bias.
Cossu 1984
Methods Randomised, double-blind trial to assess short-term therapy of CBZ and PB on cognitive
and memory function. Conducted in Italy. 3 treatment arms: CBZ, PB, and placebo
Participants Participants with newly diagnosed and untreated temporal lobe epilepsy with no seizures
in the previous month
Number randomised: CBZ = 6, PB = 6
100% focal (temporal lobe epilepsy), 100% newly diagnosed
Mean age (SD): CBZ = 26.33 (9.73), years, PB = 18.5 (2.56), years
Age range: 15-45 years
1 male and 5 female participants in each group
Trial duration: 3 weeks; all participants completed in 3 weeks
Interventions Monotherapy with CBZ or PB, dose started and achieved not stated
Outcomes • Changes in memory function from baseline after 3 weeks of treatment (verbal,
visual, (visual-verbal and visual-non-verbal), acoustic, tactile, and spatial)
Notes The trial was published in Italian; the characteristics and outcomes were translated.
Outcomes chosen for this review were not reported; IPD were not available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial was described as randomised
(“randomizzazione” in Italian); no further
information was available
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial is described as double-blind (“con-
dizioni di doppia cecità” in Italian), we as-
sume this refers to participants and person-
nel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided on blinding of
outcome assessment.
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Cossu 1984 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed this short trial
and contributed to analysis
Selective reporting (reporting bias) Unclear risk Cognitive and memory outcomes de-
scribed in methods section well reported
in results section. No seizure outcomes or
adverse events reported and outcomes cho-
sen for this review not reported. No proto-
col available so unclear if seizure outcomes
were planned a priori
Other bias High risk Very small participant numbers and very
short-term follow-up. Unclear if this trial
was adequately powered and of sufficient
duration to detect differences
Czapinski 1997
Methods 36-month randomised comparative trial
4 treatment arms: CBZ, sodium valproate, phenytoin, PB
Participants Adults with newly diagnosed epilepsy with focal complex seizures
Number randomised: PB = 30, CBZ = 30
100% focal epilepsy (focal complex seizures)
Age range: 18-40 years
Percentage male and range of follow-up: not mentioned
Interventions Monotherapy with PB or CBZ
Starting doses CBZ = 400 mg/day, PB = 100 mg/day. Dose achieved not stated
Outcomes • Proportion achieving 24-month remission at 3 years and exclusions after
randomisation due to adverse effects or no efficacy
Notes This was an abstract only. Outcomes chosen for this review were not reported. IPD were
pledged but not received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial was randomised, but no further
information was provided
Allocation concealment (selection bias) Unclear risk No information was provided.
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Czapinski 1997 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information was provided.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information was provided.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Exclusion rates” were reported for all treat-
ment groups; no further information was
provided
Selective reporting (reporting bias) Unclear risk No protocol was available; the trial was
available in abstract format only.Outcomes
for this review were not available
Other bias Low risk We detected no other bias.
de Silva 1996
Methods Randomised, parallel group, open-label paediatric trial conducted in 2 centres in the UK
4 treatment arms: CBZ, sodium valproate, phenytoin, PB
Participants Children with newly diagnosed epilepsy (2 or more untreated focal or generalised tonic-
clonic seizures in the 12 months preceding the trial)
Number randomised: PB = 10, CBZ = 54 (see notes)
35 children (55%), with focal epilepsy
34 (53%), male children
Mean age (range): 9 (3-16) years
Range of follow-up: 3 to 88 (months)
Interventions Monotherapy with PB or CBZ
Median daily dose achieved: PB = not stated; CBZ = 400 mg/day
Outcomes • Time to first seizure recurrence after start of therapy
• Time to 12-month remission from all seizures
• Adverse effects and withdrawals due to adverse events
Notes 6 of the first 10 children assigned to PB had unacceptable adverse effects, so no further
childrenwere assigned toPB.The 10 children randomised toPBwere retained in analysis.
We received IPD for all outcomes of this review
Risk of bias
Bias Authors’ judgement Support for judgement
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de Silva 1996 (Continued)
Random sequence generation (selection
bias)
Low risk A randomisation list was generated using
permuted blocks of size 8 or 16 with strat-
ification for centre, seizure type, and pres-
ence of neurological signs
Allocation concealment (selection bias) Low risk Allocation was concealed via 4 batches of
concealed opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded - the trial authors stated that
masking of treatment would not have been
“practicable or ethical” and would have
“undermine[d] compliance”. Lack ofmask-
ing could have led to early withdrawal of
the PB arm from the trial
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded - the trial authors stated mask-
ing of treatment would not have been
“practicable or ethical” and would have
“undermine[d] compliance”. Lack ofmask-
ing could have led to early withdrawal of
the PB arm from the trial, which was likely
to have influenced the overall results
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates were reported; we analysed
all randomised participants from the IPD
provideda
Selective reporting (reporting bias) Low risk All outcomes were reported or calculated
with the IPD provideda
Other bias Low risk We detected no other bias
Feksi 1991
Methods Randomised parallel-group trial conducted among residents of the Nakuru district, a
semi-urban population of rural Kenya
2 treatment arms: CBZ and PB
Participants Participants had a history of generalised tonic-clonic seizures and at least 2 generalised
tonic-clonic seizures within the preceding year (with or without other seizure types), and
untreated in the 3 months prior to the trial. 79 (26%), participants had been treated in
the past with AEDs
Number randomised: PB = 150, CBZ = 152
115 (38%) of participants had experienced focal seizures
173 (57%) male participants
Mean age (range): 21 (6-65 years)
Range of follow-up: participants followed up for up to 1 year
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Feksi 1991 (Continued)
Interventions Monotherapy with CBZ or PB
Starting doses: PB: 6-10 years of age: 30 mg/day, 11-15 years of age: 45 mg/day, 16+
years of age: 60 mg/day
CBZ: 6-10 years of age: 400 mg/day, 11-15 years of age: 500 mg/day, 16+ years of age:
600 mg/day
Dose achieved not stated
Outcomes • Adverse effects
• Withdrawals from allocated treatment
• Seizure frequency (during second 6 months of trial)
Notes IPD were made available but not used because of inconsistencies and problems with the
data provided (see Included studies for further details).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants randomised with random
number list, no information provided on
method of generating random list
Allocation concealment (selection bias) Low risk Allocation concealed via sealed opaque en-
velopes (information provided by trial au-
thor)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition rates reported, results presented
only for participants completing 12
months’ follow-up (results not presented
for 53 (17.5%) participants out of 302 who
withdrew from treatment), approach is not
ITT
Selective reporting (reporting bias) Low risk Noprotocol available, outcomes chosen for
this review not reported. Seizure outcomes
and adverse events well reported
Other bias High risk Inconsistencies with IPD and published
results so IPD could not be used (see
Included studies for further details).
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Heller 1995
Methods Randomised, parallel-group, open-label trial conducted in 2 centres in the UK
4 treatment arms: CBZ, sodium valproate, phenytoin, PB
Participants Adults with newly diagnosed epilepsy (≥ 2 untreated focal or generalised tonic-clonic
seizures in the 12 months preceding the trial)
Number randomised: PB = 58, CBZ = 61
49 participants (41%) with focal epilepsy
55 (46%) male participants
Mean age (range): 32 (13-77) years
Range of follow-up: 1-91 months
Interventions Monotherapy with PB or CBZ. Median daily dose achieved: PB = 105 mg/day; CBZ =
600 mg/day
Outcomes • Time to first seizure recurrence after start of therapy
• Time to 12-month remission from all seizures
• Adverse effects and withdrawals due to adverse events
Notes We received IPD for all outcomes of this review.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation list generated using per-
muted blocks of size 8 or 16 with stratifi-
cation for centre, seizure type and presence
of neurological signs
Allocation concealment (selection bias) Low risk Allocation concealed via 4 batches of con-
cealed opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded, trial authors state masking of
treatment would not be “practical” and
would have “introduced bias due to a very
large dropout rate.” Lack of blinding may
have led to more withdrawals of PB
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded, trial authors state masking of
treatment would not be “practical” and
would have “introduced bias due to a very
large dropout rate.” Lack of blinding may
have led to more withdrawals of PB which
is likely to have influenced the overall re-
sults
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported, all randomised
participants analyses from IPD provideda
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Heller 1995 (Continued)
Selective reporting (reporting bias) Low risk All outcomes reported or calculated with
IPD provideda
Other bias Low risk No other bias detected
Mattson 1985
Methods Multicentre, randomised, parallel-group, double-blinded trial over 10 centres in theUSA
with separate randomisation schemes used for each seizure type
4 treatments: CBZ, phenytoin, PB, primidone
Participants Adults with previously untreated or under-treated simple or complex focal or secondary
generalised tonic-clonic seizures
Number randomised: CBZ = 155, PB = 155
100% focal epilepsy
268 (88%) male participants
Mean age (range): 41 (18-82) years
Range of follow-up: 1-177 months
Interventions Monotherapy with PB or CBZ
Median daily dose achieved: PB = 160 mg/day; CBZ = 800 mg/day
Outcomes • Participant retention/time to drug failure (length of time participant continued to
take randomised drug)
• Composite scores of seizure frequency (seizure rates and total seizure control) and
toxicity
• Incidence of side-effects
Notes We received IPD for all outcomes of this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomised with stratifi-
cation for seizure type. The method of ran-
domisationwas not stated andnot provided
by the trial authors
Allocation concealment (selection bias) Unclear risk No information was provided in the pub-
lication or by the trial authors
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was double-blind (participants
and personnel), which was achieved using
an additional blank tablet
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Mattson 1985 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It was unclear if outcome assessment was
blinded; no information was provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates were reported; we analysed
all randomised participants from the IPD
provideda .
Selective reporting (reporting bias) Low risk All outcomes were reported or calculated
with the IPD provideda .
Other bias Low risk We detected no other bias.
Mitchell 1987
Methods Randomised, double-blind, single-centre, parallel paediatric trial conducted in Los An-
geles, USA
2 treatment arms: CBZ and PB
Participants Children with newly diagnosed epilepsy
Number randomised: PB = 18, CBZ = 15
100% focal epilepsy, 100% newly diagnosed
20 (61%) boys
Mean age (range): PB = 7.89 (2-12 years), CBZ = 6.07 (2-12 years)
Trial duration: 12 months
Range of follow-up: not reported
Interventions Monotherapy with PB or CBZ. Doses started and achieved not stated
Outcomes • Change in cognitive, intelligence (IQ), behavioural, and psychometric scores
between baseline, 6 months, and 12 months
• Compliance, drug changes, and withdrawal rates
• Seizure control at 6 and 12 months (excellent/good/fair/poor)
Notes 33 participants were randomised to PB (18) and CBZ (15) in this trial; 6 children were
enrolled into a six-month pilot trial (PB (4) CBZ (2)) prior to the randomised trial. The
6 children were included in six-month follow-up psychometric data
Outcomes for this review were not reported; IPD were not available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk 33 children were “randomised using a
scheme that balanced drug distribution by
age and sex”; no further details were pro-
vided on the randomisation scheme. 6 non-
randomised childrenwere also used in some
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Mitchell 1987 (Continued)
analyses
Allocation concealment (selection bias) Unclear risk No information was provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial blinded participants (and parents)
; clinicians were unblinded for clinical fol-
low-up
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The trial blinded psychometric (cognitive)
testers blinded for clinical follow-up
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates were reported; results were
reported for all children who completed
each stage of follow-up
Selective reporting (reporting bias) Low risk Cognitive/behavioural outcomes, seizure
control outcomes, and adverse events were
all well reported.Noprotocol was available;
outcomes for this review were not reported
Other bias High risk There was evidence that the trial may have
been underpowered to detect differences (e.
g. 55%power tofind a5-point difference in
IQ score). The behavioural questionnaire
was not fully validated. Non-randomised
children from a pilot trial were included in
the results for psychometric outcomes and
medical outcomes
Ogunrin 2005
Methods Double-blinded, parallel-group, randomised trial conducted in a single-centre in Nigeria
3 treatment arms: CBZ, phenytoin, PB
Participants Consectuive newly diagnosed participants aged ≥ 14 years presenting at the outpatient
neurology clinic of theUniversity TeachingHopsital, BeninCity,Nigeria, with recurrent,
untreated afebrile seizures
Number randomised: PB = 18, CBZ = 19
7 participants with focal seizures (19%)
22 male participants (59%)
Mean age (range): 23.62 years (14-38 years)
Range of follow-up: all participants followed up for 12 weeks
Interventions Monotherapy with PB or CBZ. Median daily dose (range): PB = 120 mg (60-180 mg),
CBZ = 600 mg (400 mg-1200 mg)
Outcomes • Cognitive measures (reaction times, mental speed, memory, attention)
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Ogunrin 2005 (Continued)
Notes We received IPD for all randomised participants. The trial duration was 12 weeks; all
participants completed the trial; therefore, we could not calculate the outcomes ’time to
treatment failure’, ’time to six-month remission’, and ’time to 12-month remission’. We
calculated ’time to first seizure’ from the IPD provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The trial randomised participants using
simple randomisation: each participant was
asked to pick 1 from a table of numbers (1-
60); the numbers corresponded to alloca-
tion of 1 of 3 drugs (the trial author pro-
vided information)
Allocation concealment (selection bias) Low risk Recruitment/ran-
domisation of participants and allocations
of treatments took place on different sites
(the trial author provided information)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants were single-blinded. The trial
did not blind the research assistant recruit-
ing participants and counselling on medi-
cation adherence
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators performing cognitive assess-
ments were single-blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants completed the
trial. We analysed all randomised partici-
pants from the IPD provideda .
Selective reporting (reporting bias) Low risk We calculated 1 outcome for this review
from the IPD provideda . Other outcomes
for this review were not available because of
short trial length. All cognitive outcomes
from the trial were well reported
Other bias Low risk We detected no other bias.
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Placencia 1993
Methods Randomised, parallel-group trial conducted in the context of existing community health
care in a rural highland area of Ecuador
Participants Participants with a history of at least 2 afebrile seizures and no previous AED treatment
in the 4 weeks preceding the trial were eligible
Number randomised: PB = 97, CBZ = 95
133 participants (69%) with focal epilepsy
67 (35%) male participants
Mean age (range): PB = 28.6 (2-68 years), CBZ = 29.2 (2-68 years)
Trial duration: 12 months
Range of follow-up: 0-53.4 months
Interventions Monotherapy with PB or CBZ. Minimum maintenance doses by age groups:
2-5 years: PB: 15 mg/day, CBZ: 150 mg/day; 6-10 years: PB: 30 mg/day, CBZ: 300 mg/
day; 11-15 years: PB: 45 mg/day, CBZ: 500 mg/day; > 16 PB: 60 mg/day, CBZ: 600
mg/day. Doses gradually increased
Doses achieved not stated
Outcomes • Proportion seizure-free at 3-, 6-, and 12-month follow-ups
• Proportion seizure-free, with more than 50% seizure reduction and no change in
seizure frequency in 6- to 12-month follow-up period
• Incidence of adverse effects
Notes We received IPD for all outcomes used in this review. Results in the published paper
were given for 139 participants who completed 6 months’ follow-up, but we received
IPD for all 192 participants randomised
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants randomised with random
number list, no information provided on
method of generating random list
Allocation concealment (selection bias) High risk Allocation concealed used sealed opaque
envelopes but method not used for all par-
ticipants (information provided by trial au-
thor)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
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Placencia 1993 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported, all randomised
participants analysed from IPD provideda .
Selective reporting (reporting bias) Low risk All outcomes were reported or calculated
with the IPD provideda .
Other bias High risk Inconsistencies between number and rea-
sons of withdrawals between the data and
the published paper which could not be re-
solved by the trial authors (see Sensitivity
analysis).
aFor trials for which we received IPD (Banu 2007; de Silva 1996; Heller 1995;Mattson 1985; Ogunrin 2005; Placencia 1993), attrition
and reporting bias were reduced as we requested attrition rates and unpublished outcome data.
AED: antiepileptic drug; CBZ: carbamazepine; IPD: individual participant data;IQ: intelligence quotient; ITT: intention-to-treat;
PB: phenobarbitone; WISC-R scale: the Wechsler Intelligence Scale for Children
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bird 1966 It was unclear whether this trial was randomised and whether participants received either CBZ or PB as
monotherapy
Castro-Gago 1998 The trial was not randomised, and the treatment choice was made based on types of seizures
Hansen 1980 The trial was not randomised; participants were already on CBZ or PB monotherapy upon entry into the trial
Kuzuya 1993 The trial was not randomised; participants were already on CBZ or PB monotherapy upon entry into the trial
Marjerrison 1968 CBZ or PB therapywere added to current treatment.We could notmake a comparison betweenCBZmonother-
apy and PB monotherapy
Meador 1990 We could not make a comparison between CBZ monotherapy and PBmonotherapy. This was a cross-over trial,
but some participants were receiving treatment at the start of the first period, which had to be withdrawn slowly
Sabers 1995 The trial was not fully randomised: “The treatment was chosen at random unless the individual diagnoses
required a specific drug.”
AED: antiepileptic drugs; CBZ: carbamazepine; IPD: individual participant data; PB: phenobarbitone
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D A T A A N D A N A L Y S E S
Comparison 1. Carbamazepine versus phenobarbitone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to treatment failure (any
reason related to the treatment)
4 676 Hazard Ratio (Fixed, 95% CI) 0.66 [0.51, 0.86]
2 Time to treatment failure due to
adverse events
4 676 Hazard Ratio (Fixed, 95% CI) 0.67 [0.48, 0.93]
3 Time to treatment failure due to
lack of efficacy
3 487 Hazard Ratio (Fixed, 95% CI) 0.54 [0.38, 0.77]
4 Time to treatment failure (any
reason related to the treatment)
- by seizure type
4 676 Hazard Ratio (Fixed, 95% CI) 0.66 [0.50, 0.86]
4.1 Focal onset 4 520 Hazard Ratio (Fixed, 95% CI) 0.66 [0.49, 0.88]
4.2 Generalised onset 3 156 Hazard Ratio (Fixed, 95% CI) 0.65 [0.35, 1.23]
5 Time to treatment failure due to
adverse events - by seizure type
4 619 Hazard Ratio (Fixed, 95% CI) 0.69 [0.49, 0.97]
5.1 Focal onset 4 520 Hazard Ratio (Fixed, 95% CI) 0.67 [0.46, 0.96]
5.2 Generalised onset 2 99 Hazard Ratio (Fixed, 95% CI) 0.84 [0.35, 2.00]
6 Time to treatment failure due to
lack of efficacy - by seizure type
3 487 Hazard Ratio (Fixed, 95% CI) 0.54 [0.38, 0.78]
6.1 Focal onset 3 388 Hazard Ratio (Fixed, 95% CI) 0.54 [0.36, 0.80]
6.2 Generalised onset 2 99 Hazard Ratio (Fixed, 95% CI) 0.56 [0.23, 1.35]
7 Time to first seizure 6 822 Hazard Ratio (Fixed, 95% CI) 1.15 [0.95, 1.40]
8 Time to first seizure - by seizure
type
6 822 Hazard Ratio (Fixed, 95% CI) 1.13 [0.93, 1.38]
8.1 Focal onset 6 584 Hazard Ratio (Fixed, 95% CI) 1.31 [1.04, 1.66]
8.2 Generalised onset 5 238 Hazard Ratio (Fixed, 95% CI) 0.80 [0.55, 1.15]
9 Time to first seizure - sensitivity
analysis
6 822 Hazard Ratio (Fixed, 95% CI) 1.11 [0.91, 1.35]
9.1 Focal onset 6 584 Hazard Ratio (Fixed, 95% CI) 1.31 [1.04, 1.66]
9.2 Generalised onset 5 173 Hazard Ratio (Fixed, 95% CI) 0.70 [0.45, 1.07]
9.3 Uncertain seizure type 3 65 Hazard Ratio (Fixed, 95% CI) 0.82 [0.40, 1.69]
10 Time to 12-month remission 4 683 Hazard Ratio (Fixed, 95% CI) 1.09 [0.85, 1.40]
11 Time to 12-month remission -
by seizure type
4 683 Hazard Ratio (Fixed, 95% CI) 1.09 [0.84, 1.40]
11.1 Focal onset 4 525 Hazard Ratio (Fixed, 95% CI) 0.92 [0.67, 1.25]
11.2 Generalised onset 3 158 Hazard Ratio (Fixed, 95% CI) 1.56 [0.99, 2.44]
12 Time to six-month remission 4 683 Hazard Ratio (Fixed, 95% CI) 0.98 [0.80, 1.21]
13 Time to six-month remission -
by seizure type
4 683 Hazard Ratio (Fixed, 95% CI) 1.01 [0.81, 1.24]
13.1 Focal onset 4 525 Hazard Ratio (Fixed, 95% CI) 0.86 [0.67, 1.11]
13.2 Generalised onset 3 158 Hazard Ratio (Fixed, 95% CI) 1.45 [0.99, 2.12]
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Analysis 1.1. Comparison 1 Carbamazepine versus phenobarbitone, Outcome 1 Time to treatment failure
(any reason related to the treatment).
Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenobarbitone
Outcome: 1 Time to treatment failure (any reason related to the treatment)
Study or subgroup Carbamazepine Phenobarbitone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
de Silva 1996 53 10 -1.216812 (0.4214743) 10.3 % 0.30 [ 0.13, 0.68 ]
Heller 1995 60 55 -0.3732613 (0.3230799) 17.5 % 0.69 [ 0.37, 1.30 ]
Mattson 1985 154 155 -0.4476002 (0.1772439) 58.0 % 0.64 [ 0.45, 0.90 ]
Placencia 1993 94 95 0.2493311 (0.3577443) 14.2 % 1.28 [ 0.64, 2.59 ]
Total (95% CI) 361 315 100.0 % 0.66 [ 0.51, 0.86 ]
Heterogeneity: Chi2 = 7.12, df = 3 (P = 0.07); I2 =58%
Test for overall effect: Z = 3.07 (P = 0.0022)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Carbamazepine versus phenobarbitone, Outcome 2 Time to treatment failure
due to adverse events.
Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenobarbitone
Outcome: 2 Time to treatment failure due to adverse events
Study or subgroup Carbamazepine Phenobarbitone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
de Silva 1996 53 10 -1.741723 (0.5433885) 9.5 % 0.18 [ 0.06, 0.51 ]
Heller 1995 60 55 -0.3341612 (0.3873827) 18.8 % 0.72 [ 0.34, 1.53 ]
Mattson 1985 154 155 -0.2698597 (0.2086441) 64.7 % 0.76 [ 0.51, 1.15 ]
Placencia 1993 94 95 0.0222658 (0.6327472) 7.0 % 1.02 [ 0.30, 3.53 ]
Total (95% CI) 361 315 100.0 % 0.67 [ 0.48, 0.93 ]
Heterogeneity: Chi2 = 6.96, df = 3 (P = 0.07); I2 =57%
Test for overall effect: Z = 2.39 (P = 0.017)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Carbamazepine versus phenobarbitone, Outcome 3 Time to treatment failure
due to lack of efficacy.
Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenobarbitone
Outcome: 3 Time to treatment failure due to lack of efficacy
Study or subgroup Carbamazepine Phenobarbitone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
de Silva 1996 53 10 -1.139995 (0.4779972) 14.4 % 0.32 [ 0.13, 0.82 ]
Heller 1995 60 55 -0.2234031 (0.4598163) 15.6 % 0.80 [ 0.32, 1.97 ]
Mattson 1985 154 155 -0.5963195 (0.2169552) 70.0 % 0.55 [ 0.36, 0.84 ]
Total (95% CI) 267 220 100.0 % 0.54 [ 0.38, 0.77 ]
Heterogeneity: Chi2 = 1.94, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 3.40 (P = 0.00068)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Carbamazepine versus phenobarbitone, Outcome 4 Time to treatment failure
(any reason related to the treatment) - by seizure type.
Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenobarbitone
Outcome: 4 Time to treatment failure (any reason related to the treatment) - by seizure type
Study or subgroup Carbamazepine Phenobarbitone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset
de Silva 1996 28 5 -1.716678 (0.6412772) 4.5 % 0.18 [ 0.05, 0.63 ]
Heller 1995 24 22 -0.6226315 (0.4696605) 8.4 % 0.54 [ 0.21, 1.35 ]
Mattson 1985 154 155 -0.4476002 (0.1772439) 59.0 % 0.64 [ 0.45, 0.90 ]
Placencia 1993 69 63 0.4761057 (0.4231299) 10.3 % 1.61 [ 0.70, 3.69 ]
Subtotal (95% CI) 275 245 82.2 % 0.66 [ 0.49, 0.88 ]
Heterogeneity: Chi2 = 8.78, df = 3 (P = 0.03); I2 =66%
Test for overall effect: Z = 2.79 (P = 0.0053)
2 Generalised onset
de Silva 1996 25 -0.7524528 (0.5933421) 5 5.3 % 0.47 [ 0.15, 1.51 ]
Heller 1995 36 33 -0.2316466 (0.4500431) 9.1 % 0.79 [ 0.33, 1.92 ]
Placencia 1993 25 32 -0.4348027 (0.738504) 3.4 % 0.65 [ 0.15, 2.75 ]
Subtotal (95% CI) 86 70 17.8 % 0.65 [ 0.35, 1.23 ]
Heterogeneity: Chi2 = 0.49, df = 2 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
Total (95% CI) 361 315 100.0 % 0.66 [ 0.50, 0.86 ]
Heterogeneity: Chi2 = 9.27, df = 6 (P = 0.16); I2 =35%
Test for overall effect: Z = 3.08 (P = 0.0020)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.99), I2 =0.0%
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Analysis 1.5. Comparison 1 Carbamazepine versus phenobarbitone, Outcome 5 Time to treatment failure
due to adverse events - by seizure type.
Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenobarbitone
Outcome: 5 Time to treatment failure due to adverse events - by seizure type
Study or subgroup Carbamazepine Phenobarbitone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset
de Silva 1996 28 5 -2.251845 (0.7210748) 5.7 % 0.11 [ 0.03, 0.43 ]
Heller 1995 24 22 -0.9066533 (0.61399) 7.8 % 0.40 [ 0.12, 1.35 ]
Mattson 1985 154 155 -0.2698597 (0.2086441) 67.5 % 0.76 [ 0.51, 1.15 ]
Placencia 1993 69 63 0.8931813 (0.8372467) 4.2 % 2.44 [ 0.47, 12.61 ]
Subtotal (95% CI) 275 245 85.2 % 0.67 [ 0.46, 0.96 ]
Heterogeneity: Chi2 = 10.05, df = 3 (P = 0.02); I2 =70%
Test for overall effect: Z = 2.17 (P = 0.030)
2 Generalised onset
de Silva 1996 25 5 0.0797978 (0.5179769) 11.0 % 1.08 [ 0.39, 2.99 ]
Heller 1995 36 33 -0.9037748 (0.8691213) 3.9 % 0.41 [ 0.07, 2.22 ]
Subtotal (95% CI) 61 38 14.8 % 0.84 [ 0.35, 2.00 ]
Heterogeneity: Chi2 = 0.95, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
Total (95% CI) 336 283 100.0 % 0.69 [ 0.49, 0.97 ]
Heterogeneity: Chi2 = 11.21, df = 5 (P = 0.05); I2 =55%
Test for overall effect: Z = 2.15 (P = 0.031)
Test for subgroup differences: Chi2 = 0.22, df = 1 (P = 0.64), I2 =0.0%
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Analysis 1.6. Comparison 1 Carbamazepine versus phenobarbitone, Outcome 6 Time to treatment failure
due to lack of efficacy - by seizure type.
Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenobarbitone
Outcome: 6 Time to treatment failure due to lack of efficacy - by seizure type
Study or subgroup Carbamazepine Phenobarbitone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset
de Silva 1996 28 5 -1.386797 (0.8571578) 4.5 % 0.25 [ 0.05, 1.34 ]
Heller 1995 24 22 -0.3812095 (0.6413726) 8.1 % 0.68 [ 0.19, 2.40 ]
Mattson 1985 154 155 -0.5963195 (0.2169552) 70.8 % 0.55 [ 0.36, 0.84 ]
Subtotal (95% CI) 206 182 83.5 % 0.54 [ 0.36, 0.80 ]
Heterogeneity: Chi2 = 0.95, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 3.09 (P = 0.0020)
2 Generalised onset
de Silva 1996 25 -0.8631442 (0.6028979) 5 9.2 % 0.42 [ 0.13, 1.38 ]
Heller 1995 36 33 -0.226421 (0.6722203) 7.4 % 0.80 [ 0.21, 2.98 ]
Subtotal (95% CI) 61 38 16.5 % 0.56 [ 0.23, 1.35 ]
Heterogeneity: Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
Total (95% CI) 267 220 100.0 % 0.54 [ 0.38, 0.78 ]
Heterogeneity: Chi2 = 1.45, df = 4 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 3.35 (P = 0.00080)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.94), I2 =0.0%
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Analysis 1.7. Comparison 1 Carbamazepine versus phenobarbitone, Outcome 7 Time to first seizure.
Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenobarbitone
Outcome: 7 Time to first seizure
Study or subgroup Carbamazepine Phenobarbitone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Banu 2007 54 54 -0.195606 (0.257114) 15.0 % 0.82 [ 0.50, 1.36 ]
de Silva 1996 54 10 0.278996 (0.3827441) 6.8 % 1.32 [ 0.62, 2.80 ]
Heller 1995 61 58 -0.0336438 (0.2191269) 20.6 % 0.97 [ 0.63, 1.49 ]
Mattson 1985 151 151 0.1931731 (0.1647032) 36.5 % 1.21 [ 0.88, 1.68 ]
Ogunrin 2005 19 18 1.235524 (0.5261066) 3.6 % 3.44 [ 1.23, 9.65 ]
Placencia 1993 95 97 0.25613 (0.2376446) 17.5 % 1.29 [ 0.81, 2.06 ]
Total (95% CI) 434 388 100.0 % 1.15 [ 0.95, 1.40 ]
Heterogeneity: Chi2 = 7.14, df = 5 (P = 0.21); I2 =30%
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Carbamazepine versus phenobarbitone, Outcome 8 Time to first seizure - by
seizure type.
Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenobarbitone
Outcome: 8 Time to first seizure - by seizure type
Study or subgroup Carbamazepine Phenobarbitone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset
Banu 2007 33 26 -0.1223868 (0.3458593) 8.5 % 0.88 [ 0.45, 1.74 ]
de Silva 1996 29 5 0.9806859 (0.6179757) 2.7 % 2.67 [ 0.79, 8.95 ]
Heller 1995 24 25 0.3841104 (0.3380217) 8.9 % 1.47 [ 0.76, 2.85 ]
Mattson 1985 151 151 0.1931731 (0.1647032) 37.5 % 1.21 [ 0.88, 1.68 ]
Ogunrin 2005 5 -0.3482015 (0.8702925) 2 1.3 % 0.71 [ 0.13, 3.89 ]
Placencia 1993 69 64 0.629728 (0.2957148) 11.6 % 1.88 [ 1.05, 3.35 ]
Subtotal (95% CI) 311 273 70.6 % 1.31 [ 1.04, 1.66 ]
Heterogeneity: Chi2 = 4.93, df = 5 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 2.25 (P = 0.024)
2 Generalised onset
Banu 2007 21 28 -0.2817094 (0.3952059) 6.5 % 0.75 [ 0.35, 1.64 ]
de Silva 1996 25 5 -0.634487 (0.5094808) 3.9 % 0.53 [ 0.20, 1.44 ]
Heller 1995 37 33 -0.2628398 (0.2988836) 11.4 % 0.77 [ 0.43, 1.38 ]
Ogunrin 2005 14 16 1.574365 (0.6629357) 2.3 % 4.83 [ 1.32, 17.70 ]
Placencia 1993 26 33 -0.5721611 (0.4392679) 5.3 % 0.56 [ 0.24, 1.33 ]
Subtotal (95% CI) 123 115 29.4 % 0.80 [ 0.55, 1.15 ]
Heterogeneity: Chi2 = 8.67, df = 4 (P = 0.07); I2 =54%
Test for overall effect: Z = 1.22 (P = 0.22)
Total (95% CI) 434 388 100.0 % 1.13 [ 0.93, 1.38 ]
Heterogeneity: Chi2 = 18.66, df = 10 (P = 0.04); I2 =46%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Chi2 = 5.06, df = 1 (P = 0.02), I2 =80%
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Analysis 1.9. Comparison 1 Carbamazepine versus phenobarbitone, Outcome 9 Time to first seizure -
sensitivity analysis.
Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenobarbitone
Outcome: 9 Time to first seizure - sensitivity analysis
Study or subgroup Carbamazepine Phenobarbitone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset
Banu 2007 33 26 -0.1223868 (0.3458593) 8.6 % 0.88 [ 0.45, 1.74 ]
de Silva 1996 29 5 0.9806859 (0.6179757) 2.7 % 2.67 [ 0.79, 8.95 ]
Heller 1995 24 25 0.3841104 (0.3380217) 9.0 % 1.47 [ 0.76, 2.85 ]
Mattson 1985 151 151 0.1931731 (0.1647032) 37.9 % 1.21 [ 0.88, 1.68 ]
Ogunrin 2005 5 -0.3482015 (0.8702925) 2 1.4 % 0.71 [ 0.13, 3.89 ]
Placencia 1993 69 64 0.629728 (0.2957148) 11.7 % 1.88 [ 1.05, 3.35 ]
Subtotal (95% CI) 311 273 71.2 % 1.31 [ 1.04, 1.66 ]
Heterogeneity: Chi2 = 4.93, df = 5 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 2.25 (P = 0.024)
2 Generalised onset
Banu 2007 21 28 -0.2817094 (0.3952059) 6.6 % 0.75 [ 0.35, 1.64 ]
de Silva 1996 25 5 -0.634487 (0.5094808) 4.0 % 0.53 [ 0.20, 1.44 ]
Heller 1995 28 20 -0.2939543 (0.3558309) 8.1 % 0.75 [ 0.37, 1.50 ]
Ogunrin 2005 8 3 0 (0) Not estimable
Placencia 1993 15 20 -0.3384765 (0.6298134) 2.6 % 0.71 [ 0.21, 2.45 ]
Subtotal (95% CI) 97 76 21.2 % 0.70 [ 0.45, 1.07 ]
Heterogeneity: Chi2 = 0.37, df = 3 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.63 (P = 0.10)
3 Uncertain seizure type
Heller 1995 9 13 -0.3113578 (0.5737574) 3.1 % 0.73 [ 0.24, 2.26 ]
Ogunrin 2005 6 13 1.175695 (0.7660131) 1.7 % 3.24 [ 0.72, 14.54 ]
Placencia 1993 11 13 -0.9615055 (0.6177455) 2.7 % 0.38 [ 0.11, 1.28 ]
Subtotal (95% CI) 26 39 7.6 % 0.82 [ 0.40, 1.69 ]
Heterogeneity: Chi2 = 4.78, df = 2 (P = 0.09); I2 =58%
Test for overall effect: Z = 0.54 (P = 0.59)
Total (95% CI) 434 388 100.0 % 1.11 [ 0.91, 1.35 ]
Heterogeneity: Chi2 = 17.11, df = 12 (P = 0.15); I2 =30%
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Chi2 = 7.03, df = 2 (P = 0.03), I2 =72%
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Analysis 1.10. Comparison 1 Carbamazepine versus phenobarbitone, Outcome 10 Time to 12-month
remission.
Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenobarbitone
Outcome: 10 Time to 12-month remission
Study or subgroup Carbamazepine Phenobarbitone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
de Silva 1996 54 10 0.0214456 (0.3745837) 11.6 % 1.02 [ 0.49, 2.13 ]
Heller 1995 61 58 0.1983685 (0.229981) 30.8 % 1.22 [ 0.78, 1.91 ]
Mattson 1985 154 155 0.2696123 (0.2218197) 33.2 % 1.31 [ 0.85, 2.02 ]
Placencia 1993 95 96 -0.2813333 (0.2587541) 24.4 % 0.75 [ 0.45, 1.25 ]
Total (95% CI) 364 319 100.0 % 1.09 [ 0.85, 1.40 ]
Heterogeneity: Chi2 = 2.97, df = 3 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Carbamazepine versus phenobarbitone, Outcome 11 Time to 12-month
remission - by seizure type.
Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenobarbitone
Outcome: 11 Time to 12-month remission - by seizure type
Study or subgroup Carbamazepine Phenobarbitone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset
de Silva 1996 29 -0.4357061 (0.4966534) 5 6.9 % 0.65 [ 0.24, 1.71 ]
Heller 1995 24 25 0.0512091 (0.3858894) 11.4 % 1.05 [ 0.49, 2.24 ]
Mattson 1985 154 155 0.2696123 (0.2218197) 34.4 % 1.31 [ 0.85, 2.02 ]
Placencia 1993 69 64 -0.8190156 (0.3307536) 15.5 % 0.44 [ 0.23, 0.84 ]
Subtotal (95% CI) 276 249 68.0 % 0.92 [ 0.67, 1.25 ]
Heterogeneity: Chi2 = 8.10, df = 3 (P = 0.04); I2 =63%
Test for overall effect: Z = 0.54 (P = 0.59)
2 Generalised onset
de Silva 1996 25 5 0.2279414 (0.5719332) 5.2 % 1.26 [ 0.41, 3.85 ]
Heller 1995 37 33 0.3780039 (0.2983645) 19.0 % 1.46 [ 0.81, 2.62 ]
Placencia 1993 26 32 0.7438788 (0.4646707) 7.8 % 2.10 [ 0.85, 5.23 ]
Subtotal (95% CI) 88 70 32.0 % 1.56 [ 0.99, 2.44 ]
Heterogeneity: Chi2 = 0.61, df = 2 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.93 (P = 0.054)
Total (95% CI) 364 319 100.0 % 1.09 [ 0.84, 1.40 ]
Heterogeneity: Chi2 = 12.31, df = 6 (P = 0.06); I2 =51%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Chi2 = 3.60, df = 1 (P = 0.06), I2 =72%
0.01 0.1 1 10 100
Favours PB Favours CBZ
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Analysis 1.12. Comparison 1 Carbamazepine versus phenobarbitone, Outcome 12 Time to six-month
remission.
Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenobarbitone
Outcome: 12 Time to six-month remission
Study or subgroup Carbamazepine Phenobarbitone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
de Silva 1996 54 10 0.105135 (0.3741439) 8.2 % 1.11 [ 0.53, 2.31 ]
Heller 1995 61 58 0.1876203 (0.2118923) 25.5 % 1.21 [ 0.80, 1.83 ]
Mattson 1985 154 155 0.0815794 (0.1884936) 32.2 % 1.08 [ 0.75, 1.57 ]
Placencia 1993 95 96 -0.2957436 (0.1829943) 34.2 % 0.74 [ 0.52, 1.06 ]
Total (95% CI) 364 319 100.0 % 0.98 [ 0.80, 1.21 ]
Heterogeneity: Chi2 = 3.63, df = 3 (P = 0.30); I2 =17%
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PB Favours CBZ
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Analysis 1.13. Comparison 1 Carbamazepine versus phenobarbitone, Outcome 13 Time to six-month
remission - by seizure type.
Review: Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenobarbitone
Outcome: 13 Time to six-month remission - by seizure type
Study or subgroup Carbamazepine Phenobarbitone log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Focal onset
de Silva 1996 29 -0.1628786 (0.4960439) 5 4.7 % 0.85 [ 0.32, 2.25 ]
Heller 1995 24 25 0.2521285 (0.3475113) 9.6 % 1.29 [ 0.65, 2.54 ]
Mattson 1985 154 155 0.0815794 (0.18849) 32.7 % 1.08 [ 0.75, 1.57 ]
Placencia 1993 69 64 -0.6662274 (0.227498) 22.5 % 0.51 [ 0.33, 0.80 ]
Subtotal (95% CI) 276 249 69.5 % 0.86 [ 0.67, 1.11 ]
Heterogeneity: Chi2 = 8.00, df = 3 (P = 0.05); I2 =62%
Test for overall effect: Z = 1.18 (P = 0.24)
2 Generalised onset
de Silva 1996 25 5 0.2398219 (0.5723811) 3.5 % 1.27 [ 0.41, 3.90 ]
Heller 1995 37 33 0.1984551 (0.2707491) 15.9 % 1.22 [ 0.72, 2.07 ]
Placencia 1993 26 32 0.6580273 (0.3235137) 11.1 % 1.93 [ 1.02, 3.64 ]
Subtotal (95% CI) 88 70 30.5 % 1.45 [ 0.99, 2.12 ]
Heterogeneity: Chi2 = 1.25, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.90 (P = 0.058)
Total (95% CI) 364 319 100.0 % 1.01 [ 0.81, 1.24 ]
Heterogeneity: Chi2 = 14.24, df = 6 (P = 0.03); I2 =58%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Chi2 = 5.00, df = 1 (P = 0.03), I2 =80%
0.01 0.1 1 10 100
Favours PB Favours CBZ
A D D I T I O N A L T A B L E S
Table 1. Demographic characteristics of trial participants (trials providing individual participant data)
Focal seizures: n
(%)a
Male partici-
pants: n (%)a
Age at entry
(years):
Mean (SD), range
Aged
> 30 and gener-
alised seizures: n
(%)
Epilepsy duration
(years): mean
(SD), range
Number
of seizures in prior
6 months: median
(range)
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Table 1. Demographic characteristics of trial participants (trials providing individual participant data) (Continued)
CBZ
PB
Miss-
ing
CBZ
PB
Miss-
ing
CBZ
PB
Miss-
ing
CBZ
PB
Miss-
ing
CBZ
PB
Miss-
ing
CBZ
PB
Miss-
ing
Banu
2007
33
(61%)
26
(48%)
0 24
(44%)
37
(69%)
0 6.
2 (3.
6), 1
to
15
5.
3 (3.
3), 1
to
12
0 0 0 0 2.
0 (2.
4), 0
to
11.5
1.
6 (2.
0), 0
to
10
0 24
(1 to
7200)
24
(2 to
4320)
5
de
Silva
1996
b
29
(54%)
5
(50%)
0 30
(56%)
4
(40%)
6 9.
2 (3.
8), 2
to
15
9.
1 (3.
9), 3
to
14
6 0 0 0 1.
7 (2.
6), 0
to
12
1.
3 (1.
8)
, 0.1
to 5
6 3
(1 to
500)
3
(1 to
170)
6
Heller
1995
24
(39%)
25
(43%)
0 30
(49%)
25
(43%)
0 29.3
(14.
1)
, 13
to
69
34.5
(15.
1)
, 16
to
77
1 9 13 0 4.
4 (7.
4)
, 0.
1 to
40
3.
4 (6.
6), 0
to
37
2 2
(1 to
354)
3
(1 to
579)
1
Matt-
son
1985
155
(100%)
155
(100%)
0 133
(87%)
135
(88%)
4 42.1
(15.
9)
, 18
to
82
40.1
(15.
3)
, 18
to
75
4 0 0 0 5.
9 (9.
1)
, 0.
5 to
55
5.
7 (7.
9)
, 0.
5 to
36
5 1
(1 to
100)
1
(1 to
14)
7
Ogun-
rin
2005
5
(26%)
2
(11%)
0 12
(63%)
11
(61%)
0 28.
2 (5.
8)
, 14
to
38
35.
4 (6.
2)
, 26
to
55
0 6 13 0 NA NA 37 18
(6 to
36)
12
(6 to
42)
0
Pla-
cen-
cia
1993
69
(73%)
64
(66%)
0 37
(39%)
30
(31%)
0 29.3
(18.
2), 2
to
68
28.7
(17.
1), 2
to
68
0 11 13 0 9.5
(11.
6)
, 0.
5 to
54
9.8
(11.
0)
, 0.
5 to
48
0 1
(0 to
68)
2
(0 to
100)
0
CBZ: carbamazepine; n: number of participants; NA: not available; PB: phenobarbitone; SD: standard deviation
aProportions (%) are calculated based on non-missing data.
bRandomised drug missing for 6 participants in de Silva 1996.
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Table 2. Outcomes considered and summary of results for trials with no individual participant data
Trial Outcomes reported Summary of results
Bidabadi 2009 1. Proportion seizure-free
2. Response rate
3. Rate of side-effects
4. Mean seizure frequency per month
5. Mean seizure duration
1. CBZ: 23/36 (64%), PB: 22/35 (63%)
2. No statistically significant difference between
groups
3. No statistically significant difference between
groups
4. CBZ: 0.66, PB: 0.8
5. CBZ: 12.63 seconds, PB: 15 seconds
Cereghino 1974 1. Behaviour measured with rating scale modified
from the Ward Behavior Rating Scale
2. Seizure control
3. Side-effects
4. Withdrawals
1. No change or improvement in behaviour was
more common on PB than CBZ (40% versus 12%);
predominant improvement with some deterioration
was more common on CBZ than PB (36% versus
12%)
2. No difference between PB and CBZ in terms of
seizure control
3. Gastrointestinal and “impaired function” side-
effects were more common on CBZ than PB in the
first few trial days. Side-effects of both drugs were
minimal in later stages of the trial
4. PB: 26/44 (59%), CBZ: 27/45 (60%)
Chen 1996 1. IQ scores measured with WISC-R scale
2. Time to complete the Bender-Gestalt test
3. Auditory event-related potentials
4. Incidence of allergic reactions
5. Seizure control
1. No significant difference between groups
2. No significant difference between groups
3. No significant difference between groups
4. 2 children from PB group and 1 child from CBZ
group withdrew from the trial because of allergic
reactions
5. No significant difference between groups
Cossu 1984 1. Changes in memory function from baseline after
3 weeks of treatment (verbal, visual, (visual-verbal and
visual-non-verbal), acoustic, tactile, and spatial)
1. Significant decrease in visual-verbal memory for
CBZ and acoustic memory for PB
2. No significant differences for other tests
Czapinski 1997 1. Proportion achieving 24-month remission at 3
years
2. Proportion excluded after randomisation due to
adverse effects or no efficacy
1. PB: 60%, CBZ: 62%
2. PB: 33%, CBZ: 30%
Feksi 1991 1. Adverse effects
2. Withdrawals from allocated treatment
3. Seizure frequency (during second 6 months of
trial, participants completing the trial only)
PB (n = 123), CBZ (n = 126)
1. Minor adverse effects reported in PB: 58
participants (39%) reported 86 adverse events, CBZ:
46 participants (30%) reported 68 adverse events
2. PB: all withdrawals: PB: 27 (18%), CBZ: 26
(17%); withdrawals due to side-effects: PB: 8 (5%),
CBZ: 5 (3%)
3. Seizure-free: PB: 67 (54%), CBZ: 65 (52%); >
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Table 2. Outcomes considered and summary of results for trials with no individual participant data (Continued)
50% reduction of seizures from baseline: PB: 28 (23%)
, CBZ: 37 (29%); between 50% reduction to 50%
increase of seizures: PB: 18 (15%), CBZ: 17 (13%); >
50% increase in seizures: PB: 10 (8%), CBZ: 7 (6%)
Mitchell 1987 1. Cognitive/behavioural outcomes at 1, 2, 6, and
12 months
2. Compliance, drug changes, and withdrawal rates
3. Seizure control at 6 and 12 months (excellent/
good/fair/poor)
1. No significant differences between treatment
groups (children from pilot trial included for 6 and 12
months)
2. Compliance (children from pilot trial included):
trend towards better compliance in CBZ group (not
significant)
i) Randomised participants only: trend
towards higher rate withdrawal from treatment in PB
group (not significant). More mild systemic side-effects
in CBZ group (significant). 3 children switched from
CBZ to PB and 1 from PB to CB following adverse
reactions
3. Seizure control at 6 months: excellent/good: PB =
15, CBZ = 13 (children from pilot trial included) fair/
poor PB = 5, CBZ = 3; seizure control at 12 months:
excellent/good: PB = 13, CBZ = 9 (children from pilot
trial included) fair/poor PB = 4, CBZ = 4
CBZ: carbamazepine; IQ: intelligence quotient; PB: phenobarbitone; WISC-R scale: the Wechsler Intelligence Scale for Children
Table 3. Number of participants contributing to each analysis
Trial Number
randomised
Time to treatment
failure
Time to 12-month
remission
Time to six-month
remission
Time to first seizure
CBZ PB Total CBZ PB Total CBZ PB Total CBZ PB Total CBZ PB Total
Banu
2007
a
54 54 108 Data not available Data not available Data not available 54 54 108
de
Silva
1996
b
54 10 64 53 10 63 54 10 64 54 10 64 54 10 64
Heller
1995
c
61 58 119 60 55 115 61 58 119 61 58 119 61 58 119
Matt-
son
1985
155 155 310 154 155 309 154 155 309 154 155 309 151 151 302
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Table 3. Number of participants contributing to each analysis (Continued)
d
Ogun-
rin
2005
e
19 18 37 Data not available Data not available Data not available 19 18 37
Pla-
cen-
cia
1993
f
95 97 192 94 95 189 95 96 191 95 96 191 95 97 192
Total 438 392 830 361 315 676 364 319 683 364 319 683 434 388 822
CBZ: carbamazepine; PB: phenobarbitone
aThe date of treatment failure was not recorded in all cases for Banu 2007, so we could not calculate ’time to treatment failure’. The
date of first seizure after randomisation was recorded, but none of the dates of subsequent seizures were recorded; therefore, we could
calculate ’time to first seizure’, but we could not calculate ’time to six-month remission’ and ’time to 12-month remission’.
bWe received individual participant data for 70 participants recruited in de Silva 1996; the randomised drug was not recorded in six
participants. Reasons for treatment failure were not available for one participant randomised to CBZ; we did not include this participant
in the analysis of ’time to treatment failure.’
cReasons for treatment failure were not available for four participants (one randomised to CBZ and three to PB), in Heller 1995; we
did not include these participants in the analysis of ’time to treatment failure.’
dNo follow-up data after randomisation were available for one participant randomised to CBZ in Mattson 1985. Dates of seizure
recurrence were not available for seven participants (three randomised to CBZ and four to PB); we did not include these participants
in the analysis of ’time to first seizure.’
eThe trial duration of Ogunrin 2005 was 12 weeks; therefore, six- and 12-month remission of seizures could not be achieved, so we
could not calculate these outcomes. All randomised participants completed the trial without withdrawing from treatment or treatment
failing, so we could not analyse ’time to treatment failure.’
fReasons for treatment failure were not available for three participants (one randomised to CBZ and two randomised to PB) in Placencia
1993. We did not include these participants in the analysis of ’time to treatment failure.’ Seizure data after occurrence of first seizure
were not available for one participant randomised to PB, so we did not include this participant in the analyses of time to six-month
and time to 12-month remission.
Table 4. Reasons for premature discontinuation (treatment failure)
Rea-
son for
early
termi-
nation
de Silva 1996
a
Heller 1995a Mattson 1985
a
Placencia
1993b
Banu 2007c Total
CBZ PB CBZ PB CBZ PB CBZ PB CBZ PB CBZ PB All
Ad-
verse
events
(event)
3 2 8 12 11 5 5 5 0 0 27 24 51
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Table 4. Reasons for premature discontinuation (treatment failure) (Continued)
Lack of
effi-
cacy
(event)
12 2 5 7 3 11 0 0 8 6 28 26 54
Both
adverse
events
and
lack of
effi-
cacy
(event)
6 4 4 3 31 46 0 0 0 0 41 53 94
Non-
com-
pli-
ance/
proto-
col vio-
lation
(event)
0 0 0 0 11 19 13 9 6 0 30 28 58
Ill-
ness or
death
(not
treat-
ment-
re-
lated,
cen-
sored)
0 0 0 0 17 13 2 1 0 0 19 14 33
Partici-
pant
went
into re-
mis-
sion
(cen-
sored)
18 1 6 3 0 0 0 0 0 2 24 6 30
Lost to
follow-
up
(cen-
sored)
0 0 0 0 26 26 11 5 7 15 44 46 90
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Table 4. Reasons for premature discontinuation (treatment failure) (Continued)
Other
(cen-
sored)
d
0 0 0 0 3 2 0 0 0 0 3 2 5
Com-
pleted
the
trial
(cen-
sored)
14 1 37 30 52 33 63 75 33 31 199 170 369
Total 53 10 60 55 154 155 94 95 54 54 415 369 784
CBZ: carbamazepine; PB: phenobarbitone
aFour participants for Heller 1995 (one on CBZ and three on PB) and one for de Silva 1996 (CBZ) and one for Mattson 1985 (CBZ)
had missing reasons for treatment failure.
bThere were inconsistencies between individual participant data and the publication of Placencia 1993; we performed sensitivity analysis
(see Effects of interventions). There were missing reasons for treatment failure for three participants (one on CBZ and two on PB); we
did not include these participants in the analysis.
cBanu 2007 provided reasons for treatment failure, but dates of treatment failure could not be provided for all participants, so we could
not calculate ’time to treatment failure.’
dOther reasons from Mattson 1985: participants developed other medical disorders including neurological and psychiatric disorders.
Table 5. Sensitivity analyses
Analysisa Time to treatment
failureb
Time to first
seizured
Time to 12-month
remission
Time to six-month
remission
Original analysis
(adjusted for seizure
type)
Participants Overall: 676
(Foc: 520; Gen:
156)
Overall: 822
(Foc: 584; Gen 238)
Overall: 683
(Foc: 525; Gen:
158)
Overall: 683
(Foc: 525; Gen:
158)
Pooled HR (95%
CI),
P value, I² (%)
Foc: 0.66 (0.49 to 0.
88)
P = 0.005, I² = 66%
Gen: 0.65 (0.35 to
1.23)
P = 0.19, I² = 0%
Overall: 0.66 (0.50
to 0.86)
P = 0.002, I² = 35%
Foc: 1.31 (1.04 to 1.
66)
P = 0.02, I² = 0%
Gen: 0.80 (0.55 to
1.15)
P = 0.22, I² = 54%
Overall: 1.13 (0.93
to 1.38)
P = 0.22, I² = 46%
Foc: 0.92 (0.67 to 1.
25)
P = 0.59, I² = 63%
Gen: 1.56 (0.99 to
2.44)
P = 0.05, I² = 0%
Overall: 1.09 (0.84
to 1.40)
P = 0.52, I² = 51%
Foc: 0.86 (0.67 to 1.
11)
P = 0.24, I² = 62%
Gen: 1.45 (0.99 to
2.12)
P = 0.06, I² = 0%
Overall: 1.01 (0.81
to 1.24)
P = 0.95, I² = 58%
Sensitivity analysis
excluding Placencia
1993b
Participants Overall: 487
(Foc: 388; Gen 99)
Overall: 630
(Foc: 451; Gen:
179)
Overall: 492
(Foc: 392; Gen:
100)
Overall: 492
(Foc: 392; Gen:
100)
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Table 5. Sensitivity analyses (Continued)
Pooled HR (95%
CI),
P value, I² (%)
Foc: 0.58 (0.42 to 0.
79)
P = 0.0006, I² =
45%
Gen: 0.66 (0.32 to
1.32)
P = 0.24, I² = 0%
Overall: 0.59 (0.44
to 0.79)
P = 0.0003, I² = 6%
Foc: 1.22 (0.94 to 1.
58)
P = 0.13, I² = 0%
Gen: 0.86 (0.57 to
1.28)
P = 0.46, I² = 62%
Overall: 1.10 (0.89
to 1.37)
P = 0.38, I² = 39%
Foc: 1.14 (0.80 to 1.
62)
P = 0.47, I² = 0%
Gen: 1.41 (0.84 to
2.37)
P = 0.19, I² = 0%
Overall: 1.22 (0.91
to 1.63)
P = 0.18; I² = 0%
Foc: 1.10 (0.81 to 1.
49)
P = 0.56, I² = 0%
Gen: 1.23 (0.76 to
1.99)
P = 0.40, I² = 0%
Overall: 1.13 (0.87
to 1.47)
P = 0.34, I² = 0%
Sensitivity analysis
for de Silva 1996c
Participants Overall: 633
(Foc: 498: Gen:
135)
Overall: 779
(Foc: 562; Gen:
217)
Overall: 640
(Foc: 503; Gen:
137)
Overall: 640
(Foc: 503; Gen:
137)
Pooled HR (95%
CI),
P value, I² (%)
Foc: 0.69 (0.51 to 0.
93)
P = 0.01, I² = 47%
Gen: 0.73 (0.37 to
1.45)
P = 0.37, I² = 0%
Overall: 0.69 (0.53
to 0.91)
P = 0.009, I² = 0%
Foc: 1.30 (1.02 to 1.
64)
P = 0.03; I² = 0%
Gen: 0.81 (0.56 to
1.19)
P = 0.29, I² = 53%
Overall: 1.14 (0.93
to 1.39)
P = 0.21; I² = 42%
Foc: 0.94 (0.68 to 1.
29)
P = 0.69, I² = 62%
Gen: 1.68 (1.06 to
2.69)
P = 0.03, I² = 0%
Overall: 1.13 (0.87
to 1.46)
P = 0.37, I² = 51%
Foc: 0.87 (0.67 to 1.
13)
P = 0.31; I² = 65%
Gen: 1.51 (1.02 to
2.23)
P = 0.04, I² = 0%
Overall: 1.03 (0.83
to 1.28)
P = 0.79, I² = 65%
Sensitivity analysis
classifying
generalised onset
seizures
and age at onset > 30
as focal onset
seizures
Participants Overall: 676
(Foc: 566; Gen:
110)
Overall: 822
(Foc: 649; Gen:
173)
Overall: 683
(Foc: 571; Gen:
112)
Overall: 683
(Foc: 569; Gen:
114)
Pooled HR (95%
CI),
P value, I² (%)
Foc: 0.66 (0.49 to 0.
88),
P = 0.005, I² = 63%
Gen: 0.67 (0.35 to
1.28)
P = 0.22, I² = 0%
Overall: 0.66 (0.5
to 0.86)
P = 0.002, I² = 31%
Foc: 1.29 (1.04 to 1.
62)
P = 0.02, I² = 0%
Gen: 0.70 (0.45 to
1.07)
P = 0.10, I² = 0%
Overall: 1.14 (0.93
to 1.39)
P = 0.20, I² = 17%
Foc: 0.97 (0.73 to 1.
30)
P = 0.85, I² = 52%
Gen: 1.53 (0.96 to
2.44)
P = 0.08, I² = 0%
Overall: 1.10 (0.86
to 1.40)
P = 0.45, I² = 41%
Foc: 0.91 (0.71 to 1.
15)
P = 0.41, I² = 43%
Gen: 1.30 (0.82 to
2.08)
P = 0.27, I² = 0%
Overall: 0.97 (0.79
to 1.20)
P = 0.81, I² = 21%
Sensitivity analysis
classifying
generalised onset
seizures
and age at onset > 30
as uncertain seizure
type
Participants Overall: 676
(Foc: 520; Gen:
110; Unc: 46)
Overall: 822
(Foc: 584; Gen:
173; Unc: 65)
Overall: 683
(Foc: 525; Gen:112;
Unc: 46)
Overall: 683
(Foc: 525; Gen:112;
Unc: 46)
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Table 5. Sensitivity analyses (Continued)
Pooled HR (95%
CI)
P value, I² (%)
Foc: 0.66 (0.49 to 0.
88)
P = 0.005, I² = 66%
Gen: 0.67 (0.35 to
1.28)
P = 0.22, I² = 0%
Unc: 0.77 (0.18 to
3.27)
P = 0.72, I² = 0%
Overall: 0.66 (0.51
to 0.86)
P = 0.002, I² = 16%
Foc: 1.31 (1.04 to 1.
66)
P = 0.02, I² = 0%
Gen: 0.70 (0.45 to
1.07)
P = 0.10, I² = 0%
Unc: 0.82 (0.40 to
1.69)
P = 0.59, I² = 58%
Overall: 1.11 (0.91
to 1.35)
P = 0.32, I² = 30%
Foc: 0.92 (0.67 to 1.
25)
P = 0.59, I² = 63%
Gen: 1.53 (0.96 to
2.44)
P = 0.08, I² = 0%
Unc: 1.85 (0.77 to
4.42)
P = 0.17, I² = 0%
Overall: 1.12 (0.87
to 1.43)
P = 0.42, I² = 42%
Foc: 0.86 (0.67 to 1.
11)
P = 0.24, I² = 62%
Gen: 1.30 (0.82 to
2.08)
P = 0.27, I² = 0%
Unc:1.67 (0.85 to
3.28)
P = 0.14, I² = 3%
Overall: 1.00 (0.81
to 1.23)
P = 0.27, I² = 0%
CI: confidence interval; Foc: focal onset seizures; Gen: generalised onset seizures; HR: hazard ratio; Unc: uncertain seizure type
aFor time to treatment failure and time to first seizure, HR < 1 indicates a clinical advantage for carbamazepine and for time to 12-
month and six-month remission, HR < 1 indicates a clinical advantage for phenobarbitone. All results presented are calculated from
fixed-effect meta-analysis.
bWeperformed sensitivity analysis excluding all randomised participants in Placencia 1993 because of inadequate allocation concealment
in the trial. We performed further sensitivity analysis for the outcome ’time to treatment failure’ because of inconsistencies between
published data and individual participant data for Placencia 1993 and for the outcome ’time to treatment failure due to adverse events’
(see Sensitivity analysis and Effects of interventions for full details).
cWe performed sensitivity analysis including only the participants in de Silva 1996, who were randomised before the phenobarbitone
arm was withdrawn. We also performed this sensitivity analysis for the outcomes ’time to treatment failure due to adverse events’ and
’time to treatment failure due to lack of efficacy (see Sensitivity analysis and Effects of interventions for full details).
dWe performed sensitivity analyses due to inconsistencies between published data and individual participant data for Banu 2007 (see
Sensitivity analysis and Effects of interventions for full details).
Table 6. Adverse event data (narrative report)
Trial Adverse event dataa Summary of reported results
CBZ PB
Banu 2007b Reported list of ’problems’ at the
last visit (provided as IPD)
n = 54
• speech/learning delay (n = 6)
• headaches (n = 3)
• restlessness/hyperactivity/
poor attention/irritability (n = 6)
• psychomotor deterioration/
delay (n = 2)
• sleep disturbances (n = 2)
• fatigue (n = 1)
• hydrocephalus (build up of
fluid on the brain) (n = 1)
• CBZ hypersensitivity (n = 1)
• aggression (n = 1)
• temper tantrums (n = 1)
n = 54
• speech/learning delay (n = 7)
• restlessness/hyperactivity/
poor attention/irritability (n = 8)
• sleep disturbances (n = 1)
• fatigue (n = 1)
• poor cognition (n = 2)
• aggression (n = 1)
• temper tantrums (n = 3)
• breath-holding attacks (n = 1)
• other behavioural problems
(n = 3)
• facial twitching (n = 1)
• left-sided weakness (n = 1)
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Table 6. Adverse event data (narrative report) (Continued)
• other behavioural problems
(n = 5)
• poor cognition (n = 1)
• mild stroke (n = 1)
• mild right-sided weakness (n
= 1)
• intolerable behavioural
problems (n = 6)
• leg pain (n = 1)
• vomiting (n = 1)
• intolerable behavioural
problems (n = 4)
Bidabadi 2009c Rate of drug side-effects No statistical significant difference
was seen after treatment between 2
groups in the rate of drug side-ef-
fects
No statistical significant difference
was seen after treatment between 2
groups in the rate of drug side-ef-
fects
Cereghino 1974b,d Most frequently observed side-ef-
fects
Gastrointestinal side-ef-
fects and “impaired function” (gen-
eral malaise). Frequency not clearly
stated
Gastrointestinal side-ef-
fects and “impaired function” (gen-
eral malaise). Frequency not clearly
stated
Chen 1996 Withdrawal from the trial due to
’allergic reactions’
n = 24
1 participant withdrew due to an
allergic reaction
n = 23
2 participants withdrew due to al-
lergic reactions
Cossu 1984 No adverse events reported Not reported Not reported
Czapinski 1997c “Exclusions due to adverse events or
no efficacy”
n = 30
Proportion “excluded”: 30%
n = 30
Proportion “excluded”: 33.3%
de Silva 1996e,f “Unacceptable” adverse events lead-
ing to drug withdrawal
n = 54
• drowsiness (n = 1)
• blood dyscrasia (n = 1)
n = 10
• drowsiness (n = 1)
• behavioural (n = 5)
Feksi 1991 Reports ofminor adverse events and
side-effects leading to drug with-
drawal
n = 150
• withdrawals due to side-
effects
◦ skin rash (n = 4)
◦ psychosis (n = 1)
◦ aggressive behaviour (n
= 1)
• minor adverse events
◦ 46 participants reported
68 adverse events
n = 152
• withdrawals due to side-
effects
◦ skin rash (n = 1)
◦ psychosis (n = 1)
◦ hyperactivity (n = 3)
• minor adverse events
◦ 58 participants reported
86 adverse events
Heller 1995e “Unacceptable” adverse events lead-
ing to drug withdrawal
n = 61
• drowsiness (n = 3)
• rash (n = 2)
• headache (n = 1)
• depression (n = 1)
n = 58
• drowsiness (n = 4)
• lethargy (n = 4)
• rash (n = 1)
• dizziness (n = 2)
• headaches (n = 1)
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Table 6. Adverse event data (narrative report) (Continued)
• nausea and vomiting (n = 1)
Mattson 1985b Narrative report of “adverse effects”
and “serious side-effects”
n = 155
• motor disturbance (ataxia,
incoordination, nystagmus,
tremor) 33%
• dysmorphic and idiosyncratic
side-effects (gum hypertrophy,
hirsutism, acne, and rash) 14%
• gastrointestinal problems
27%
• decreased libido or
impotence 13%
No serious side-effects
n = 155
• motor disturbance (ataxia,
incoordination, nystagmus,
tremor) 24%
• dysmorphic and idiosyncratic
side-effects (gum hypertrophy,
hirsutism, acne, and rash) 11 %
• gastrointestinal problems
13%
• decreased libido or
impotence 16%
No serious side-effects
Mitchell 1987 Systemic side-effects and side-ef-
fects leading to drug change
n = 15
4 participants switched from CBZ
to PB; 3 due to systemic side-effects
(1 with persistent rashes and 1 with
marked granulocytopenia (decrease
of granulocytes (white blood cells))
and 1 due to behavioural changes
n = 18
1 participant switched from PB to
CBZ due to substantial behavioural
side-effects
Ogunrin 2005b Participant-reported symptomatic
complaints (provided as IPD)
n = 19
• memory impairment (n = 9)
• psychomotor retardation (n =
1)
• inattention (n = 1)
• transient rash (n = 1)
• CBZ-induced cough (n = 1)
n = 18
• memory impairment (n = 13)
• psychomotor retardation (n =
8)
• inattention (n = 9)
Placencia 1993 Number of participants reporting
side-effects
n = 95
53 participants reported at least 1
side-effect
n = 97
50 participants reported at least 1
side-effect
CBZ: carbamazepine; IPD: individual participant data; n: number; PB: phenobarbitone
aWe recorded adverse event data as reported narratively in the publications; therefore, exact definition of a symptom may vary. Adverse
event data were supplied as IPD for Banu 2007 and Ogunrin 2005. Adverse event data were not requested in original IPD requests (de
Silva 1996; Heller 1995; Mattson 1985; Placencia 1993).
bParticipants may report more than one adverse event.
cBidabadi 2009 and Czapinski 1997 are abstracts only so reported very little information.
dNote that the recruited participants in this trial were institutionalised; therefore, the “precise nature of side-effects was not always
determinable”. The two most frequently occurring side-effects were reported as the frequency of participants reporting the side-effect
on each day of the treatment period; however, overall totals of participants reporting each side-effect were not reported.
eParticipants may have withdrawn due to adverse event alone or a combination of adverse events and poor efficacy (seizures).
fThe phenobarbitone arm of de Silva 1996 was stopped prematurely after 10 children were randomised to this arm because of concerns
over behavioural adverse events (see the ’Characteristics of included studies’ tables).
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A P P E N D I C E S
Appendix 1. Cochrane Register of Studies (CRS Web) search strategy
1. MeSH DESCRIPTOR Carbamazepine Explode All AND CENTRAL:TARGET
2. Carbamazepine OR Carbamezepine OR CBZ OR SPD417 OR Apo-Carbamazepine OR Atretol OR Biston OR Calepsin OR
Carbagen OR Carbamazepen OR Carbatrol OR Carbazepine OR Carbelan OR Epitol OR Equetro OR Finlepsin OR Karbamazepin
OR Lexin ORNeurotop ORNovo-Carbamaz ORNu-Carbamazepine OR Sirtal OR Stazepin OR Stazepine OR Taro-Carbamazepine
OR Tegretal OR Tegretol OR Telesmin OR Teril OR Timonil AND CENTRAL:TARGET
3. #1 OR #2 AND CENTRAL:TARGET
4. MeSH DESCRIPTOR Phenobarbital Explode All AND CENTRAL:TARGET
5. Phenobarbital OR Fenobarbital ORPhenobarbitol OR Phenobarbitone OR “Phenobarbituric Acid” ORPhenylethylbarbiturate OR
“Phenylethylbarbituric Acid” OR Phenylethylmalonylurea OR Adonal OR Aephenal OR Agrypnal OR Amylofene OR Aphenylbarbit
OR Aphenyletten OR Barbenyl OR Barbinal OR Barbiphen OR Barbiphenyl OR Barbipil OR Barbita OR Barbivis OR Barbonal
OR Barbophen OR Bardorm OR Bartol OR Bialminal OR Blu-Phen OR Cabronal OR Calmetten OR Calminal OR Cardenal OR
Chinoin OR Codibarbita OR Coronaletta OR Cratecil OR Damoral OR Dezibarbitur ORDormina ORDormiral OR Dormital OR
Doscalun ORDuneryl OR Ensobarb OREnsodorm OR Epanal OR EpidormOR Epilol OR Episedal OR Epsylone OR Eskabarb OR
EtilfenOREunerylORFenbital ORFenemalORFenosedORFenylettaeORGardenalORGardepanylORGlysolettenORHaplopan
OR Haplos OR Helional OR Hennoletten OR Henotal OR Hypnaletten OR Hypnette OR Hypno-Tablinetten OR Hypnogen OR
Hypnolone OR Hypnoltol OR Hysteps OR Lefebar OR Leonal OR Lephebar OR Lepinal OR Lepinaletten OR Linasen OR Liquital
OR Lixophen OR Lubergal OR Lubrokal OR LumenOR Lumesettes OR LumesynOR Luminal OR Lumofridetten OR Luphenil OR
Luramin OR Molinal OR Neurobarb OR Nirvonal OR Noptil OR Nova-Pheno OR Nunol OR Parkotal OR Pharmetten OR Phen-
Bar OR Phenaemal OR Phenemal OR Phenemalum OR Phenobal OR Phenobarbyl OR Phenoluric OR Phenolurio OR Phenomet
OR Phenonyl OR Phenoturic OR Phenyletten OR Phenyral OR Phob OR Polcominal OR Prominal OR Promptonal OR Seda-
Tablinen OR Sedabar OR Sedicat OR Sedizorin OR Sedlyn OR Sedofen OR Sedonal OR Sedonettes OR Sevenal OR Sinoratox OR
Solfoton OR Solu-Barb OR Sombutol OR Somnolens OR Somnoletten OR Somnosan OR Somonal OR Spasepilin OR Starifen OR
Starilettae OR Stental OR Talpheno OR Teolaxin OR Teoloxin OR Thenobarbital OR Theoloxin OR Triabarb OR Tridezibarbitur
OR Triphenatol OR Versomnal OR Zadoletten OR Zadonal OR PB AND CENTRAL:TARGET
6. #4 OR #5 AND CENTRAL:TARGET
7. ((adjunct* or “add-on” or “add on” or adjuvant* or combination* or polytherap*) not (monotherap* or alone or singl*)):TI AND
CENTRAL:TARGET
8. (#3 AND #6) NOT #7
9. MESH DESCRIPTOR Epilepsy EXPLODE ALL AND CENTRAL:TARGET
10. MESH DESCRIPTOR Seizures EXPLODE ALL AND CENTRAL:TARGET
11. (epilep* OR seizure* OR convuls*):AB,KW,MC,MH,TI AND CENTRAL:TARGET
12. #9 OR #10 OR #11 AND CENTRAL:TARGET
13. #8 AND #12
14. >18/08/2016:CRSINCENTRAL AND CENTRAL:TARGET
15. #13 AND #14
Appendix 2. MEDLINE search strategy
The following search strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomised trials inMEDLINE
(Lefebvre 2011).
1. exp Carbamazepine/
2. (Carbam?zepine or CBZ or SPD417 or Apo-Carbamazepine or Atretol or Biston or Calepsin or Carbagen or Carbamazepen or
Carbatrol or Carbazepine or Carbelan or Epitol or Equetro or Finlepsin or Karbamazepin or Lexin or Neurotop or Novo-Carbamaz or
Nu-Carbamazepine or Sirtal or Stazepin or Stazepine or Taro-Carbamazepine or Tegretal or Tegretol or Telesmin or Teril or Timonil).tw.
3. 1 or 2
4. exp Phenobarbital/
5. (Fenobarbital or Phenobarbit?l or Phenobarbitone or “Phenobarbituric Acid” or Phenylethylbarbiturate or “Phenylethylbarbituric
Acid” or Phenylethylmalonylurea or Adonal or Aephenal or Agrypnal or Amylofene or Aphenylbarbit or Aphenyletten or Barbenyl or
Barbinal or Barbiphen or Barbiphenyl or Barbipil or Barbita or Barbivis or Barbonal or Barbophen or Bardorm or Bartol or Bialminal
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or Blu-Phen or Cabronal or Calmetten or Calminal or Cardenal or Chinoin or Codibarbita or Coronaletta or Cratecil or Damoral or
Dezibarbitur or Dormina or Dormiral or Dormital or Doscalun or Duneryl or Ensobarb or Ensodorm or Epanal or Epidorm or Epilol
or Episedal or Epsylone or Eskabarb or Etilfen or Euneryl or Fenbital or Fenemal or Fenosed or Fenylettae or Gardenal or Gardepanyl
or Glysoletten or Haplopan or Haplos or Helional or Hennoletten or Henotal or Hypnaletten or Hypnette or Hypno-Tablinetten or
Hypnogen or Hypnolone or Hypnoltol or Hysteps or Lefebar or Leonal or Lephebar or Lepinal or Lepinaletten or Linasen or Liquital
or Lixophen or Lubergal or Lubrokal or Lumen or Lumesettes or Lumesyn or Luminal or Lumofridetten or Luphenil or Luramin
or Molinal or Neurobarb or Nirvonal or Noptil or Nova-Pheno or Nunol or Parkotal or Pharmetten or Phen-Bar or Phenaemal or
Phenemal or Phenemalum or Phenobal or Phenobarbyl or Phenoluric or Phenolurio or Phenomet or Phenonyl or Phenoturic or
Phenyletten or Phenyral or Phob or Polcominal or Prominal or Promptonal or Seda-Tablinen or Sedabar or Sedicat or Sedizorin or
Sedlyn or Sedofen or Sedonal or Sedonettes or Sevenal or Sinoratox or Solfoton or Solu-Barb or Sombutol or Somnolens or Somnoletten
or Somnosan or Somonal or Spasepilin or Starifen or Starilettae or Stental or Talpheno or Teolaxin or Teoloxin or Thenobarbital or
Theoloxin or Triabarb or Tridezibarbitur or Triphenatol or Versomnal or Zadoletten or Zadonal or PB).tw.
6. 4 or 5
7. exp Epilepsy/
8. exp Seizures/
9. (epilep$ or seizure$ or convuls$).tw.
10. 7 or 8 or 9
11. exp Pre-Eclampsia/ or exp Eclampsia/
12. 10 not 11
13. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
14. clinical trials as topic.sh.
15. trial.ti.
16. 13 or 14 or 15
17. exp animals/ not humans.sh.
18. 16 not 17
19. 3 and 6 and 12 and 18
20. ((adjunct$ or “add-on” or “add on” or adjuvant$ or combination$ or polytherap$) not (monotherap$ or alone or singl$)).ti.
21. 19 not 20
22. limit 21 to ed=20160818-20180524
23. 21 not (1$ or 2$).ed.
24. 23 and (2016$ or 2017$ or 2018$).dt.
25. 22 or 24
26. remove duplicates from 25
Earlier versions of this review used the following search strategy.
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. exp Randomized Controlled Trials/
4. exp Random Allocation/
5. exp Double-Blind Method/
6. exp Single-Blind Method/
7. clinical trial.pt.
8. exp Clinical Trials/
9. (clin$ adj trial$).ab,ti.
10. ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).ab,ti.
11. exp PLACEBOS/
12. placebo$.ab,ti.
13. random$.ab,ti.
14. exp Research Design/
15. or/1-14
16. (animals not humans).sh.
17. 15 not 16
18. phenobarbit$.tw. or exp Phenobarbital/
19. carbamazepin$.tw.
94Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
20. exp Carbamazepine/
21. 18 and (19 or 20)
22. (epilep$ or seizure$ or convulsion$).tw.
23. exp Epilepsy/
24. exp Seizures/
25. 22 or 23 or 24
26. 21 and 25
27. 26 and 17
Appendix 3. ClinicalTrials.gov search strategy
Interventional Studies | Epilepsy | carbamazepine and phenobarbital | First posted on or after 08/18/2016
Appendix 4. ICTRP search strategy
Condition: epilepsy
Intervention: carbamazepine and phenobarbital
Date of registration between 18/08/2016 and 24/05/2018
Appendix 5. Scopus search strategy
(((TITLE(carbamazepine OR carbamezepine OR cbz OR spd417 OR apo-carbamazepine OR atretol OR biston OR calepsin OR
carbagenORcarbamazepenORcarbatrolOR carbazepineOR carbelanOR epitolOR equetroORfinlepsinORkarbamazepinOR lexin
OR neurotop OR novo-carbamaz OR nu-carbamazepine OR sirtal OR stazepin OR stazepine OR taro-carbamazepine OR tegretal OR
tegretol OR telesmin OR teril OR timonil)) OR (ABS(carbamazepine OR carbamezepine OR cbz OR spd417 OR apo-carbamazepine
OR atretol OR biston OR calepsin OR carbagen OR carbamazepen OR carbatrol OR carbazepine OR carbelan OR epitol OR equetro
OR finlepsin OR karbamazepin OR lexinOR neurotol OR novo-carbamaz OR nu-carbamazepine OR sirtal OR stazepin OR stazepine
OR taro-carbamazepine OR tegretal OR tegretol OR telesmin OR teril OR timonil))) AND ((TITLE(phenobarbital OR fenobarbital
OR phenobarbitol OR phenobarbitone OR “Phenobarbituric Acid” OR phenylethylbarbiturate OR “Phenylethylbarbituric Acid” OR
phenylethylmalonylurea OR adonal OR aephenal OR agrypnal OR amylofene OR aphenylbarbit OR aphenyletten OR barbenyl OR
barbinal OR barbiphen OR barbiphenyl OR barbipil OR barbita OR barbivis OR barbonal OR barbophen OR bardorm OR bartol
OR bialminal OR blu-phen OR cabronal OR calmetten OR calminal OR cardenal OR chinoin OR codibarbita OR coronaletta
OR cratecil OR damoral OR dezibarbitur OR dormina OR dormiral OR dormital OR doscalun OR duneryl OR ensobarb OR
ensodorm OR epanal OR epidorm OR epilol OR episedal OR epsylone OR eskabarb OR etilfen OR euneryl OR fenbital OR fenemal
OR fenosed OR fenylettae OR gardenal OR gardepanyl OR glysoletten OR haplopan OR haplos OR helional OR hennoletten OR
henotal OR hypnaletten OR hypnette OR hypno-tablinetten OR hypnogen OR hypnolone OR hypnoltol OR hysteps OR lefebar
OR leonal OR lephebar OR lepinal OR lepinaletten OR linasen OR liquital OR lixophen OR lubergal OR lubrokal OR lumen
OR lumesettes OR lumesyn OR luminal OR lumofridetten OR luphenil OR luramin OR molinal OR neurobarb OR nirvonal
OR noptil OR nova-pheno OR nunol OR parkotal OR pharmetten OR phen-bar OR phenaemal OR phenemal OR phenemalum
OR phenobal OR phenobarbyl OR phenoluric OR phenolurio OR phenomet OR phenonyl OR phenoturic OR phenyletten OR
phenyral OR phob OR polcominal OR prominal OR promptonal OR seda-tablinen OR sedabar OR sedicat OR sedizorin OR sedlyn
OR sedofen OR sedonal OR sedonettes OR sevenal OR sinoratox OR solfoton OR solu-barb OR sombutol OR somnolens OR
somnoletten OR somnosan OR somonal OR spasepilin OR starifen OR starilettae OR stental OR talpheno OR teolaxin OR teoloxin
OR thenobarbitalOR theoloxinOR triabarbOR tridezibarbiturOR triphenatolORversomnalOR zadolettenORzadonalORpb))OR
(ABS(phenobarbital OR fenobarbital OR phenobarbitol OR phenobarbitone OR “Phenobarbituric Acid” OR phenylethylbarbiturate
OR “Phenylethylbarbituric Acid”ORphenylethylmalonylureaOR adonal OR aephenalOR agrypnal OR amylofeneOR aphenylbarbit
OR aphenyletten OR barbenyl OR barbinal OR barbiphen OR barbiphenyl OR barbipil OR barbita OR barbivis OR barbonal OR
barbophen OR bardorm OR bartol OR bialminal OR blu-phen OR cabronal OR calmetten OR calminal OR cardenal OR chinoin
OR codibarbita OR coronaletta OR cratecil OR damoral OR dezibarbitur OR dormina OR dormiral OR dormital OR doscalun
OR duneryl OR ensobarb OR ensodorm OR epanal OR epidorm OR epilol OR episedal OR epsylone OR eskabarb OR etilfen OR
euneryl OR fenbital OR fenemal OR fenosed OR fenylettae OR gardenal OR gardepanyl OR glysoletten OR haplopan OR haplos
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OR helional OR hennoletten OR henotal OR hypnaletten OR hypnette OR hypno-tablinetten OR hypnogen OR hypnolone OR
hypnoltol OR hysteps OR lefebar OR leonal OR lephebar OR lepinal OR lepinaletten OR linasen OR liquital OR lixophen OR
lubergal OR lubrokal OR lumenOR lumesettesOR lumesynOR luminal OR lumofridettenOR luphenil OR luramin ORmolinal OR
neurobarbORnirvonalORnoptil ORnova-phenoORnunolORparkotalORpharmettenORphen-barORphenaemalORphenemal
OR phenemalum OR phenobal OR phenobarbyl OR phenoluric OR phenolurio OR phenomet OR phenonyl OR phenoturic OR
phenyletten OR phenyral OR phob OR polcominal OR prominal OR promptonal OR seda-tablinen OR sedabar OR sedicat OR
sedizorin OR sedlyn OR sedofen OR sedonal OR sedonettes OR sevenal OR sinoratox OR solfoton OR solu-barb OR sombutol OR
somnolens OR somnolettenOR somnosan OR somonal OR spasepilin OR starifenOR starilettae OR stental OR talphenoOR teolaxin
OR teoloxin OR thenobarbital OR theoloxin OR triabarb OR tridezibarbitur OR triphenatol OR versomnal OR zadoletten OR
zadonal OR pb))) AND ((TITLE-ABS-KEY(epilep* OR “infantile spasm” OR seizure OR convuls* OR (syndrome W/2 (aicardi OR
angelman OR doose ORdravet OR janz OR jeavons OR “landau kleffner”OR “lennox gastaut” OR ohtahara OR panayiotopoulos OR
rasmussen OR rett OR “sturge weber” OR tassinari OR “unverricht lundborg” OR west)) OR “ring chromosome 20” OR “R20” OR
“myoclonic encephalopathy” OR “pyridoxine dependency”) ANDNOT (TITLE(*eclampsia) OR INDEXTERMS(*eclampsia))) OR
(TITLE-ABS-KEY(lafora* W/4 (disease OR epilep*)) AND NOT (TITLE(dog OR canine) OR INDEXTERMS(dog OR canine))))
AND (TITLE((randomiz* OR randomis* OR controlled OR placebo OR blind* OR unblind* OR “parallel group” OR crossover OR
“cross over” OR cluster OR “head to head”) PRE/2 (trial OR method OR procedure OR study)) OR ABS((randomiz* OR randomis*
OR controlled OR placebo OR blind* OR unblind* OR “parallel group” OR crossover OR “cross over” OR cluster OR “head to
head”) PRE/2 (trial ORmethod OR procedure OR study)))) ANDNOT (TITLE((adjunct* OR “add-on” OR “add on” OR adjuvant*
OR combination* OR polytherap*) AND NOT (monotherap* OR alone OR singl*)))
WH A T ’ S N E W
Date Event Description
24 May 2018 New citation required but conclusions have not changed Conclusions remain the same.
24 May 2018 New search has been performed Searches updated 24 May 2018; no new trials have been
included.The term ’partial’ has been replaced by ’focal’, in
accordancewith themost recent classificationof epilepsies
of the International League Against Epilepsy (Scheffer
2017).
H I S T O R Y
Protocol first published: Issue 1, 2000
Review first published: Issue 1, 2003
Date Event Description
26 April 2017 Amended Declarations of interest section updated.
18 August 2016 New citation required but conclusions have not
changed
Conclusions are unchanged.
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(Continued)
18 August 2016 New search has been performed Searches updated 18 August 2016; no new studies
identified.
22 September 2014 New search has been performed Searches updated 22 September 2014.
22 September 2014 New citation required but conclusions have not
changed
Four new included studies. Conclusions remain un-
changed.
12 August 2009 Amended Copyedits made at editorial base.
24 September 2008 Amended Converted to new review format.
1 October 2006 New search has been performed We re-ran our searches on 1st October 2006; no new
studies were identified
C O N T R I B U T I O N S O F A U T H O R S
• SJ Nevitt assessed trials for inclusion in the review update, obtained individual participant data from trial investigators for the
review update, assessed risk of bias in all included trials, performed analyses in Stata version 14, added survival plots and a ’Summary
of findings’ table, and updated the text of the review.
• C Tudur Smith was the lead investigator on the original review, assessed eligibility and methodological quality of original
individual trials, organised and cleaned the IPD sets, performed data validation checks and statistical analyses, and co-wrote the
original review.
• AG Marson obtained IPD from trial investigators, provided guidance with the clinical interpretation of results, assessed
eligibility and methodological quality of individual trials, and co-wrote the original review.
D E C L A R A T I O N S O F I N T E R E S T
• Sarah J Nevitt: nothing to declare
• Anthony G Marson: a consortium of pharmaceutical companies (GSK, EISAI, UCB Pharma), funded the National Audit of
Seizure Management in Hospitals (NASH), through grants paid to The University of Liverpool. Professor Tony Marson is part
funded by National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care North West
Coast (NIHR CLAHRC NWC).
• Catrin Tudur Smith: nothing to declare
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S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
December 2014: the title was changed to specify that the review uses individual participant data (IPD).
Update 2015: we added sensitivity analyses following the discovery of inconsistencies between IPD provided and published papers.
The existence of such inconsistencies could not have been known at the time of writing the original protocol.
Update 2015: we added the outcomes ’time to six-month remission’ and ’adverse events’ for consistency with the other reviews in the
series of Cochrane IPD reviews investigating pair-wise monotherapy comparisons.
Update 2016: we added ’Summary of findings’ tables to the update in 2015 and added text in the Methods section for ’Summary of
findings’ tables in August 2016.
Update 2018: ’Time to withdrawal of allocated treatment’ was re-defined as ’Time to treatment failure’ due to feedback received from
the Cochrane Editorial Unit regarding potential confusion regarding ’withdrawal’ as a positive or negative outcome of anti-epileptic
monotherapy.
Additional analyses of ’Time to treatment failure’ (due to lack of efficacy and due to adverse events), following feedback on published
anti-epileptic drug monotherapy reviews that these sub outcomes would be useful for clinical practice.
The term ’partial’ has been replaced by ’focal’, in accordance with the most recent classification of epilepsies of the International League
Against Epilepsy ( Scheffer 2017).
N O T E S
Sarah J Nolan (lead author of the 2015 and 2016 update), is now Sarah J Nevitt.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anticonvulsants [∗therapeutic use]; Carbamazepine [∗therapeutic use]; Epilepsies, Partial [∗drug therapy]; Epilepsy, Generalized [∗drug
therapy]; Epilepsy, Tonic-Clonic [drug therapy]; Phenobarbital [∗therapeutic use]; Randomized Controlled Trials as Topic; Remission
Induction; Seizures [prevention & control]
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MeSH check words
Adult; Child; Humans
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